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ABSTRACT
During the erythrocytic cycle, the malaria parasite Plasmodium falciparum, 
inserts it’s own molecules into the membrane of the infected red blood cell (Pf- 
iRBC). One of these molecules, Plasmodium falciparum Erythrocyte Membrane 
Protein-1 (PfEMP-1) belong to a large gene family (Far) with around 60 copies per 
haploid genome distributed in all chromosomes. Far genes show extreme diversity 
but all contain a number of domains displaying homology to the previously described 
Duffy Binding Like (DBL) molecules or in the case of CD36 binding, to another 
relatively conserved region, the Cysteine Rich Interdomain Region (CIDR-la). Due 
to their surface location, antigenicity and involvement in pathogenesis of severe 
malaria, these molecules form an important candidate for a malaria vaccine.
Previously, we studied the CD4 T cell response to relatively conserved 
recombinant segments expressed from three different domains of PfEMP-1: EXON 2, 
CIDR-la and DBL-a. We measured in vitro CD4 T cell proliferation, Interferon- 
(IFN)-y and Interleukin (IL)-10 production in peripheral mononuclear cells (PBMC). 
Only responses to EXON 2 and DBL-a were associated with exposure to malaria. 
The response to CIDR-la was striking in that both exposed and non-exposed donors 
responded similarly. In the studies presented here, the cell phenotypes responding to 
CIDR-la, the cytokines they make and their kinetics were analysed. In addition, the 
requirements for HLA restriction and T Cell Receptor (TCR) engagement for the CD4 
T cell and IFN-y responses were investigated.
CIDR-la activated human myeloid DCs in either whole PBMC or separately 
(isolated DC) to produce IL-10, IL-12 and IL-18. The IL-10 and IL-18 responses 
could be reproduced with intact Pf-iRBC. IL-10 and IL-12 were produced with 
different kinetics highlighting the need for time course experiments in studies 
investigating cytokine production by DCs. The IFN-y response to CIDR-la in 
malaria-unexposed individuals was largely independent of MHC class II/TCR 
engagement whilst both the CD4 T cell and IFN-y responses in malaria-exposed 
donors were MHC class II restricted. These findings suggest that the CD4 T cell 
response to CID R-la in malaria semi-immune adults has an element of 
immunological memory on top of the pre-existing responses seen in the malaria- 
unexposed adult.
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CHAPTER 1
INTRODUCTION
1.1 Malaria - perspective
Evolutionary evidence suggests that the association of human ancestors with the 
malaria parasite predates the origin of hominids, implying that malaria is an ancient 
human disease (Ayala et al., 1999). Hippocrates (460 BC) and other ancient philosophers 
reported and described the symptomatology of malaria induced fevers (Linnaeus, 1733), 
and periodic fevers had been described in China and India 3000 years ago (Desowitz, 
1991). However, the discoveries that malaria is caused by protozoan parasites in blood 
and is transmitted by mosquitoes by Laveran (Laveran, 1880) and Ross (Ross, 1897),
tlirespectively, were not made until the late 19 century.
In spite of such seminal discoveries more than 100 years ago, malaria continues to be 
a devastating scourge killing an estimated 1 million people, mainly children below the 
age of five, and pregnant women, every year (Snow et al., 1999). Almost all of these 
deaths are caused by Plasmodium falciparum, one of the four species of malaria parasites 
that infects humans (reviewed in (WHO, 1997)). Other species infecting humans are 
Plasmodium vivax, Plasmodium malariae and Plasmodium ovale. This high burden of 
mortality due to Plasmodium falciparum malaria is not evenly distributed but falls 
heavily on Sub-Saharan Africa, where over 90% of these deaths are thought to occur and 
5% of children die before the age of 5 years (reviewed in (Greenwood and Mutabingwa, 
2002; Phillips, 2001)). Among new boms of Africa, an estimated 3 million suffer a 
spectrum of complications ranging from low birth weight to death arising from malaria 
infections during pregnancy. Globally, 2.4 billion people (40% of the world’s population)
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from over 90 countries are at risk of being infected and up to 500 million suffer from the 
disease with varying degrees of severity (Greenwood and Mutabingwa, 2002; Phillips, 
2001). The toll from malaria is still growing with malaria specific mortality in young 
African children estimated to have doubled during the last two decades (Snow et al.,
2001). This increased malaria mortality has been associated with the parasite becoming 
resistant to preventative and therapeutic drugs, spread of insecticide resistant mosquitoes, 
lack of effective vaccines, and poverty, which together with social and ecological 
disruption hinders application of the current control measures.
Malaria is also a primary cause of poverty as a consequence of factors that include 
effects of the disease on fertility, population growth, saving and investment, worker 
productivity, absenteeism, premature death and medical costs (Sachs and Malaney,
2002). It is estimated that malaria lowers the economic growth of affected countries by 
1.3% of their gross domestic product (GDP) (Lycett and Kafatos, 2002) thus contributing 
to the poverty of these already impoverished communities.
After HIV/AIDS, malaria remains the world’s worst public health problem. Several 
factors have contributed to the worsening situation. Malaria is transmitted by the female 
Anopheline mosquito and so a major strategy of control is application of insecticides. 
However, extended use leads to the emergence of insecticide resistant mosquitoes thus 
reducing the effectiveness of this intervention. In addition, the cost of insecticide based 
control programs has also forced their reduction and abandonment in most regions. The 
creation of new breeding sites for mosquitoes through road-building, deforestation, 
mining, irrigation projects and new agricultural practices has also led to increased malaria 
transmission. The steep rises in the populations of some malarious regions, together with
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migration of people from rural to more densely populated urban areas have also led to 
increased rates of transmission and people with little or no immunity being exposed to 
higher rates of infection. However, the rapid spread of drug resistant parasites to the first 
line antimalarial drugs is thought to be the primary reason for the dramatic increase in 
deaths from malaria in the last three decades (reviewed in (Greenwood and Mutabingwa, 
2002; Phillips, 2001)). Additionally, the few effective drugs available are too expensive 
for many populations at risk and developing new therapies is not a commercial priority 
for the major pharmaceutical companies of the world.
1.2 Plasmodium falciparum life cycle (figure 1.1)
P. falciparum has a complex life cycle with many different developmental stages in 
the mosquito vector and human host. The bite of an infected Anopheline mosquito injects 
sporozoites into the human host, where they are transported rapidly via the blood stream 
to hepatocytes in the liver. Within the hepatocyte, the parasite matures, differentiates, and 
undergoes several rounds of asexual multiplication forming approximately 20000 - 40000 
haploid merozoites that are released into the blood stream. This stage takes about 7 days 
and does not give rise to clinical symptoms. The released merozoites immediately invade 
red blood cells and undergo a process of growth and asexual multiplication to produce 
between 8 and 32 daughter merozoites per every infected erythrocyte over a period of 48 
hours.
When the daughter merozoites are fully mature (the schizont stage), the infected red 
cell bursts, releasing the merozoites to invade other erythrocytes. This period of 
exponential growth is responsible for all the clinical symptoms of malaria and continues 
until the parasite multiplication is controlled by drug treatment or the immune response,
3
or death in some cases. A small proportion of the invading merozoites undergo an 
alternative pathway of differentiation and develop into either male or female gametes, 
which are subsequently taken up in a mosquito blood meal. In the mosquito mid-gut, the 
male and female gametocytes fuse to form a zygote, which then undergoes a series of 
complicated differentiation, and growth stages that results in the production of infective 
sporozoites in the salivary glands of the mosquito.
Figure 1.1: the life cycle of Plasmodium species
human
host
sporozoites
trophozoite
ring stage
■■ o  o
scmzonts 
merozoites
a Mk
macrogametocyte 
microgametocyte
(Modified from Long, C.A & Hoffman, S.L., Science 2002)
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1.3 Malaria -  the disease
Most individuals living in malaria endemic areas will be intermittently re-infected 
by P. falciparum resulting in an acute illness characterised by recurrent fevers, muscle 
aches and head aches (every 48 hours). However, in the young child or the non-immune 
visitor, P. falciparum infection may result in a life threatening illness characterised by 
severe anaemia, respiratory distress, coma or even death. Pregnant women are also at an 
increased risk from P. falciparum infection, and malaria infection has been associated 
with low birth weight and at lower endemicity, higher risk of mortality, especially for the 
primigravidae (Brabin, 1983). In older children and adults, a degree of acquired 
resistance persists resulting mainly in asymptomatic, or mild malaria.
Severe malaria in African children has been classified in to three overlapping clinical 
syndromes; cerebral malaria, severe anaemia and respiratory distress (Marsh et al., 1995). 
Cerebral malaria is characterised by impaired levels of consciousness, confusion or un- 
arousable coma. The mortality rate associated with this form of severe malaria varies 
from 7-33% in different studies (Kwiatkowski et al.9 1993; Marsh et al., 1995; Molyneux 
et al., 1989; White et al., 1985) and is associated with the depth of the coma (Marsh et 
al., 1995; Molyneux et al., 1989; Taylor et al., 1988). It is estimated that severe anaemia 
associated with P. falciparum malaria infections accounts for almost 20% of malaria 
admissions in most African hospitals but this percentage may be higher in areas of high 
transmission (Marsh et al., 1995).
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1.4 Epidemiology of malaria
Using transmission to describe the distribution of malaria
Malaria transmission may be broadly classified into stable and unstable depending 
on the variation of transmission over time. Under stable transmission, there is year-to- 
year transmission but there may be variation within the same year and between 
subsequent years. The populations that live in stable endemic areas develop high levels of 
immunity irrespective of seasonal variations. In unstable malaria transmission, there is a 
greater variability in transmission over time and space and populations in such areas have 
low levels of immunity. Areas with stable malaria are said to be endemic and those with 
unstable malaria are non-endemic and are prone to epidemics.
In 1959, a more detailed classification scheme of malaria endemicity was 
presented (Metselaar and Van Thiel, 1959). This scheme, illustrated in table 1.1, is still 
used by epidemiologists to describe different levels of endemicity at the international 
level. Spleen and parasite rates derived from cross-sectional surveys were used to 
determine different levels of endemicity.
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Table 1.1: Classification o f  malaria transmission as described by Metselaar and Van Thiel (1959)
Type Spleen rates Parasite rates Description
Hypoendemicity Not exceeding 
10% in children 
aged 2-9 year 
olds
Not exceeding 10% in 
children aged 2-9 years 
but may be higher for 
part of the year
Areas where there is little 
transmission and the effects, 
during the average year, upon the 
g e n e ra l p o p u la tio n  are 
unimportant
Meso-endemicity Betw een 11- 
50% in children 
aged 2-9 years
Between 11-50% in 
children aged 2-9 years 
but may be higher for 
part of the year
Typically found among rural 
communities in subtropical zones 
w here w ide g eo g rap h ica l 
variations in transmission risk 
exist
Hyper-endemicity Constantly over 
50% in children 
aged 2-9 years. 
Also high in 
adults (>25%)
Constantly over 50% 
among children aged 2-9 
years
Areas where transm ission is 
intense but seasonal where 
transmission is insufficient in all 
age groups
Holo-endemicity Constantly over 
75% in children 
2-9 years but 
low in adults
Constantly over 75% 
among infants aged 0-11 
months
Perennial, intense transmission 
resulting in a considerable degree 
o f im munity outside early 
childhood
The relationship between transmission, age and distribution of disease (figure 1.2)
In malaria endemic areas, malaria morbidity and mortality is concentrated in 
young children and becomes less frequent with age, with the exception of pregnant 
women who are especially susceptible during their first pregnancy (Greenberg et a l , 
1989). Malaria specific mortality is rare, if not absent, in adults. This trend of an age 
dependent distribution of disease provides strong evidence that people develop malaria-
specific immunity following repeated exposure. Infants below the age of six months are 
normally relatively protected from malaria by a number of mechanisms that probably 
include maternal antibody, foetal haemoglobin and less contact with infective mosquitoes 
(Hogh et al., 1995; Sehgal et al, 1989; Snow et al, 1998). This protection wanes by the 
age of six months of life and disease incidence increases rapidly, reaches a peak and then 
decreases gradually. If the transmission intensity is very high, severe malarial disease 
incidence peaks in the first year of life and by the fourth year children experience only a 
few mild episodes (Bloland et al, 1999). The prevalence of mild disease continues to rise 
even at the age where immunity to severe disease is essentially complete. In contrast, the 
disease incidence-age curve is flattened in areas of very low transmission as disease 
episodes are spread over a wide age range and the incidence peak occurs at a later age 
(Modiano et al., 1999; Rogier et al., 1999; Snow et a l, 1994). The prevalence of severe 
malaria, mild malaria and parasite rates when plotted against age give characteristic 
curves, as shown in figure 1.2, that best represent how they are related. These curves shift 
to the left with increasing intensity of transmission and to the right with decreasing 
transmission if all other factors are held constant.
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Figure 1.2: Hypothetical representation o f the relationship between parasitaemia, 
non-severe malaria and severe malaria with age in endemic areas
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The incidences for the two main syndromes of severe disease, severe anaemia and 
cerebral malaria exhibit different age profiles. The incidence of severe anaemia peaks at 
one to two years of life while that of cerebral malaria peaks between two to four years in 
The Gambia (Bloland et al., 1999), coastal Kenya and western Kenya (Marsh and Snow, 
1997; Snow et al., 1997). These three sites experience meso- to hyperendemic malaria. 
The reasons for this difference are not known. It is likely that there is an immune 
mediated element in cerebral malaria that requires time to mature and be sensitised.
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1.5 Malaria control
P. falciparum  is a highly successful human parasite and its co-existence with 
Anopheles gambiae, the most successful malaria vector, renders malaria a persistent 
problem in Sub-Saharan Africa. Drug treatments of infected individuals combined with 
insecticide treated bed net programs are currently the main methods of disease control. 
However, deaths from severe malaria continue to rise due to such factors as the 
emergence and spread of drug resistant parasites (White et al., 1999) and insecticide 
resistant mosquitoes (Chandre et al., 1999), widespread poverty, and poor or non-existent 
health services. In addition, the emergence of resistance to the only insecticides available 
for malarial control, pyrethroid insecticides, in West and South Africa is reducing the 
effectiveness of insecticide treated bed net programs (Chandre et al., 1999). As a result, 
the current malaria control strategies have failed to arrest the ever-increasing burden of 
malarial disease and additional control methods are urgently needed.
The publication of the complete genome of P. falciparum two years ago has offered 
renewed hope for the discovery of new drug and vaccine targets. However, the biggest 
hurdle lies in getting enough funds and industrial expertise to move promising drugs and 
vaccines from the laboratory to clinical trials and commercialisation. It is encouraging to 
note that the past few years have seen several international initiatives launched to fight 
malaria by sourcing funds for capacity building in the areas of disease control and 
research. The creation of the Multilateral Initiative on Malaria (in 1997) bringing together 
research agencies, donors, charities and scientists with the aim to train and empower 
scientists from endemic areas and bridge the gap between research and malaria control 
was a good step forward. The same can be said of the Roll Back Malaria initiative that
was started by the director of WHO in 1998 with an aim of halving the number of malaria 
deaths by the year 2010. Whilst efforts must be made to improve the access to effective 
treatment and provision of insecticide treated nets to save lives, the development of an 
effective anti-malarial vaccine remains a high priority, for vaccination remains a highly 
effective and low cost means of controlling infectious diseases.
1.6.0 Immunology of malaria
1.6.1 Introduction
The vast majority of deaths from malaria in endemic areas occur in children under 5 
years of age (as discussed in section 1.4). Adults who have grown up in endemic areas 
have a very low case fatality rate, suggesting that naturally acquired immunity is effective 
in preventing severe malaria. In order to progress from these observations of naturally 
acquired protective immunity and develop effective anti-malaria vaccines, several tasks 
must be accomplished. Firstly, the mechanisms of protection must be identified and well 
characterised. Secondly, the antigenic targets of these mechanisms must be identified. 
Thirdly, in vitro correlates of protection and appropriate vaccine delivery systems must 
be developed.
To achieve these targets, more efforts should be invested in studying the basic 
biology of the P. falciparum parasite and it interactions with the human immune system. 
This thesis describes the activation of the main antigen presenting cells in the human 
immune response, dendritic cells (DCs), and T cells by the cystein rich interdomain 
region-la (CIDR-la), the CD36 binding domain of Plasmodium falciparum erythrocyte 
membrane protein-1 (PfEMP-1), a large variable parasite derived protein expressed on 
the surface of the intact P. falciparum-infected red blood cells (Pf-IRBC). Before a
detailed description of immunity to P. falciparum, a brief description of the human 
immune response to infectious agents is given.
1.6.2 Immune responses to infectious agents
Immune responses to infectious agents can be broadly categorised into innate and 
adaptive responses.
Innate immunity
Innate immunity provides the human (vertebrate) host with the first line of 
defence against infections. Innate immunity was formerly thought to be a non-specific 
response characterised by phagocytosis and the subsequent killing of microorganisms by 
macrophages and leukocytes. However, with the discovery of Toll-like receptors (TLRs), 
which are involved in the recognition of patterns characteristic of groups of 
microorganisms, the role of the innate immune system as a discriminating system has 
been revaluated (reviewed in (Granucci et al., 2004)). It is becoming increasingly clear 
that innate immunity has considerable specificity and is able to discriminate between 
pathogens and self. In addition, the activation of the innate immune response can be a 
prerequisite for the triggering of a specific adaptive immune response (Akira et al., 
2001).
Adaptive immunity
Adaptive immune responses depend mainly on lymphocytes (T and B cells), 
which can provide life-long immunity following exposure to disease or vaccination. Of 
the two functional sets of T cells, CD8 and CD4 T cells, this thesis will focus mainly on 
CD4 T cells which are involved in immunity to blood stage malaria either as effectors or
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by providing help for antibody production by B cells (Langhome et al., 1998b; Wipasa et 
al, 2002), which is the main focus of this thesis.
Adaptive immunity is characterised by the generation of helper CD4 T cell 
subsets and the subsequent production of effector cytokines by these cells as illustrated in 
figure 1.3 (reviewed in (Akira et al, 2001)). Naive CD4 T cells, when stimulated with 
antigens presented by antigen presenting cells (APCs), differentiate into two cell subsets: 
TH1 and TH2. TH1 cells secrete IFN-y and promote mainly cellular immunity, which 
involves destruction of infected cells by cytotoxic T cells, or destruction of intracellular 
pathogens by macrophages activated by TH1 cells. Cell mediated immunity is directed 
principally at intracellular pathogens like Mycobacterium tuberculosis, Mycobacterium 
leprae, Leishmania donovani and Pneumocystis carini all of which are found in the 
vesicles of infected macrophages (Janeway et al., 1999). TH1 cells can also contribute to 
humoral immunity by inducing the production of strongly opsonizing antibodies. TH2 
cells produce IL-4, IL-5, IL-10 and IL-13 and primarily promote humoral immunity by 
activating naive B cells to secrete IgM, and other antibody isotypes including weakly 
opsonizing antibodies such as IgGl and IgG3 (mouse) and IgG2 and IgG4 (human) as 
well as IgA and IgE (mouse and human). All antibody responses are directed at 
extracellular pathogens including Clostridium tetani, Staphylococcus aureus, 
Staphylococcus pneumoniae, Polio virus and Pneumocystis carini which are found in the 
extracellular fluid (Janeway et a l, 1999). However, both cell-mediated and humoral 
immunity are involved in many infections, such as the response to Pneumocystis carini, 
which requires antibody for ingestion by phagocytes and macrophage activation for 
effective destruction of the ingested pathogen. IL-12 drives TH1 differentiation, whereas
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IL-4 induces TH2 differentiation. These two ‘instructive’ cytokines are produced in the 
early phase of infection.
DCs are the main APCs and inducers of the adaptive immune response. The 
activation of DC by pathogens is discussed in the next section, which is then followed by 
a discussion on CD4 T cell activation.
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Figure 1.3
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Regulation o f CD4 T helper cell development by toll-like receptors (TLRs) on 
DCs/antigen presenting cells. Through the recognition o f pathogens or their products, 
TLRs can induce the production o f cytokines such as IL-12 and IL-18 in APCs. These 
cytokine function as “instructive ” cytokines and drive naive T cells to differentiate into 
TH1 cells. Pathogens are also captured in multiple ways, including phagocytosis, 
endocytosis or via TLRs themselves. Captured pathogens are then processed and 
presented to T cells as major histocmpatibilty complex-antigen. For expansion o f antigen 
specific T cell clones, antigen requires concomitant up-regulated expression o f  
costimulatory molecules on the surface of APCs. This up-regulation is triggered by TLR 
signalling. TLRs stimulated APC mainly induce TH1 development. It remains unclear at 
present whether TLRs in APCs are involved in TH2 development. (Adapted from Nature 
immunology 2001 volume 2(8) page 676).
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Activation of DC bv Pathogens or their components
The central role of DCs in the induction of adaptive immune responses to 
infectious agents has been extensively described (Banchereau and Steinman, 1998; 
Steinman, 1991). In addition, a new role of DC as a link between the innate and the 
adaptive immune response has been proposed (Ricciardi-Castagnoli and Granucci, 2002) 
(see figure 1.5). DCs are widely distributed in all the tissues of the body where they 
perform a sentinel function for incoming pathogens and have the capacity to recruit and 
activate cells of the innate immune system in the respective tissues (Fernandez et al., 
1999a; Rescigno et al., 1999; Sallusto et al., 1998). Uptake of pathogens induces a state 
of activation, which lead to migration of the antigen loaded DC to the T cell area of 
secondary lymphoid organs where the antigen specific cells of the adaptive immune 
response can be alerted (reviewed in (Granucci et al., 2004)). Thus understanding the 
interaction of pathogens with DCs, and the early molecular events resulting from this 
interaction, should shed some light on the mechanisms of initiation of the immune 
response to infectious agents and on aspects of the pathogenicity and persistence of 
certain infections. Studies on the interaction between DCs and pathogens may provide 
answers to many key questions regarding how the immune response to infectious agents 
is induced and how to intervene when potentiation or inhibition is required (Granucci et 
al., 2004). Such questions include the identification of receptors involved in the 
internalisation of microorganisms and/or in the activation of DCs, the intracellular 
signalling routes in the DC, and the strategies whereby microorganisms can evade or can 
impede DC function, thus escaping immune recognition.
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Interaction of DCs with pathogens involves sets of germline-encoded receptors 
that are referred to as pattem-recognition receptors (PRRs), which recognise conserved 
molecular patterns (pathogen associated molecular patterns) shared by large groups of 
microorganisms (Akira et al., 2001). Studies performed during recent years have 
demonstrated that TLRs, which comprise a large family of at least 10 members, are the 
most important set of PRRs in mammals. TLRs play an essential role in the recognition 
of microbial components that are not present in mammals but are conserved between 
pathogens, and thereby detect the invasion of microorganisms such as bacteria, fungi, 
protozoa and viruses (Akira et al., 2001; Medzhitov and Janeway, 1997). A second 
functional set of innate receptors expressed by DCs includes phagocytic receptors, such 
as scavenger receptors (including CD36, implicated in immunomodulation in malaria as 
discussed later in section 1.8.2), and mediates pathogen internalization (Rescigno et al., 
2002). The TLR family is also responsible for DC maturation by transducing signalling 
pathways that lead to NF-kB and/or stress-induced kinase activation (Rescigno et al., 
1998b). The signalling pathway via TLRs originates from a conserved cytoplasmic 
Toll/IL-1 receptor (TIR) domain (reviewed in (Takeda and Akira, 2004)). The TIR 
domain containing the adaptor, myeloid differentiation marker 88 (MyD88), is common 
to TLR-mediated-signalling, which leads to the production of inflammatory cytokines by 
DCs. However, individual TLRs may have their own signalling cascades. So far, the roles 
of eight members of the TLR family have been described as illustrated in figure 1.4 
(Takeda and Akira, 2004). The known roles for TLRs are still expanding. There is 
evidence that TLR activation may be involved in protecting mammals from various
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viruses (reviewed in (Akira et al., 2001)). In addition, TLR activation is involved in 
recognition and the subsequent killing of M. tuberculosis (Akira et al., 2001).
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TLRs and their ligands. TLR2 is essential for recognition o f microbial lipopeptides. TLR1 
and TLR6 cooperate with TLR2 to discriminate subtle differences between triacyl and 
diacyl lipopeptides, respectively. TLR4 is the receptor for LPS. TLR9 is essential in CpG 
DNA recognition, whereas TLR3 is implicated in the recognition o f viral dsRNA. TLR5 
recognizes flagellin. Thus, the TLR family members recognize specific patterns o f  
pathogen components. (Adapted from; the innate immune response to infection, ASM  
Press, 2004, Washington, DC, page 258).
Activation of CD4 T cells bv pathogen stimulated DC
DCs form an important link between the innate and adaptive immune arms of the 
immune response by antigen presentation, and the subsequent activation of naive T cells 
as illustrated in figure 1.5. Of great interest, is the observation that DC not only 
upregulate surface costimulatory molecules and exhibit an enhanced ability to present 
antigen but also produce IL-2 in response to various pathogens (Granucci et a l , 2001). 
This is a unique feature of DCs since macrophages failed to produce IL-2 upon bacterial 
activation. DC-derived IL-2 is thought to cooperate with other costimulatory proteins in 
the activation of T cells. Two waves of IL-2 production by DC upon bacterial encounter 
have been observed (reviewed in (Granucci et al., 2004)). The first wave is between 4 
and 8 hours after bacterial uptake, and the second wave is between 14 and 18 hours 
following activation. This timing is compatible with the respective appearance of MHC 
class II peptide and MHC class I peptide complexes at the cell surface (Rescigno et al., 
1998a). Interestingly, DCs are able to present exogenous captured antigens to CD4 T 
cells in a few hours, whereas at least 8 hours is required to process and present bacterial 
antigens in association with MHC class I molecules (Rescigno et al., 1998a). This ability 
of DC to rapidly respond to microbial interaction with IL-2 has also been demonstrated 
with parasites such as Leishmania mexicana or with helminths such as Schistosoma 
(Granucci et al., 2004) suggesting that TLRs activation is involved in immune responses 
to these parasites. Interestingly, only the inflammatory stages of these two parasites, the 
Schistosoma egg or the Leishmania promastigote, are able to induce IL-2 production.
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DCs link innate and adaptive immune responses. Following microbial encounter, 
immature DC increases the efficiency o f antigen presentation and express, with a strictly 
defined kinetic IL-2. At early time points, DC-derived IL-2 helps activate NK cells. At 
later time points, when DCs have not yet reached the final stage o f maturation and still 
express low levels o f costimulatory molecules (CD83 and CD86) and peptide MHC class 
complexes at the cell surface, DC-derived IL-2 cooperates in the activation o f T cell 
responses. CTL, cytotoxic T lymphocyte. (Adapted from; the innate immune response to 
infection, ASM Press, 2004, Washington, DC, page 105).
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The activation of naive T cells requires, in addition to TCR-MHC class II/peptide 
interaction, a second costimulatory signal through CD28, provided by CD80/CD86 
molecules on the DC (APC) (Lenschow et al., 1996). The combination of antigen 
presentation and costimulation induces naive T cells to express IL-2 and its receptor; IL-2 
then induces clonal expansion of the naive T cell and the differentiation of its progeny. 
Late in the proliferation phase of the response, after 4-5 days of rapid growth, these T 
cells differentiate into effector T cells that are able to synthesise all the proteins required 
for their specialised functions as helper T or cytotoxic T cells. Once a T cell has 
differentiated into an armed effector T cell, further encounter with its specific antigen 
results in immune attack without the need for costimulation. Unlike naive T cells, 
effector T cells also express high levels of the cell adhesion molecules LFA-1 and CD2 
and lose their cell surface L-selectin. Instead, they express the integrin VLA-4, which 
allows them to bind to endothelium at sites of inflammation. These changes in the 
adhesion molecules expressed on the surface enable armed effector T cells to enter the 
sites of infection and put their armoury of effector proteins to use.
It has been postulated that the expression of costimulatory molecules must be 
inducible by microbial infection because such regulation would only allow activation of 
T cells specific for pathogen derived, but not self-peptides (reviewed in (Pasare and 
Medzhitov, 2004). The expression of the costimulatory molecules is induced and 
controlled by TLR triggering in DCs. In addition, TLR contributes to T cell activation by 
controlling their suppression by regulatory T cells (Tr). IL-6 is thought to act in concert 
with other DC-derived cytokines on T helper cells to make them refractory to suppression 
by Trs (Pasare and Medzhitov, 2004).
It has been argued that the requirement for the cognate DC-T cell interaction, 
which provides the costimulatory signal, ensures that bystander T cells are not non- 
specifically activated by cytokines produced by DCs during infection (reviewed in 
(Pasare and Medzhitov, 2004)). However, Jianfei Yang and colleagues have 
demonstrated that IL-12 and IL-18 can induce synergistic transcription of IFN-y that is T 
cell receptor independent and not inhibited by cyclosporin A (Yang et al., 1999; Yang et 
al., 2001). Cyclosporin A inhibits TCR-induced IFN-y production, but not IL-12/IL-18 
induced IFN-y production biologically discriminating between the two pathways (Yang et 
al., 1999). In addition, stimulation of naive T cells with a high dose of IL-2 rendered 
these cells responsive to IL-12 and or IL-18 without a requirement for TCR ligation 
(Chakir et al., 2003). IL-12 or IL-18 alone do not induce IFN-y mRNA, and only 
modestly augment antigen induced IFN-y mRNA from TH1 cells (Yang et al.9 1999). 
However, IL-12 and IL-18 together fully induce IFN-y transcription independently of 
TCR activated signals, a mechanism that does not simply involve Stat4 and NFkB 
activation, but also requires additional protein synthesis (Yang et al., 1999). Collectively, 
these studies suggested that DC activation by antigens might result in the stimulation of T 
cells to produce IFN-y via at least two pathways, and that these pathways are functionally 
segregated.
Activation of T cells bv superantigens and mitogens
In addition to activation via the APC by conventional antigens, T cells can be 
activated directly by superantigens and mitogens. Superantigens are not processed by the 
APC but cross-link the MHC class II and the variable p (Vp) chain of the TCR 
independently of a direct interaction between the MHC class II and TCR molecules (Li et
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al, 1999b). Superantigens stimulate whole lymphocyte sub-populations sharing the same 
TCR Vp family independently of antigen specificity. Conversely, mitogens stimulate 
many clones of T (or B) cells irrespective of antigen specificity. Mitogenic stimulations 
are not limited to particular lymphocyte sub-populations.
1.6.3 Innate immunity to malaria 
Genetic resistance to malaria
Highly virulent pathogens like P. falciparum that cause mortality in pre- 
reproductive age groups select for genetic traits that confer resistance to infection or 
disease. It is believed that selection over many thousands of years has led to variation 
between humans in their inherent susceptibility to malaria. Genetically determined 
physiological differences that affect the ability of the parasite to infect and or replicate in 
host cells include sickle cell trait, thalasaemmia, glucose-6-phosphate deficiency and 
ovalocytosis (Allen et al., 1997; Gilles et al, 1967; Miller, 1999; Ruwende et al., 1995; 
Willcox et a l, 1983a; Willcox et a l, 1983b). In addition, certain polymorphisms in 
immune response associated genes have been associated with either protection, or 
susceptibility to P. falciparum infections (reviewed in (Stevenson and Riley, 2004)). 
These genes together with their observed effects on malaria are tabulated in table 1.2 
below.
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Table 1.2: Genetic traits that affect immunity to malaria
Components Trait Gene/
Allele
Effect/mechanism
Serum factors Manose-
binding
lectin
deficiency
MBL Low serum MBL levels associated with increased risk of 
severe malaria (Luty et a l, 1998)
Enzymes Inducible 
nitric oxide 
synthase
NOS2
(iNO)
NOS2A-1659T associated with increased susceptibility to 
cerebral malaria.
NOS2A-954C and NOS2A-1173T associated with protection 
from clinical malaria and severe anaemia, respectively 
(Burgner et a l,  2003; Hobbs et al., 2002; Kun et a l,  2001; 
Luty et a l, 2000)
Cells surface 
molecules
HLA HLA-
Bw53
Associated with reduced risk o f severe malaria (Hill et a l,  
1991)
IFN-y
receptor
IFNGR1
-56
Heterozygous individuals protected from cerebral malaria 
(Koch et al., 2002)
IFN-a
receptor
IFNAR1 17470-G/G and L168V-G/G genotypes associated with 
protection from cerebral malaria (Aucan et a l,  2003)
CD36/scav
enger
receptor
CD36 Promoter polymorphisms associated with protection from 
cerebral malaria; mutations leading to reduced expression 
associated with increased risk of severe malaria; nonsense 
mutation associated with protection from severe malaria 
(Aitman et al., 2000; Omi et al., 2003; Pain et al., 2001b)
CD40L CD40L
726C
X-linked; marked reduction in risk for severe malaria in 
homozygous males (Sabeti et a l, 2002)
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KIR KIR3DL
2
Association with malaria specific IFN-y production by NK 
cells (Artavanis-Tsakonas et al., 2003)
CR1 CR1 SI (a-) red blood cells are unable to form rosettes with P. 
falciparum infected red cells (a virulence factor in falciparum 
malaria) (Chen et al., 1998; Rowe et a l,  1997)
CD31 CD31/P
ECAM
The frequency o f the 125 V/V 563 N/N genotype was 
significantly high in CM patients as compared with severe 
cases without CM (Kikuchi et al., 2001)
Cytokine TNF TNF2 Promoter polymorphism that affects OCT1 binding increases 
susceptibility to cerebral malaria (Knight et al., 1999; 
McGuire et a l, 1994)
IL-4 IL-4-
524T
Increased malaria-specific antibody levels (Luoni et al., 2001)
IL-12p70 IL-12B Promoter polymorphism leading to decreased IL-12 
production associated with increased mortality in Tanzanian 
but not Kenyan children (Morahan et al., 2002)
This table was modified from (Stevenson and Riley, 2004) and all the data apply to P. 
falciparum.
Innate immune responses control acute asexual blood stage parasitaemia
There is longstanding evidence suggesting that the survival of mice infected with 
various Plasmodium species is strongly linked to their ability to control the replication of 
blood stage parasites within the first 7 - 1 4  days after infection (reviewed in (Stevenson 
and Riley, 2004)). During infection with P. chabaudi AS, for instance, it is clear that 
control of the primary peak of parasitaemia occurs before the production of marked levels 
of specific IgG antibodies suggesting that non-adaptive immune effector mechanisms are 
involved in parasite clearance (Stevenson and Riley, 2004). Even though CD4 T cells are
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necessary for the resolution of parasitaemia, there is accumulating evidence that innate 
immune responses operate to control the first peak of parasitaemia. For example, in the 
absence of natural killer (NK) cells, peak parasitaemia is higher during acute infection 
and there is marked recurring parasitaemia during the chronic phase (Mohan et al., 1997).
It is also evident that early IFN-y production by NK cells is associated with 
spontaneously resolving infection in mice infected with various species of plasmodium, 
whereas such infections are lethal in the absence of early IFN-y production by NK cells 
and possibly yS T cells (Mohan et al., 1997). Recent evidence from clinical studies 
support the observations made in mice indicating that innate immune responses 
contribute to the control of the primary peak of parasitaemia in humans.
Reanalysis of the clinical records of repeated infections in non-immune 
neurosyphililis patients that were treated with malaria induced fevers between 1940 and 
1963 at the National Institutes of Health Laboratories, Columbia, USA, showed that the 
density of parasitaemia at which parasite growth is controlled is highly predictable in an 
individual, and is independent of the strain or species of infection. The authors concluded 
that this data is best explained by the induction of innate immune mechanisms 
(Molineaux et al., 2002). In other words, they suggested that humans might vary in their 
ability to make a rapid innate immune response that acts to control parasitaemia before 
the onset of adaptive immune responses.
Hermsen and colleagues (Hermsen et al., 2003) recently showed that malaria 
naive individuals experimentally infected with P. falciparum already had a coordinated 
increase in the levels of pro-inflammatory cytokines IFN-y, IL-12p70 and IL-18 
(normally made by cells of the innate system) in the serum at the first appearance of Pf-
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iRBCs in the blood. These data are in support of in vitro studies that have shown that Pf- 
iRBCs induce TNF, IL-12p70 and IFN-y production in peripheral blood mononuclear 
cells (PBMC) of naive donors within 10 hours of stimulation (Scragg et al., 1999). In 
addition, it has been suggested in a mathematical model, that innate immune mechanisms 
are triggered when the parasite density crosses a predefined threshold which leads to 
oscillation of Pf-iRBC densities between a lower level (at which innate responses are not 
triggered) and a higher level (at which innate responses are triggered and partially clears 
parasitaemia) in individuals exposed to repeated infections (Kwiatkowski and Nowak,
1991). This model is supported by recent observations from a large longitudinal study of 
multiple species and genotypes conducted in asymptomatic children in Papua New 
Guinea (Bruce and Day, 2003). The authors proposed that the mechanism underlying the 
species independent density dependent regulation of parasitaemia around a threshold 
observed in these semi-immune children could involve chemicals released during innate 
inflammatory responses. Collectively, these data suggest that innate immune mechanisms 
are triggered early in an infection and act to limit the maximum parasite density, but 
gradually adaptive immune responses are required for complete parasite elimination. In 
that case, innate responses lower the virulence of the infection and therefore reduce the 
likelihood of early host death, increasing the chance that the parasite will be transmitted .
The fact that density-dependent mechanisms seem to limit the growth of all blood 
stage parasites irrespective of species or strain, suggest that innate immunity is triggered 
by molecules that are conserved between species and strains. Such ligands and their 
receptors are just beginning to be characterised (Adachi et al., 2001; Robinson et al., 
2003; Serghides et al., 2003; Urban et a l, 1999). Activation of DCs and possibly
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macrophages might be one of the earliest events in the innate response to malaria. DCs 
might interact with parasite ligands via toll like receptors (TLR) and other pattern 
recognition receptors. The potential for TLR mediated signals to contribute to anti­
parasite mechanisms has been shown in studies where unmethylated CPG moieties 
conferred resistance to sporozoite induced infections in mice (Gramzinski et al., 2001). 
Studies in both humans and mice indicate an important role for mononuclear phagocytes 
in innate immunity to malaria due to their ability to phagocytose Pf-iRBC in the absence 
of opsonizing antibodies (Serghides et al., 2003). Studies by Kain and colleagues 
indicated an important role for CD36 in opsonin-independent phagocytosis of Pf-iRBC 
by monocytes from malaria-unexposed donors (Serghides et al., 2003). In addition, DCs 
and macrophages function as antigen presenting cells in malaria, thereby inducing 
adaptive immune responses. Macrophages are also thought to be important effector cells 
in the adaptive immune response by mediating antibody dependent cellular inhibition or 
producing antiparasite molecules like NO after activation by IFN-y (reviewed in (Good, 
2001)).
1.6.4 Acquired immunity to malaria
Despite decades of research, naturally acquired immunity to malaria is still poorly 
understood. It rarely if ever provides sterile immunity but is highly effective at 
moderating the clinical effects of infection and reducing mortality. In areas of intense, 
perennial transmission, the main load of malarial disease is experienced by children, 
adolescents and pregnant women, and a degree of immunity to severe, life threatening 
malaria is apparent only after a few disease episodes and is essentially complete by the 
age of five years (Gupta et al., 1999). However, the vast majority of adults may have low
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levels of circulating parasites and yet few will have mild, if any, symptoms. Defining the 
immunological components of both clinical protection and anti-parasite immunity has 
proved difficult.
Immune mechanisms against the pre-ervthrocvtic stage
Despite the fact that immune mechanisms completely protect both humans and 
animals from malaria in the irradiated sporozoite vaccine model (discussed in section 
1.6.4) sterile immunity in humans to this stage of infection is not known to occur under 
natural conditions. A lot of work has been done in animal models to elucidate these 
mechanisms. It was originally thought that pre-erythrocytic immunity was mediated by 
antibodies that neutralized the sporozoite infectivity of the hepatocyte (reviewed in 
(Nussenzweig and Nussenzweig, 1989)). However, the sporozoite only circulates in 
blood for 20-30 minutes before entering the hepatocyte which means that antibody 
meditated protective immunity is unlikely to be completely effective (Saul, 1987) unless 
antibody is present at very high titre. It is now generally accepted that the intra-hepatic 
Plasmodium parasite is also an important target for protective immunity directed at the 
pre-erythrocytic stage (Hoffman et al., 1996). Evidence from mouse models suggests that 
these responses are primarily mediated by CD8 T cells. In vivo depletion of CD8 T cells 
completely abrogates protection, while adoptive transfer of CD8 T cells to naive mice 
confers protection (Good et a l , 1988; Hoffman et al., 1996). Furthermore, (3-2- 
microglobulin-/- mice, which lack MHC class I are not protected by either active 
immunisation or passive transfer of wild type, splenic T cells from immune mice (White 
et al., 1996). These observations led investigators to conclude that CD8 T cells were 
mainly responsible for protection.
Later studies associated IFN-y and NO production with protective immunity 
(Hoffman et al., 1996). In vitro treatment of Plasmodium spp infected hepatocytes with 
IFN-y eliminated P. berghei or P. falciparum parasites from culture while in vivo 
administration of IFN-y partially protected against sporozoite challenge with P. berghei 
in mice, and P. cynomolgi in monkeys (Hoffman et al., 1996). In vivo depletion of IFN-y 
led to abrogation of protective anti-sporozoite immunity. Additionally, it was 
demonstrated that IFN-y induces the production of nitric oxide in vitro and in vivo 
following P. berghei, P. yoelii or P. falciparum sporozoite infection. It is now well 
established that protection in mice induced by immunisation with irradiated P. berghei 
(Schofield et al., 1987; Seguin et al., 1994) or P. yoelii (Doolan and Hoffman, 1997) 
sporozoites is absolutely dependent on CD8 T cells, IFN-y and nitric oxide. These data 
suggested that the protective mechanism involves activated CD8 T cells secreting IFN-y, 
which subsequently activates iNOS (inducible nitric oxide synthase) and L-arginine- 
dependent nitric oxide pathway. More recently, IL-12 and NK cells involvement in this 
mechanism has been demonstrated (Hoffman et al., 1997).
An alternative mechanism involving CD4 T cells has also been proposed. This 
mechanism is based on data from immunisation of mice with linear peptides derived from 
P. yoelii proteins PySSP2 or PyHEP17 which conferred solid protective immunity 
mediated by CD4 T cells and was completely dependent on IFN-y (Charoenvit et al., 
1995). ybT cells are also thought to have a protective role against the liver stages of the 
malaria parasite. It was shown that ap  T cell-deficient mice immunised by the bites of 
irradiated Plasmodium-infected mosquitoes could mount a response that conferred partial 
protective immunity against sporozoite challenge (Tsuji et al., 1994). When yb T cells
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were depleted from these sporozoite-immuinised a p  T cell-deficient mice using a 
specific MAb, the protective immunity was almost completely abolished. Further studies 
on the protective role of these cells have shown an enhanced liver stage infection in yb T 
cell-deficient mice (McKenna et al., 2000).
Immune mechanisms against the erythrocytic stage
The data collected between 1940 and 1963 from the treatment of neurosyphilis 
with malaria infections provided direct experimental evidence of acquired immunity in 
humans (Covell and Nicol, 1951; Jeffery, 1966). In these studies, infection with either P. 
falciparum or P. vivax led to species-specific immunity, which either moderated or 
prevented subsequent infections. This protection was most effective with the homologous 
parasite strain although also to some extent the heterologous strain (Covell and Nicol, 
1951; Jeffery, 1966).
The malaria life cycle has various points of weakness during which the naturally 
acquired immunity might act either to limit the replication of the parasite or to disrupt 
pathogenesis. Antibodies, for instance,, may block merozoite invasion of red cells by 
neutralizing any of several molecular interactions required for successful invasion, or 
agglutination of merozoites. Antibodies directed to the antigens on the surface of infected 
red cell may target the Pf-iRBC for complement mediated lyses or phagocytosis (Perraut 
et al., 1995). These antibodies may also prevent or reverse adherence of mature Pf-iRBC 
to the endothelium and thus prevent sequestration and in the process enhance splenic 
clearance and reduce disease severity (David et al., 1983; Smith et al., 2000). It has also 
been suggested that antibodies interacting with merozoite surface proteins might interact 
with mononuclear cells leading to release of soluble immune effectors that kill the intra-
erythrocytic parasite (Bouharoun-Tayoun et al., 1995). Toxic substances (malaria toxin) 
released when mature schizonts rupture might be neutralized by antibodies thereby 
interfering with pathogenesis of disease (Bate et al., 1992). Finally, antibodies to sexual 
stages may reduce gametocytemia in the host (Naotunne et al., 1991), or inhibit 
fertilization and oogenesis in the mosquito (Carter, 2001).
Identification of immune effector mechanisms active in naturally acquired immunity 
to this stage of the parasite has been difficult. One particular difficulty is the fact that 
mechanisms that mediate immunity to blood stage infection seem to vary with particular 
host-parasite combinations. For example, P. yoelii and P. berghei infections were not 
controlled in B cell depleted mice (Roberts and Weidanz, 1979; Weinbaum et al., 1978) 
while P.c. chabaudi, P.c. adami and P. vinckei are partially controlled (Cavacini et al., 
1990; Langhome et al., 1998a; van der Heyde et dl., 1996; von der Weid and Langhome, 
1993) suggesting that, although antibodies are critical for clearing infections, different 
parasite species vary in their susceptibility to non-antibody mediated mechanisms. 
However, there is long standing evidence from human studies suggesting that antibodies 
play a major role in naturally acquired immunity.
Humoral immunity to the ervthrocvtic stage
Perhaps the strongest evidence yet that antibody has an important anti-parasitic as 
well as an anti-disease effect comes from the adoptive transfer of immune serum into 
malaria naive individuals in the 1960s. Cohen and colleagues (Cohen et al., 1961) 
purified y-globulin from adult Gambians and transferred these preparations into 12 
Gambian children with high P. falciparum parasitaemia by intramuscular injections. This 
treatment resolved fevers and either eliminated or reduced parasitaemia in these children
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by a factor of 104 while non-immune y-globulin had no effect. Similar results were 
obtained in Nigeria in 1962 (Edozien et al., 1962). A third passive transfer experiment 
was carried out to find out whether this transferred immunity was specific to local 
parasite strains. Purified y-globulin from West African adults was adoptively transferred 
into East African children with similar results (McGregor and Carrington, 1963). These 
studies were reproduced and extended further in 1991, when purified y-globulin prepared 
from immune West African adults was adoptively transferred into Thai children 
(Sabchareon et al., 1991). In both cases, parasitaemia was reduced. The findings that both 
East African and Thai children could be treated with purified y-globulin from immune 
West African adults suggest that either there may be few regional differences in the 
distribution of parasite variants (Conway et al., 1992; Jongwutiwes et a l, 1994) or that 
the protective epitopes recognized by antibody are not strain specific.
Data from in vitro studies suggested that the protection seen in the passive transfer 
model was mediated by cytophilic antibodies that interact with monocytes. In an antibody 
dependent cellular inhibition assay (ADCI), the protective IgG did not inhibit parasite 
growth and invasion in vitro when added alone to cultures, but did so when added in the 
presence of mononuclear cells from malaria naive donors (Bouharoun-Tayoun et al., 
1990). In contrast, IgG preparations from healthy European donors, European adults with 
a primary infection of malaria and the Thai passive transfer recipients prior to receiving 
the transferred antibody were inactive in ADCI. Compared to sera from non-immune 
groups (French blood donors and travellers suffering from a primary malaria attack), the 
protective and ADCI active sera were found to have high levels of the cytophilic 
antibodies IgGl and IgG3 and relatively lower levels of IgG2 and IgM (Bouharoun-
Tayoun and Druilhe, 1992a, b). IgG3 was associated with reduced frequency of malaria 
attacks in Senegal further strengthening the hypothesis that cytophilic IgG participates in 
protective mechanisms (Aribot et al., 1996). It has been suggested that the mechanism 
underlying ADCI involves the interaction of merozoites or Pf-iRBC with antibody and 
monocytes leading to the release of soluble mediators) responsible for parasite killing 
(Bouharoun-Tayoun et al, 1995). This finding is supported by others that have 
investigated the ability of soluble mediators to kill intra-erythrocytic parasites, which 
suggest that TNF may be an important effector molecule in the elimination of Pf-iRBC 
(Butcher, 1990; Naotunne et al., 1991). The activity of the soluble mediator was inhibited 
by anti-TNF antibodies but could not be mimicked by purified recombinant TNF 
suggesting that other mediators are also required (Bouharoun-Tayoun et al., 1995). 
However, ADCI is not the only mechanism that could explain the massive reduction in 
parasitaemia observed in the passive antibody transfer experiments described above. In 
contrast to the observation by Bouharoun-Tayoun (1990), other studies have 
demonstrated that immune IgG can inhibit parasite growth in vitro in the absence of 
adherent cells (Brown et al., 1982; Cohen et al., 1969).
Cellular immunity to the erythrocytic stage
During the erythrocytic stage, the malaria parasite spends most of its time in the 
red blood cell. Red blood cells do not express appreciable levels of either MHC class I or 
class II and it is therefore unlikely that parasite antigens would be presented by Pf-iRBC 
to induce T cell activation. However, antigen presentation by antigen presenting cells, 
particularly DCs and macrophages will result in T cell activation which will in turn make 
cytokines that will either have a direct or indirect effect on parasite killing. T cells may
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also provide help for the production of antibody. Most of the available evidence for a role 
of T cells in blood stage malaria comes from animal models and in vitro T cell 
stimulations using PBMC from people living in malaria endemic areas. Perhaps the 
strongest evidence to date that CD4 T cells have a protective role in human naturally 
acquired immunity to malaria comes from very recent immunoepidemiological data on 
malaria-HIV interactions (as described further in page 38) (French and Gilks, 2000; 
French et al., 2001; Moore et al., 2000; Mount et al., 2004; Whitworth et a l, 2000).
It is clear from murine malaria models that CD4 T cells provide help to B cells to 
make protective antibodies. B cell deficient mice failed to control P. yoelii parasitaemia 
(Weinbaum et al., 1978), and protection from challenge in naive-irradiated mice could be 
transferred by a mixture of immune CD4 T and B cells (Jayawardena et a l, 1982). In the 
P. c. chabaudi and P. c. adami models, infection can be controlled up to an extent in mice 
depleted of B cells by treatment with anti-p antibodies (Grim and Weidanz, 1981; von der 
Weid and Langhome, 1993) or by gene targeting (Langhome et al., 1998a; von der Weid 
et al., 1996). Furthermore, mice lacking CD4 T cells suffer persistent parasitaemia that 
can be controlled by adoptive transfer of immune CD4 T cells (Brake et a l, 1986; 
McDonald and Phillips, 1978; Suss et al, 1988). Complete resolution of parasitaemia is 
dependent on B cells in the P. chabaudi model (Grun and Weidanz, 1981; Langhome et 
al., 1998a; von der Weid and Langhome, 1993; von der Weid et al., 1996). During the 
acute phase, the responding T cells are predominantly TH1 which are thought to act by 
inducing cell mediated parasiticidal mechanisms and there is a shift to a TH2 phenotype 
later in the infection reflecting the importance of CD4 T cell help to B cells in order to 
make antibodies to eliminate parasitaemia (Langhome et al., 1989; Stevenson and Tam,
1993). There is some evidence that y8-T cells are activated and may have a role in the 
control of P. chabaudi infections. In both normal (Langhome et al., 1993; van der Heyde 
et a l, 1993) and B cell deficient (van der Heyde et a l, 1996) mice there is marked 
expansion of y8-T cells following resolution of parasitaemia and the removal of y8 T cells 
from pMT mice increased susceptibility (Seixas and Langhome, 1999). Additionally, 
mice lacking y8-T cells took slightly longer to control parasitaemia than normal mice 
(Langhorne et al., 1995). However, other studies have failed to reproduce these 
observations. There was no effect, for instance, of y8-T cell depletion on a P. chabaudi 
model or in a P. yoelii 17XNL infection in TCR-8 chain double mutant model (Tsuji et 
a l , 1994). Collectively, these studies in murine models suggest that the major function of 
T cells is the provision of help for B cells to produce antibody.
Studies on T cell responses in humans are mainly restricted to identifying 
responses to various malarial antigens in peripheral blood of patients and semi-immune 
residents of endemic areas. These studies are often difficult to interpret because of a 
number of factors. Firstly, T cells from malaria non-exposed donors that are normally 
used as controls may proliferate in response to malaria antigens (Currier et a l , 1995; 
Good, 1994; Goodier et a l, 1992; Zevering et al., 1992). Malaria specific T cell 
responses, independent of previous exposure to malaria were found at high frequencies 
and they sometimes exceeded responses to tetanus toxoid in magnitude (Zevering et al.,
1992). These cells are thought to have arisen from cross-reactivity with other common 
environmental microorganisms. The biological relevance of such pre-existing malaria 
specific T cells in a malaria infection are not known but there have been suggestions that 
they could contribute to disease (Good and Zevering, 1994). However, it has also been
demonstrated that T cells from malaria non-exposed donors have the potential to 
eliminate malaria parasites in vitro via non-IFN-y mechanisms (Fell et al., 1994). 
Secondly, malaria specific T cells may sequester in lymphoid organs during on going 
infections resulting in the poor responsiveness often encountered in peripheral blood 
mononuclear cells (PBMC) collected in field studies (Hviid et al., 1991; Langhome and 
Simon-Haarhaus, 1991).
There is evidence that T cells from malaria-exposed donors proliferate and produce 
cytokines in response to malaria antigens (reviewed in (Troye-Blomberg, 1994)). A 
limited number of studies have reported in vitro data using T/B cell cooperation assays 
suggesting that CD4 T cells give help to B cells resulting in antibody production. 
Stimulation of T/B cell mixtures from patients with acute malaria with crude P. 
falciparum extracts or with partially purified RESA antigen led to the production of 
antibodies against Pf-iRBC (Kabilan et al., 1987). T/B cell mixtures from endemic area 
residents also produced anti-RESA antibodies when stimulated with, peptides 
corresponding to a T cell epitope from RESA (Chougnet et al., 1991). There is also 
limited evidence that CD4 T cells may have an effector role beyond giving help to B cells 
in malaria. It has been demonstrated that fractionated P. falciparum specific CD4 T cells 
in the presence of adherent cells can inhibit parasite growth in vitro (Fell et al., 1994). It 
has also been suggested that CD4 T cells may produce IFN-y in response to malaria 
antigens and that this IFN-y may potentiate the ADCI effect demonstrated with protective 
sera from clinically immune individuals (Bouharoun-Tayoun et al., 1995). More recently, 
experimental P. falciparum malarial infections were initiated in non-immune volunteers 
aimed at inducing anti-parasite cell mediated immune responses (Pombo et al., 2002).
After repeated challenges with numbers of blood stage P. falciparum followed by 
extended periods without drug cure, volunteers were protected against malaria as 
evidenced by the absence of clinical symptoms, parasitized red cells and parasite DNA in 
their blood. This protection was characterised by the absence of detectable antibodies in 
the blood but by the presence of a proliferative T cell response, involving both CD4 T 
and CD8 T cells, IFN-y production, high concentrations of nitric oxide synthase activity 
in PBMC and a drop in the number of NK cells. The results of this study do suggest an 
important role for T cells and possibly T cell derived IFN-y in mediating protective 
mechanisms in vivo.
y8-T cells are activated in human P. falciparum infections but there is no evidence 
that they participate in naturally acquired immunity to malaria. The frequency and 
number of y8-T cells in the peripheral circulation increases markedly in the malaria naive 
patient following a P. falciparum infection (Chougnet et al., 1992; Ho et al., 1994; 
Roussilhon et al., 1994). However, such an expansion was not observed in children 
exposed to endemic malaria in West Africa (Hviid et al., 1996). Proliferation of y8-T 
cells in in-vitro cultures of non-exposed PBMC stimulated with malaria antigens has also 
been demonstrated (Goodier et al., 1992; Goodier et al., 1993). This in vitro proliferation 
of y8-T cells, just like that found in mice infected with P. c. adami, depends on CD4 T 
cells (Elloso et al., 1996; Jones et al., 1996).
The accumulation of evidence for the involvement of CD4 T cells in naturally 
acquired immunity to malaria has been further enhanced by epidemiological studies on 
the interaction between malaria and HIV-1. HIV-1 has been associated with increased 
frequency of clinical malaria and parasitaemia in an adult cohort in Uganda (French et
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al., 2001; Whitworth et al., 2000), and pregnant women in Malawi (Mount et al., 2004; 
Mwapasa et al, 2004; Steketee et al, 1996) and Kenya (Chaisavaneeyakom et a l, 2002; 
Moore et al., 2000). In each of these studies, this association was more pronounced with 
increased depletion of CD4 T cells. HIV was also found to impair IgG antibody 
responses to pregnancy malaria associated variable surface antigens (VSA) and AMA1 
(Mount et a l, 2004), and anti-P. falciparum IFN-y production by intervillous blood 
mononuclear cells in pregnant women (Chaisavaneeyakom et a l, 2002; Moore et a l, 
2000). Collectively, these data underlines a critical role for CD4 T cells in mechanisms 
that mediate anti-malarial immunity during the asexual blood stage cycle in people who 
are naturally exposed to endemic malaria.
1.7.0 Malaria vaccines
Malaria vaccines have been broadly divided into three main groups according to the 
parasite stage they target: pre-erythrocytic stage, blood stage and sexual stage. Different 
antigens are expressed at each of these stages and an effective vaccine may need to 
combine antigens from different stages to form a multicomponent vaccine. The rapid 
development of molecular biology and particularly recombinant DNA technology and 
genome mapping in recent years has opened up the possibility of constmcting malaria 
epitopes and recombinant protein based vaccines. Due to the limitation of space and 
scope of this thesis, only blood stage vaccines will be mentioned.
Blood stage vaccines
The feasibility of blood stage vaccines is highlighted by naturally acquired immunity, 
passive antibody-transfer experiments and repeated experimental immunisations with Pf- 
iRBC. These vaccines particularly are targeted to severe disease and death. In areas
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where malaria transmission is high, individuals that survive past the age of five will only 
get either mild disease or asymptomatic parasitaemia on re-infection but rarely severe 
disease or death. This decrease with age of the incidence of P. falciparum infections, the 
density and prevalence of parasitaemia, and morbidity and mortality associated with P. 
falciparum infections is consistent with anti-malarial immunity in humans (Baird, 1998; 
Snow et al., 1998). Thus in addition to the artificial immunisation experiments in humans 
with live Pf-iRBC (Pombo et al., 2002), and the passive antibody transfer experiments 
(Cohen et al., 1961; McGregor, 1964; Sabchareon et al., 1991) of the early 1960s, 
epidemiological studies provide overwhelming evidence that natural immunisation can be 
effective against blood stage malaria.
1.8.0 Asexual erythrocytic stage immune targets
The genomic sequence of P. falciparum has now been published offering 
vaccinologists 5300 gene products to study and target as possible vaccine candidates 
(Gardner et al., 2002). This large number of possible proteins underlines the complexity 
of the malaria parasite and perhaps also of its relationship with the human host. It is no 
wonder that we still do not understand the mechanisms that mediate naturally acquired 
immunity despite so many decades of work. A number of different P. falciparum 
antigens expressed during the asexual blood stage of malaria have been well 
characterised and a number of them are leading vaccine candidates. Figure 1.6 shows 
where in the asexual blood stage cycle these antigens are expressed. In this section, a 
brief description of immune studies on the best characterised merozoite surface antigens 
(MSP) is given followed by a review of studies on Plasmodium falciparum derived
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variable antigens found on the P. falciparum infected red cell surface, one of which is the 
subject of this thesis.
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Figure 1.6 Microneme
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Schematic representation o f the location o f target antigens for protective immune 
responses to the asexual blood stage o f P. falciparum. EBA, erythrocyte binding antigen; 
MSP, merozoite surface antigen; PfEMP-1, Plasmodium falciparum erythrocyte 
membrane protein-1; RAP, rhoptry associated protein; RBC, red blood cell; RESA, ring 
erythrocyte surface antigen. (Modifiedfrom Wipasa, 2002)
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1.8.1 Immune targets on the Merozoite surface
Merozoites are susceptible to immune attack although only briefly between 
schizont rupture and the invasion of a new red cell. Merozoite Surface Protein 1 (MSP-1) 
is the best characterised of those antigens expressed on the merozoite surface and is 
thought to play a vital role in the binding to and invasion of erythrocytes by merozoites 
(Cowman and Crabb, 2002). Several studies have demonstrated associations of antibody 
titres to MSP-1 with protection in both animal immunisation experiments (Daly and 
Long, 1995; Hall et a l., 1984; Long et a l., 1994; Siddiqui et a l., 1987) and natural human 
populations (Branch et a l., 1998; Conway et a l., 2000; Egan et a l., 1996; Fruh et a l.,  
1991; Riley et a l ,  1992). Merozoite surface protein 2 (MSP-2) is a 42-kDa protein that 
exists in two allelic families: 3D7/CAMP and FC27. MSP-2 has five sequence blocks, 
with relatively conserved blocks 2 and 4 flanking a variable block 3 that defines the two 
alleles. Evidence for immunogencity and protective immune responses to MSP-2 comes 
from animal models (Saul et a l ,  1992) and immuno-epidemiological surveys (al-Yaman 
et a l., 1997; Al-Yaman et a l., 1997; Genton et a l., 2002; Rzepczyk et a l ,  1997; Taylor et 
a l . ,  1998). Another well characterised merozoite stage antigen is Apical Membrane 
Antigen-1 (AMA-1), an 82-kDa antigen that originates from the apical end of the 
merozoite before being transported to its surface. Immunisation experiments in animals 
(Collins et a l., 1994) and antibody measurements in samples from exposed donors 
(Ockenhouse et a l., 1998; Thomas et a l., 1994) suggest that this protein is highly 
immunogenic and hence an important target for immune responses.
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1.8.2 Parasite derived variable surface antigens (VSA) on the P. falciparum 
infected red cell (Pf-iRBC)
P. falciparum can be distinguished from other Plasmodia that infect humans 
because only immature, ring infected erythrocytic forms circulate in the peripheral blood. 
Mature erythrocytic forms (schizonts and trophozoites) bind to vascular endothelium 
through parasite-induced modifications of the red cell surface that enable them to be 
sequestered in the post-capillary venules and avoid elimination by the spleen. These 
modifications include insertions of parasite-derived proteins into the erythrocyte 
membrane, which are organized into structures called knobs. The particular virulence of 
P. falciparum has been partly attributed to the ability of these proteins to mediate Pf- 
iRBC adherence to variety of host receptors and escape from immune clearance. 
Accumulation of Pf-iRBC in the placenta during pregnancy may contribute to low 
neonatal weight and high maternal and infant mortality, and infected red blood cells 
bound to vessels in the brain may contribute to severe complications in cerebral malaria.
Parasite derived proteins on the Pf-iRBC surface are highly diverse and variable 
and are thought to mediate antigenic variation, a process responsible for causing chronic 
infections, a characteristic feature of human and simian malaria. These observations gave 
investigators sufficient reason for the exploration of the molecular basis of the 
cytoadherence and antigenic variation of Pf-iRBC. Due to their variant nature, these 
proteins are hereby collectively referred to as VS A (variant surface antigens) for the 
purposes of this discussion. To date at least three different highly variable families of P. 
falciparum proteins associated with the surface of Pf-iRBC have been described. Three of 
these proteins, together with band 3, a red cell membrane anion transporter modified by
P. falciparum infection are hereby briefly described followed by a detailed description of 
antigenic variation and P. falciparum erythrocyte membrane protein-1 (PfEMP-1) which 
consist of various domains including CIDR-la, the main subject of this thesis.
Rifins (repetitive interspersed family of genes)
The repetitive interspersed family of genes (rif) encode a group of 30-45 kDa 
proteins. There are 200 -  500 rif genes per a haploid genome, which are expressed 14 — 
16 hours post-invasion. They were originally referred to as rosettins because they were 
associated with rosetting Pf-iRBC lines but recent studies have shown that they are not 
always associated with the rosetting phenotype (Fernandez et al., 1999b). Rifins are 
found in all clinical isolates, are trypsin resistant and antisera raised against the deduced 
amino acid sequence immunoprecipitated proteins of the expected molecular size from 
Pf-iRBC material (Fernandez et al., 1999b; Kyes et al, 1999). A recent study suggests 
that rifins may not be on the Pf-iRBC surface since antibodies raised against rifins can 
stain antigens present in permeabilized Pf-iRBCs but the same antibodies do not bind to 
intact Pf-iRBC (Abdel-Latif et al., 2002). In addition mass spectrometry data suggests 
that rif genes are preferentially expressed at the sporozoite stage and not the red cell stage 
(Chen et al, 1998). The precise function of rifins is unknown.
Subtelomeric variant open reading frame (STEVORI
STEVOR belong to a multi-gene family with a highly characteristic distribution at 
the subtelomeric ends of each chromosome (reviewed in (Craig and Scherf, 2001)). The 1 
KB stevor gene is transcribed in both asexual and sexual stages and the protein product 
can be localized in maurer’s clefts (Kaviratne et a l, 2002). There is no published data yet 
showing that this protein goes to the surface of the Pf-iRBC.
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Deletion of clag 9 (cytoadherence linked asexual gene) has been associated with 
the loss of the ability to cytoadhere in certain P. falciparum lines maintained in vitro 
(Day et al., 1993). This gene is located on chromosome 9 and is transcribed in mature 
stage Pf-iRBC and translated into a 220 kDa protein but distinct from PfEMP-1. Artificial 
disruption of this gene abolished adherence (Holt et a l, 1999). It is hydrophobic with 
four predicted transmembrane domains, which suggests that it is associated with the Pf- 
iRBC membrane and presumably exposed to the surface (Trenholme et al., 2000). This 
was confirmed by the fact that anti-clag 9 antibodies labelled the Pf-iRBC surface and 
inhibited binding to CD36.
Sequestrin
Sequestrin is a 270-kDa protein that was first identified in a knobless 
cytoadherent line using an anti-idiotype antibody to the anti-CD36 MAb OKM8 
(Ockenhouse et a l, 1991). It is similar to PfEMP-1 in that it can be surface labelled with 
iodine, is Pf-iRBC specific and has a similar molecular size. However, unlike PfEMP-1 it 
is reportedly antigenically conserved among all isolates and insoluble in Triton X-100 
(Ockenhouse et al., 1991). For now, there is no published sequence of sequestrin.
Band 3
Unlike the other neo-antigens associated with the Pf-iRBC membrane, band 3 is 
not of parasite origin. Band 3 is a truncated (modified) form of an intrinsic red cell 
membrane anion transporter but is specific to Pf-iRBC (Crandall and Sherman, 1991, 
1994; Maguire et al., 1991). Human band 3 residues 546-553 and 824-829, located in 
putative exfocal loops were able to block Pf-iRBC adhesion to C32 amelanotic melanoma
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cells in a dose dependent manner as did antibodies to these sequences (reviewed in 
(Sherman et al., 2003)). When infused into Aotus or Saimiri monkeys infected with P. 
falciparum, large numbers of trophozoites and schizonts were observed in peripheral 
blood 24 hours post-infusion suggesting that these peptides delayed or reversed 
sequestration (Crandall et al., 1993). These cytoadherence blocking peptides of band 3 
were termed pfalhesin. It is thought that the amino acid sequence for pfahelsin is cryptic 
in normal human red cells and comes to the surface (by some undefined mechanism) as 
the parasite grows. The endothelial cell receptors for pfahelsin have been identified as 
TSP and CD36 (Eda et al., 1999).
Antigenic variation and the discovery of Plasmodium falciparum ervthrocvte membrane 
protein (TfEMPVl
The demonstration that P. knowlesi schizont-infected red cells (Pk-iRBC), and not 
non-infected red blood cells, could be agglutinated by serum from rhesus monkeys 
infected with P. knowlesi (Eaton, 1938) initiated a series of investigations that culminated 
in the precipitation of, and naming of PfEMP-1 in 1984 (Leech et al., 1984). This 
schizont-infected cell agglutination reaction, called SICA, showed that the antigenicity of 
the PkiRBC was altered by the presence of the parasite and that SICA was both species 
and stage specific. Eaton and colleagues also showed that there was serial expression of 
antigenic types and that immunity was due to the development of variant specific 
opsonising antibodies (Eaton, 1938). It was suggested that antigens of parasite origin on 
the surface of PkiRBC were responsible for SICA.
Using SICA, Brown and colleagues were able to show that recrudescent P. 
knowlesi parasites from a single inoculum in rhesus monkeys differed in their antigenic
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type (Brown et al., 1986; Brown and Brown, 1965; Brown et al., 1970). Since the earlier 
experiments were done with uncloned parasites, Barnwell and colleagues repeated these 
experiments to rule out the possibility that the change in antigenicity was a result of 
immune selection rather than clonal antigenic variation using cloned P. knowlesi parasite 
lines and obtained similar results (Barnwell et a l, 1983a). Collectively, these data 
demonstrated that P. knowlesi has the genetic capacity to vary the antigenic determinants 
on the surface of the PkiRBC with time. The same phenomenon of clonal antigenic 
variation has also been demonstrated for P. fragile in the toque monkey, P. chabaudi in 
mice, and for P. falciparum in Saimiri monkeys (reviewed in (Kyes et al., 2001)).
Immunoprecipitation and metabolic labelling revealed the SICA antigens to be of 
high molecular weight, polymorphic and of parasite origin distributed evenly on the 
PkiRBC (Howard et al., 1983). The SICA antigens were trypsin sensitive, accessible to 
surface iodination and insoluble in ionic detergents (Howard and Barnwell, 1984). Serial 
passage of PkiRBC in splenectomised animals gave rise to parasites that no longer 
expressed the surface antigens but were able to re-express the antigen when transferred 
back into intact animals (Barnwell et al., 1982, 1983b). This observation suggested that 
the spleen mediated the expression of VSA (Barnwell et al., 1983a).
In 1984, a similar protein was metabolically labelled and radio iodinated on the 
surface of Pf-iRBC (Leech et a l, 1984). This protein was of a high molecular weight 
(180 -  210 kDa), was trypsin sensitive and its size and antigenicity varied between 
strains. By repeatedly infecting monkeys with the same parasite line, strain specific sera 
could be obtained; i.e. these sera agglutinated Pf-iRBC of the homologous but not the 
heterologous strain. Using sera from the immunized monkeys, a high molecular weight
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protein (260 -  380kDa) was immunoprecipitated from the homologous strain and this 
molecule was called Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP-1) 
(Leech et al., 1984).
It was later demonstrated that treatment of Pf-iRBC with low concentrations of 
trypsin not only cleaved PfEMP-1 but also led to the loss of binding to endothelial cells 
or purified endothelial receptors indicating that this protein is the Pf-iRBC ligand for 
endothelial receptors (Leech, 1991). Sera raised against particular strains were also 
shown to inhibit binding of the homologous parasite strains to endothelial cells (Leech, 
1991). Moreover, when Pf-iRBC were selected for particular adherence characteristics by 
panning on C32 melanoma cells, changes were observed on the molecular size of the 
newly expressed PfEMP-1 as assessed by electrophoretic migration in SDS-PAGE gels 
of radioactive proteins after in vitro iodination (Magowan et al., 1988).
Biggs and colleagues (Biggs et al., 1991) demonstrated that a cloned line of P. 
falciparum maintained in vitro gave rise to progeny clones that expressed antigenically 
distinct forms of PfEMP-1. PfEMP-1 also appeared on the surface of Pf-iRBC at the 
same time that Pf-iRBC became adherent (Biggs et al., 1991). Immuno-epidemiological 
studies in Kenya suggest that the presence of antibodies to specific PfEMP-l types 
protects children against subsequent clinical challenge with P. falciparum isolates 
expressing that variant (Bull et al., 1998). This finding suggested that PfEMP-1 is highly 
immunogenic, is the parasite ligand for endothelial cell binding and is involved in 
immune evasion through antigenic variation.
PfEMP-1 is thought to be the major component of VS A on the Pf-iRBC surface 
and is coded for by a large gene family called var (Baruch et al., 1995). There are
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approximately 60 var genes per haploid genome, which are located on all the 14 
chromosomes of P. falciparum (Gardner et al., 2002). Var genes are highly diverse and 
share a similar organisation: a larger 5’ exon with high sequence variability is separated 
from a smaller highly conserved 3’ exon by a transmembrane domain. The 3’ exon 
encodes the acidic terminal segment (ATS), presumed to anchor PfEMP-l to the knobs 
while the 5’ end is exposed on the surface of the Pf-iRBC and contains 2 to 5 copies of a 
motif denoted DBL, duffy binding ligand. The nomenclature of DBL is based on 
numbering them in the order from 5’ end and to identify the homology group by the 
Greek letter a  - e . A second motif common to all PfEMP-1 is the cysteine rich 
interdomain region (CIDR) of which there are one or two copies termed a  and p. The 
first CIDR, CIDR-la is found immediately after DBL l a  in most var genes. The detailed 
domain structure of PfEMP-1 is illustrated in figure 1.7.
It is thought that many var genes are transcribed during the early ring stage and 
only one single dominant mRNA coding for the surface expressed PfEMP-1 appears to 
be selected for further development (Newbold, 1999). Protein is detected on the surface 
16 hours post-invasion. Switching to a variant from the parental type can occur at a rate 
as high as 2% per generation in vitro and occurs in the absence of immune pressure 
(Roberts et al., 1992). However, it has been argued that this high switching rate is 
unlikely in vivo as the variant repertoire could be rapidly exhausted (Sherman et al., 
2003). There are suggestions that only a limited number of antigenic types are expressed 
in vivo, and that homologous anti-variant specific antibody acts as a signal for switching. 
The mechanisms that regulate var transcriptional switching are not known but are thought 
to be under epigenetic control. Recent in vitro data suggest that the information that
determines the probability of activation or repression of var genes is present in their 
surrounding DNA, and that some transitions appear to be disallowed depending on the 
recent variant antigen expression history of a parasite clone (Horrocks et al., 2004).
Figure 1.7
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Plasmodium falciparum erythrocyte membrane protein-1 (PfEMP-1) architecture and its 
binding domains. The intracellular domain, ATS, is highly conserved and anchors 
PfEMP-1 to the red cell membrane. The extra cellular part is highly variable but 
assembled from four domains: NTS, DBL, CIDR-1 and C2. Mapped binding traits are 
indicated with the domain and sequence class that is bound. CD36 is considered to be the 
major endothelial sequestration receptors, the others being recognized less frequently but 
might be important in disease pathogenesis. Abbreviation: ATS, acidic terminal segment; 
CIDR-1, cysteine-rich interdomain region; CR1, complement receptor 1; DBL, duffy 
binding-like domain; ICAM-l-l, intercellular adhesion molecule-1; CSA, chondroitin 
sulphate; NTS, N-terminal segment; TM, transmembrane domain. (Adapted from Smith 
and colleagues, 2001, Trends in parasitology 17(11) 538-45).
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PfEMP-1 receptors
Due to the high sequence diversity of var genes, it is not possible at this time to 
predict the binding phenotype of a var gene from its primary sequence. Nonetheless, 
several adhesion domains have been defined (Baruch et al., 2002b). These adhesion 
domains plus their respective receptors on the human host cells are shown in figure 1.7. 
Utilising these PfEMP-l adhesive domains, P. falciparum can interact with human cells 
in a variety of ways. Figure 1.8 illustrates the various scenarios resulting from these 
interactions including the cells and molecules involved.
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Figure 1.8
Serum proteins/Ig Platelet
Blood group antigen A/B 
CR1, HS_______________
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US___________Non immune IgG/M
Interaction o f P. falciparum infected red blood cell (Pf-iRBC) with the human host. P. 
falciparum erythrocyte membrane protein-1 (PfEMP-1) (here shown as cork-crew-like 
structures) is thought to be the main adhesive protein on the Pf-iRBC surface. PfEMP-1
DCs, stimulates B and T cells that generate both specific and non-specific responses to 
the parasite. It binds various serum proteins including non-immune immunoglobulin to 
form rosettes with uninfected RBC and binds CD3 6 on platelets that bridge the formation 
o f clumps o f Pf-iRBCs. Pf-iRBC sequester in the microvasculature through adhesion to 
heparan sulphate (HS)-like glycosyminoglycan, blood group antigens or complement 
receptor 1 (CR1) on the un-infected red cell (rosetting), to CD36, CD31/PECAM-1, 
ICAM-1, VCAM-1, HS and chondroitin sulphate (CSA) on endothelial cell lines, to CSA, 
hyaluronic acid (HA) and non-immune immunoglobulin on syncytiotrophoblasts in 
placenta. (Modified from Klickand Chen, Mole. & Bioch. Parasit. 143 (2004) 1-9). 
Rosetting domain
Pf-iRBCs can spontaneously adhere to uninfected red cells to form rosettes in 
vitro (rosetting). Rosetting has also been observed in post-mortem histological samples
could interact with the host in a variety o f ways; it binds to and inhibits maturation o f
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suggesting that this phenomenon may occur in vivo and this may contribute to the 
pathological process that lead to severe disease. Moreover, P. falciparum isolates that 
formed rosettes were associated with severe malaria and parasitaemia in Kenyan children 
(Rowe et al., 1995; Rowe et al., 2002a). The parasite ligand for rosetting in P. falciparum 
clones is PfEMP-1 and recombinant DBL-la proteins from a rosetting parasite line, 
FCR3S1.2, both binds non-infected red cells and inhibits rosetting suggesting that this 
domain mediates rosetting (Chen et al., 1998; Rowe et al., 1997). Rosetting properties 
such as disruption by various agents and sensitivity to heparinase can vary between 
parasite strains suggesting that various host factors interact with DBL-la to mediate 
rosette formation (Baruch, 1999; Baruch et al., 2002b; Cooke et al., 2001). Host factors 
that play a role in rosette formation include complement-receptor 1 (CR1) on the surface 
of erythrocytes (Rowe et al., 2000), blood group A (Barragan et a l, 2000) and 
immunoglobulin M (IgM) (Clough et al., 1998; Rowe et a l, 2002b; Somner et al., 2000; 
Treutiger et al, 1999). Erythrocytes with a common African CR1 polymorphism (SI(a-)) 
have reduced adhesion to DBL-a and there are reports indicating that CR1 
polymorphisms may confer protection from severe disease in Melanesian populations 
(Cockburn et al., 2004). Such genetic associations with either protection from, or 
susceptibility to disease strengthens further the speculation that rosetting is an important 
virulence factor in P. falciparum malaria.
Chondroitin Sulphate-A (CSA') binding domain
CSA is a glycosaminoglycan (GAG) linked to the cell surface by a membrane- 
associated protein. It consists of a heteropolymer of alternating gluconic acid and 4- 
sulphated N-acetylglycosamine residues. The sulphation pattern may vary substantially
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depending on the source of CSA. Pf-iRBC adhesion is strongly dependent on sulphation 
in the fourth position as well as the specific saccharide chains (Beeson et al., 1998; Fried 
et al., 1998). In most cases, the Pf-iRBCs that bind CSA do not bind CD36 and this 
dichotomy has been explained by conformational attributes of PfEMP-1 (Gamain et al., 
2002).
CSA is abundant in the placenta where Pf-iRBCs accumulates especially during 
the first pregnancy (Fried and Duffy, 1996). This accumulation of Pf-iRBCs in the 
placenta for the primigravida and not in subsequent pregnancies has been associated with 
accumulation of antibodies to the parasite phenotypes that bind CSA with previous 
exposure (Beeson et al., 2004; Fried et al., 1998; Khattab et al., 2004; Ricke et al., 2000). 
Some Pf-iRBC can also bind to hyaluronic acid (HA) (Beeson et al., 2000), a non- 
sulphated high molecular weight GAG (glycosyminoglycan) composed of alternating N- 
acetylglucosamine and glucuronic residues which is also expressed in the placenta.
There is evidence suggesting that DBL-y is the CSA binding domain of PfEMP-1. 
Antibodies to recombinant DBL-y inhibited CSA binding of a cloned cell line (Reeder et 
al., 1999), and the expression of FCR3varCSA in Chinese hamster ovary cells (CHO) 
cells (that do not express CSA) indicated that DBL-y is the domain that binds biotinylated 
CSA and mediated Pf-iRBC adhesion to CSA (Buffet et al., 1999). However, the 
presence of DBL-y does not always predict CSA binding since the A4 line expressing A4 
var, which has DBL-y did not bind CSA and there are reports of CIDR-la involvement 
in some isolates (Degen et al., 2000; Reeder et al., 2000).
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Inter cellular adhesion molecule 1 fICAM-1 adhesive domain
ICAM-1 is a member of the immunoglobulin super family and contains five 
immunoglobulin-like domains. It is expressed on lymphocytes, monocytes, macrophages 
and human umbilical vein endothelial cells (HUVEC). ICAM-1 expression is up 
regulated by pro-inflammatory cytokines including TNF during acute malaria (McGuire 
et al., 1996), and is known to act as a receptor for leukocyte integrin (LFA-1) on 
lymphocytes (reviewed in (van de Stolpe and van der Saag, 1996)). Studies correlating 
the binding attributes of field isolates to disease outcome and post-mortem 
histopathological analyses of individuals who died from cerebral malaria have implicated 
ICAM-1 as a potential host receptor involved in cerebral malaria (Newbold et a l, 1997; 
Turner et al, 1994). In addition, a dimorphism in human ICAM-1 was found to alter the 
risk of cerebral malaria in Kenya (Femandez-Reyes et a l, 1997).
By using a parasite line (A4) selected for ICAM-1 binding on HUVEC, the 
binding site for Pf-iRBC was localized to the first Ig domain (Smith et a l, 1998). Pf- 
iRBC selected for ICAM-1 binding express particular var genes that differ from those 
expressed by non ICAM-1 binders. Since antibodies to DBL-p from the A4 var line 
blocked adhesion of both A4 var and A4TRES strains, it was concluded that the DBL-P 
domain mediates adhesion to ICAM-1 (Smith et a l, 1998). Attempts to use CHO cells 
transiently transfected with DBL-p and CIDR-2 domains from the A4TRES parasite line 
to demonstrate DBL-P involvement yielded mixed results with some studies reporting 
binding and others no binding to ICAM-1 (Smith et al, 2000).
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Thrombospondin (TSP1
Thrombospodin is a large protein of three identical 140 kDa chains linked to each 
other by disulphide bonds. It is found in the extra cellular matrix, in platelet granules, on 
the surface of macrophages, melanoma cells and a variety of endothelial cells. TSP binds 
to CD36, CD47 and Pf-iRBC, and plays an important role in platelet clotting. Most 
clinical isolates and laboratory lines of Pf-iRBC bind to TSP (Baruch et a l , 1996).
The role of PfEMP-1 and var genes in Pf-iRBC binding to TSP is controversial. 
Initially, Baruch et al., (Baruch et al., 1996) used immobilised ICAM-1, TSP and CD36 
to affinity purify Pf-iRBC iodinated molecules and their tryptic fragments and based on 
this it was concluded that PfEMP-1 is the ligand for all these receptors. However, the 
properties of Pf-iRBC binding to TSP differs from those of ICAM-1 and CD36 binders 
(Gardner et al., 1996). For example, binding of Pf-iRBC to ICAM-1 and CD36 showed 
sensitivity to sequence specific proteases, that was variant specific and was reversed by 
immune serum. The converse was true for TSP binding. Specific binding to ICAM-1 and 
CD36 also appeared simultaneously in the cell cycle, while binding to TSP appeared two 
hours earlier in the cell cycle. It has been suggested that another ligand, possibly 
modified band 3 (a non-PfEMP-1 adhesin), was responsible for TSP binding (Eda et a l , 
1999; Newbold et al., 1999).
CD36 binding domain
CD36 is an 88-kDa glycoprotein found on the surface of platelets, monocytes, 
DCs and microvascular endothelial cells. It is now generally agreed that the vast majority 
of P. falciparum isolates collected from non-pregnant malaria patients bind to CD36 
(Newbold et a l, 1997; Ockenhouse et al., 1991; Roberts et a l, 1992; Rogerson and
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Beeson, 1999) suggesting that CD36 is a major endothelial receptor for parasite 
sequestration. CD36 binding of Pf-iRBC in post-capillary venules is strong and long 
lasting (Cooke et al., 1994). The PRBC binding domain has been shown to lie within an 
immunodominant region of CD36, between amino acids 139-184 (Baruch et al., 1999). 
The anti-CD36 MAb, OKM5, blocks cytoadherence of Pf-iRBC to CD36 (Barnwell et 
al., 1989). The evidence for the CIDR-la of PfEMP-1 being the CD36 binding domain 
comes from the fact tryptic peptides containing the CIDR-la domain bound to CD36, 
and that anti-CIDR-la antibodies blocked the binding of Pf-iRBC to immobilised CD36 
(Baruch et al., 1999). Moreover CIDR-la or fragments of CIDR-la from different var 
genes specifically bound to CD36. The minimal CD36 binding motif in one var gene 
(MCI) was mapped to a 179 amino acid long stretch (rCl-2), and antibodies to 
recombinant rCl-2 block Pf-iRBC binding to CD36 in a non-strain specific manner 
(Cooke et a l, 1998). However, antibodies against the recombinant rCl-2 blocked 
adhesion of all CD36 binding Pf-iRBC to CD36 regardless of the sequence diversity. 
These results suggested that no matter what the CIDR-la sequence of various var genes, 
the protein could fold into a conserved structure thereby mediating binding to CD36 
(Baruch et a l, 2002b).
In addition to the observation that most P. falciparum clinical isolates bind CD36, 
it has been reported that 62% (34 of 55) of the encoded PfEMP-ls (CIDR-la domain) of 
the 3D7 P. falciparum parasite clone bind CD36 (Robinson et al., 2003). Together these 
data suggest that the interaction between CIDR-la domain and CD36 receptor is 
important for the parasite survival in the human host. Besides its implication in 
pathogenesis of malaria by mediating the binding of Pf-iRBC to the vascular
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endothelium, CIDR-la-CD36 interaction has also been implicated in inhibition of 
dendritic cell function (Urban et a l , 2001b; Urban and Roberts, 2002). DCs are important 
antigen presenting cells and thus an inviting target for modulation by pathogens. 
Although Pf-iRBC modulated DCs produce TNF, they fail to activate T cells and secrete 
IL-10 (Urban et al., 2001b). CIDR-la has also been implicated in polyclonal B cell 
activation and hypergammaglobulinaemia, which are prominent features of P. falciparum 
malaria. Donati and colleagues (Donati et al., 2004) recently showed that Pf-iRBC of the 
laboratory isolate FCR3S1.2 directly adhere to and activate peripheral blood B cells from 
malaria non-exposed donors and this interaction is thought to involve CIDR-la binding 
surface Ig molecules. Stimulation with recombinant CIDR-la derived from var gene 
FCR3S1.2 induced proliferation, an increase in B cell size, expression of activation 
molecules and secretion of IgM and cytokines (TNF and IL-6) (Donati et al., 2004). 
However, the effect on B-cells seems to be mediated by binding of this specific CIDR 
sequence to Ig molecules rather than binding to CD36. Nevertheless, by modulating 
dendritic cell and B cell function, the malaria parasite may subvert the immune response 
to enhance its survival.
CD36 binding has not been directly associated with disease severity (reviewed in 
(Sherman et al., 2003)) and a nonsense mutation of CD36 was not associated with 
susceptibility to severe malaria in one study (Pain et al., 2001b) but associated with 
susceptibility in another study (Aitman 2000). In addition, Pain and colleagues did find 
that CD36 was involved in platelet-mediated clumping of Pf-iRBC, and that such 
clumping was strongly associated with severe malaria (Pain et al., 2001a). Platelet 
mediated clumping seemed to be specific feature of the expressed PfEMPl of one
laboratory isolate and was also observed in field isolates. There are also reports from 
patients with severe malaria that show accumulation of platelets in cerebral vessels and 
co-localisation with malaria pigment (Grau et al., 2003; Pain et al., 2001a). However, 
detailed clinical data to demonstrate the importance of this phenomenon in cerebral 
malaria is lacking (Sherman et al., 2003). More recently, Smith and colleagues (Smith et 
al., 2003) demonstrated that CD36 is involved in the phagocytosis of red cells containing 
gametocyte stage parasites by macrophages. Thus the malaria parasite, via CIDR-la, is 
involved in a series of complicated host-parasite interactions that include parasite 
favouring phenomena; sequestration, host pathology, inhibition of dendritic cell 
maturation, polyclonal B cells activation as well as host immunity, eg non-opsonic 
phagocytic clearance of parasites by macrophages. These phenomena may be a generic 
property of almost all CIDR-la variants such as adhesion to CD36 or specific properties 
of some CIDR-la such as B-cell activation and platelet mediated clumping.
The main theme of this thesis is immune responses to CIDR-la. As already 
mentioned, almost all parasite variants that infect children bind to CD36 suggesting that 
immunising against CIDR-la may protect children living in endemic areas from severe 
disease. Furthermore, such a vaccine could be used as an immunotherapeautic agent that 
can reverse sequestration and its pathological effects thus reducing disease severity. 
Indeed the feasibility of vaccines directed at functional adhesive domains of PfEMP-l, 
and particularly CIDR-la and DBL-y (the CSA binding domain discussed above) is 
being explored by a number of malaria research groups. Not much has been 
accomplished in terms of understanding immunity to CIDR-la in naturally exposed
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populations, but animal immunisation experiments have provided some encouraging data. 
The results of these experiments are discussed in section 1.9.0.
1.9.0 Immune responses to the PfEMP-1 
Humoral responses to PfEMP-1
The primary function of VSA on the surface of the infected red cell is to avoid 
immune clearance through cytoadherence and antigenic variation (reviewed in (Saul, 
1999; Sherman et a l , 2003)). Deep tissue sequestration of Pf-iRBC containing the 
trophozoite and schizont stages is generally believed to favour the survival of parasites by 
preventing Pf-iRBC passage through the spleen where they would otherwise be 
recognized as abnormal and removed. Sequestration in deep tissue microvasculature may 
also place the Pf-iRBC in a parasite favouring micro-aerophilic environment thereby 
promoting rapid asexual multiplication. Adherence of Pf-iRBC onto uninfected red cells, 
rosetting, is thought to shield Pf-iRBC from destruction by mechanisms of the immune 
system and enhance their re-invasion of red blood cells. Sequestration and rosetting, 
according to this hypothesis would favour parasite growth and reproduction, but would 
have also severe consequences for the host, resulting in micro vascular occlusion, tissue 
hypoxia and cerebral complications. Adherence of Pf-iRBC to DCs via CD36 has been 
associated with inhibition of dendritic cell maturation in vitro (Urban et al., 1999; Urban 
et al., 2001a; Urban et al., 2001b). By doing so, the malaria parasite is thought to 
modulate the host’s immune response in its favour, and in the process escape immune 
clearance (Good, 1999; Urban and Roberts, 2003).
An alternative hypothesis has been proposed; that the primary function of VSA on 
the surface of the Pf-iRBC is to allow recognition by the host, thereby leading to control
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of the parasite multiplication and hence preventing host death before mosquito 
transmission could occur (Saul, 1999). In this scenario, cytoadherence is secondary to 
inducing an immune response. Critics of this postulate have argued that it is unlikely 
since “lines expressing no detectable parasite antigens on the surface are less virulent and 
reach lower parasitaemias than their wild counterparts” (Kyes et al., 2001). Whether 
exposure of the parasite to the immune system is the true primary function of VSA or not, 
it is quite clear that these antigens are highly immunogenic in both animals as well as 
humans. Their immunogenicity was first demonstrated by experimentally infecting 
squirrel monkeys with P. falciparum (Hommel et al., 1983). Convalescent sera from 
these animals stained the homologous parasites as demonstrated by indirect 
immunofluorescence. Studies in children living in malaria endemic areas have 
demonstrated the presence of antibodies to VSA of various P. falciparum isolates in their 
sera (Marsh and Howard, 1986; Marsh et al., 1989) using agglutination. Both the 
antigenic and functional properties of VSA can be largely attributed to PfEMP-l 
(reviewed in (Bull and Marsh, 2002)). Immune responses to PfEMP-1 have been largely 
analysed by the agglutination of Pf-iRBCs (Marsh et al., 1986; Newbold et al., 1992) 
and/or by immunofluorescence on flow cytometry (Staalsoe et al., 1999). The former 
technique is time consuming and only semi-quantitative while the latter is quicker and 
permits quantitative measurement of VSA specific antibodies. These two techniques have 
been applied extensively in various epidemiological studies to investigate the role of 
VSA in naturally acquired immunity to malaria.
In an early longitudinal study in the Gambia (Marsh et al., 1989), the titre of anti- 
VSA antibodies was shown to be the only one of a series of immune assays that was
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associated with subsequent protection against disease. More recent studies have given 
variable results with some reporting association of VSA with protection (reviewed in 
(Bull and Marsh, 2002). The ability of pre-season sera to recognize VSA in an isolate 
from Kenya was not associated with any protection from disease in the malaria season 
following the sample collection in Kenyan children (Bull et al., 1998). In Sudan (Giha et 
al., 2000), pre-season anti-VSA antibodies to a Ghanaian parasite isolate were associated 
with protection from disease, but the responses to six Sudanese isolates were not. In a 
large longitudinal study of surface antigens of P. falciparum-mfQcted erythrocytes from 
Kenyan children, malaria tended to be caused by parasite isolates expressing VSA 
variants corresponding to gaps in the repertoire of antibodies carried by the children 
before they became ill (Bull et al., 1998). In Ghana, the levels of IgG to VSA on a 
Sudanese and a Ghanaian parasite isolate remained significantly higher in protected than 
in susceptible children (Dodoo et al., 2001). These studies suggested that responses to 
some VSA and not others are associated with protection.
Two observations from these studies have led to the conclusion that naturally 
acquired immunity is associated with piece meal acquisition of a repertoire of variant 
specific antibodies (Bull et a l, 1998; Marsh et al., 1989). Firstly, convalescent sera from 
P. falciparum infected children generally agglutinated homologous, but not heterologous 
Pf-iRBC within the same region (Marsh and Howard, 1986). Secondly, sera from 
immune adults in the same area agglutinate Pf-iRBC from most of the children. In 
addition, when immune adult sera is added to deliberately mixed parasite populations, the 
agglutinates they generally form contain only one isolate of parasite, indicating that these 
adults have acquired a repertoire of variant specific antibodies, rather than antibodies
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against conserved determinants (Newbold et al., 1992). Furthermore, the prevalence of 
variant specific antibodies increases in an age dependent manner, and this increase is 
associated with both the prevalence and density of parasitaemia (Piper et a l, 1999). 
Collectively, these observations suggest that clinical immunity probably develops once 
individuals have acquired antibodies against multiple PfEMP-1 variants. This may 
explain why immunity to malaria takes several years to develop.
More evidence for an important role of PfEMP-1 in inducing naturally acquired 
immunity to malaria comes from recent studies on primigravida and multigravida 
women. With the exception of pregnant women, adults living in malaria endemic areas 
are naturally protected from clinical malaria (Riley et al., 1994). The loss of immunity 
that occurs amongst primigravida was shown to correlate with an absence of antibodies 
that block the binding of parasites to CSA on the placenta (onto which Pf-iRBC sequester 
in the case of placental malaria) (Fried et al., 1998) or bind to the surface placental Pf- 
iRBCs (Beeson et al., 1999). By the second pregnancy, such antibodies are present, 
presumably as a result of selected parasites present during the first pregnancy. Protective 
immunity to pregnancy associated malaria is acquired as a function of parity (Brabin, 
1983) and is associated with increasing levels or prevalence of antibodies to CSA-binding 
and placental isolates (Beeson et al., 1999; Fried et al, 1998; Ricke et al., 2000; Staalsoe 
et al., 2001).
Some parasite isolates are more commonly recognized than others. Interestingly, 
Pf-iRBC isolated from children with severe malaria were more frequently agglutinated by 
a panel of sera collected from the same area than Pf-iRBC isolated from mild malaria 
cases (Bull et al., 1999; Bull et al., 2000). The agglutination frequency decreased with
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the age of the child from which the parasite was isolated suggesting that the parasites that 
cause severe disease may occur more frequently in younger children with low immunity. 
It has been hypothesized that these variants may have optimal cytoadherence 
characteristics that enable them to expand rapidly and dominate (Bull et al., 2000). 
Alternatively, pre-existing immunity in older children may select for novel variants that 
are less pathogenic (Bull et al., 2000).
Surface location (Marsh and Howard, 1986, Forsyth, 1989 #165), 
immunogenicity and involvement in pathogenesis of severe malaria (Gardner et al.,
1996), makes PfEMPl an attractive component of a malaria vaccine. However, the high 
level of antigenic variability has been an impediment to the development of such a 
vaccine. Interestingly, despite the fact that naturally acquired immunity seems to depend 
on the acquisition of variant specific antibodies to PfEMP-1 (Bull et al., 1998; Giha et 
al., 1999), it has been demonstrated that there can be cross-reactivity between different 
variants suggesting that a pan reactive PfEMP-1 based vaccine may be a possibility 
(Gamain et al., 2001a). In addition, even in regions of the molecule that are extremely 
diverse, some var gene sequences sampled from different geographical locations are very 
similar (Taylor et al., 2000; Ward et al., 1999). These observations are consistent with 
the recognition by antibodies of parasite isolates (VSA) from different geographical 
regions (Aguiar et al., 1992) and the existence of commonly recognized parasite isolates 
(Bull et al., 2000).
The CD36 binding domain of PfEMP-1, CIDR-la, has been a focus of interest as 
a possible PfEMP-1 based vaccine. Such a vaccine might be expected to reduce deaths in 
infants and children since parasites isolated from children generally bind CD36. A
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vaccine oriented towards a functional domain of PfEMP-1 like CIDR-la would also help 
overcome the problem of antigenic diversity since such domains are functionally 
conserved (Gratepanche et a l , 2003). Recent studies on CIDR-la as a possible vaccine 
candidate have reported cross-reactivity between different variants of CIDR-la. A MAb 
specific for a single CIDR-la variant, cross-reacted with multiple strains of parasites 
(Gamain et al., 2001a) suggesting that this region is (functionally) conserved among 
parasite strains (Baruch et al., 1997). Furthermore, Gratepanche and colleagues 
(Gratepanche et al., 2003) recently demonstrated that cross-reactivity of the antibody 
response to CIDR-la could be increased by immunising mice with more than one variant 
of CIDR-la simultaneously. CIDR-la is however poorly immunogenic (Baruch et al.,
1997) but such epitopes that are not likely to be under immune pressure could be 
potentially effective vaccines (Wipasa et al., 2002). In a vaccine trial with CIDR-la of 
the Malayan camp (MC) strain of P. falciparum, vaccination with one copy of MC 
CIDR-la protected Aotus monkeys against an otherwise lethal challenge with MC 
parasites (Baruch et al., 2002a). However, they were not protected against another strain 
of P. falciparum, FVO. The improvement of the level of cross-reactivity by immunising 
mice with three variants of CIDR-la simultaneously raises hope that that the 
effectiveness of the CIDR-la vaccine will be improved in future trials. DNA shuffling to 
generate libraries of chimeric CIDR-la antigens for use in a PfEMP-1 vaccine that would 
induce cross-strain protection is also being explored. Shuffled clones from these libraries 
incorporate sequence diversity from different P. falciparum isolates throughout the 
respective recombinant polypeptides (Heinrichs et al., 2004). A number of shuffled 
clones have shown improved CD36 binding activity and studies to test cross-reactivity of
mouse sera generated from immunisations with these clones with Pf-iRBC isolated from 
children are ongoing.
CD4 T cell responses to PfEMP-1 in humans
As already discussed earlier, PfEMP-l on the surface of the Pf-iRBC interacts 
with the various cells of the human host’s immune system resulting in the induction or 
modulation of immune responses. A good understanding of these interactions and 
immune responses to PfEMP-1 may help elucidate the mechanisms that mediate naturally 
acquired immunity to asexual blood stage malaria, and the immuno-pathological 
mechanisms associated with this stage of malaria infections. However, not much in terms 
of cellular immunology has been done to help understand the interactions between the Pf- 
iRBC surface, professional antigen presenting cells and CD4 T cells of the human 
immune system. Most of the work done so far has been directed on the variant antibody 
response to PfEMP-1 (discussed above).
The role of antigen presenting cells (APC) in innate immunity to malaria has been 
described elsewhere in this thesis. Their role in activating the adaptive immune system is 
critical as these are the cells that link innate responses and adaptive responses by 
processing and presenting antigens to both T and B cells. DCs, because of their unique 
ability to sample sites of antigen entry, respond to microbial stimuli, uptake and process 
antigens, and activate both naive and memory T cells (reviewed in (Sher et al., 2003)) 
have received considerable interest in malaria immunology recently. Their role in both 
innate and adaptive immunity is controversial with some studies indicating that Pf-iRBC 
inhibits dendritic cell maturation. Urban and colleagues (Urban et al., 1999; Urban et al., 
2001b), have shown that Pf-iRBC bind to CD36 on in vitro monocyte derived DCs and
inhibit normal lipopolysaccharide (LPS) induced up regulation of MHC class II, ICAM- 
1, CD40, CD80, CD83 and CD86. When exposed to, P. falciparum, DCs were found to 
secrete IL-10 instead of the expected IL-12, and their ability to activate an allogeneic 
mixed lymphocyte reaction or to activate memory CD4 T cells was reduced. In contrast, 
other studies in P. yoelii have shown that DCs from malaria infected mice are fully 
functional antigen APCs (Perry et a l , 2004). Seixas and colleagues (Seixas et al., 2001) 
demonstrated that P. chabaudi infected red cells directly activate DCs to up regulate 
MHC class II, CD40 and CD86 and produce TNF, IL-6, IL-12p40 and IL-12p70. There 
are also reports, of haemozoin, an insoluble product of late stage P. falciparum, inducing 
the up regulation of co stimulatory molecules and IL-12 production by myeloid DCs in 
mice (Coban et al., 2002). Additionally, the administration of a DNA vaccine (in mice) 
encoding Pfs25, a sexual stage antigen together with haemozoin markedly increased the 
ratio of cytophilic IgG2a to non cytophilic IgGl antibodies compared with the group that 
received the vaccine alone suggesting that haemozoin potentiated rather than inhibited 
the vaccine efficacy in inducing a THi cell response (Coban et al., 2002). Thus, results 
from both in vitro and in vivo dendritic cell stimulations with malaria parasites remain 
conflicting. It is likely that the initial DC activation is normal and transient but followed 
by a refractory period during which pro-inflammatory signals are absent or down 
regulated to avoid pathology. In this case, investigators studying dendritic cell activities 
will observe different responses at different time points. It is, however, clear that pro- 
inflammatory cytokines from both DCs and macrophages are present within hours of the 
emergence of parasitized erythrocytes in the circulation of humans (Hermsen et al., 2003) 
and mice (Stevenson et al., 2001), and are required for protection (Singh et al., 2002;
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Stevenson et al., 2001). However, low levels of IL-12 and IL-18 are associated with 
severe malaria pathology in humans (Malaguamera et al., 2002), while IL-12 production 
is inversely associated with the risk of infection, positively associated with IFN-y and 
TNF production and is protective against malarial anaemia (Dodoo et al., 2002).
Apart from their role as antigen presenting cells in malaria, macrophages are also 
thought to mediate antibody-dependent cellular inhibition or to produce anti-parasite 
molecules such as nitric oxide after activation by CD4 T cell derived IFN-y (reviewed in 
(Good and Doolan, 1999; Good, 2001)). Collectively, studies on APC interactions with 
Plasmodium parasites have produced conflicting data. There is however, overwhelming 
evidence that these cells are involved in both innate and adaptive immune responses in 
malarial infections.
Perhaps because of the highly variable nature of PfEMP-l, there has been little 
research on T cell responses to this antigen. However, the current interest in developing 
and evaluating PfEMP-1 based vaccines and understanding immune responses to it would 
be greatly aided if there were a better understanding of both T cell and antibody 
responses to PfEMP-1. As has already been discussed, previous work in Kilifi, Kenya, 
has demonstrated that serological recognition of a given parasite isolate is associated with 
strong protection against infection associated with that isolate (Bull et al., 1998) 
suggesting that antibodies to variable surface antigens are protective. Despite the extreme 
diversity of PfEMP-1, the majority of subjects in endemic areas develop antibody 
responses to a large proportion of the var repertoire fairly quickly. There is therefore a 
possibility that helper CD4 T cell responses to conserved epitopes could provide a way of
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priming hosts to enable them make rapid responses, during the course of parasite 
expansion, to diverse B cell epitopes to which they have not been previously exposed.
In a preliminary study, Allsopp and colleagues (Allsopp et al., 2002) investigated 
whether exposure to malaria led to accumulation of PfEMPl specific CD4 T cell 
responses to three recombinant P/EMP1 protein fragments; 2 proteins from the A4 
parasite isolate, one from a region of EXON 2 and the other from a region of DBLa, and 
a third protein from a region of CIDR-la from the Malayan Camp isolate in 27 malaria 
exposed children, 27 exposed adults, and 25 non-exposed Europeans by flow cytometry. 
The magnitude of the proliferative response to EXON 2 and DBL-a was significantly 
higher in the malaria-exposed donors when compared with unexposed controls (p= 0.045 
and 0.0085 for malaria exposed adults and children respectively). The cytokine response 
to the CIDR-la fragment was strikingly different as large proportions of both exposed 
and non-exposed donors produced high levels of IL-10 and IFNy cytokines (74% of 
exposed adults, 74% of exposed children, 100% of non-immune controls produced IL-10 
while 59% of exposed adults, 66% of exposed children and 96% of non-immune controls 
produced IFN y).
Nature of cellular immune responses to the CIDR-la domain of PfEMP-l in malaria 
naive individuals
The observation of the CIDR-la induced responses described above in practically 
malaria naive individuals led to the studies described in this thesis. The study described 
above, measured IFN-y and IL-10 production in addition to CD4 T cell proliferation. 
These three parameters of the immune response are important in the immunology of 
malaria (and other infectious diseases) and are hereby described briefly before the
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presentation a series of studies describing the nature of the immune response to CIDR-la 
in malaria naive and exposed individuals.
IFN-y, a pro-inflammatory cytokine normally associated with the TH1 subset of 
CD4 T cells (Gately et al, 1998), and its induction may mediate mechanisms involved in 
the clearance of malaria (and other intracellular) parasites (Li et al., 1999a; Stevenson et 
a l, 1990) as discussed earlier. The other cells that are known to make IFN-y are CD8 T, 
NK and y8-T cells. For a long time, it was presumed that the production of IFN-y, at least 
by CD4 T cells requires antigen activation via the T cell receptor (TCR). However, it has 
become clear that an alternative pathway of IFN-y induction (as discussed in section 
1.6.2) exists. This pathway involves the presence of both IL-12 and IL-18 and is 
pharmacologically distinct with TCR induced IFN-y induction being completely sensitive 
to cyclosporin A (Chakir et al., 2003; Yang et al, 1999). IL-18 has also been shown to 
enhance NK cell activity and T cell proliferation (Kohno et a l, 1997; Okamura et a l, 
1995). In investigating IFN-y induction by malaria antigens, it is important to consider 
these observations since as discussed earlier in this thesis IFN-y production is a 
prominent feature of malaria infections. More over, malaria parasites do induce IL-12 and 
IL-18 production in vivo.
Antigen induced CD4 T cell proliferation and IFN-y responses can be 
discriminated from mitogen or cytokine induced responses by anti-MHC class II 
antibodies. In this case, the antigen could function as either a standard antigen that is 
taken up by APCs, processed and then presented to T cells in an MHC class II complex 
or a super-antigen that cross-links the MHC class II molecule and the TCR.
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IL-10 is involved in the differentiation of T cell subsets to a TH2 phenotype (De 
Smedt et al., 1997; Liu et al., 1998) and induction of anergy (Groux et al., 1997b). 
Repeated stimulation of T cells in the presence of IL-10 may also induce regulatory T 
cells (Joss et al., 2000). IL-10 is also known to down regulate TH1 responses, which in 
the case of malaria have been associated with protective mechanisms. Since both exposed 
and non-exposed individuals respond similarly, the induction of these cytokine responses 
by the CIDR-la domain may involve among other things, binding to CD36.
1.9.1 JUSTIFICATION AND OBJECTIVES
The number of malaria specific deaths has more than doubled in the last three 
decades. New effective control measures are urgently needed to arrest the worsening 
situation. While an effective malaria vaccine may not be on the horizon for now, 
vaccination remains a cost effective way of protecting the populations at risk from 
infection. A fuller understanding of the parasite’s biology and its interaction with the 
human immune system is needed if we are to increase our understanding of naturally 
acquired immunity to malaria and the chances of having an effective vaccine in the near 
future. As it has already been pointed out, PfEMP-l, is expressed on the surface of the 
infected red cell, is highly immunogenic and involved in the pathogenesis of severe 
malaria. It is therefore a key immune target. It is expected that an anti-PfEMP-1 vaccine 
would induce anti-adhesive antibodies that would inhibit sequestration and hence the 
disease process as well. However, the fact that PfEMP-1 is highly variable makes the 
identification of potential immune targets and vaccine epitopes difficult. In spite of this 
difficulty, there have been some encouraging reports from animal immunisation 
experiments with the CD36 binding domain of PfEMP-1, CIDR-la, indicating that
recombinant CIDR-1 is immunogenic and that there is cross reactivity between different 
C ID R -la variants (Gamain et al., 2001a). Moreover, vaccination with CIDR-la 
protected Aotus monkeys from challenges with a lethal parasite strain (Baruch et al., 
2002a), and it was possible to increase the scope antibody cross-reactivity by vaccinating 
mice with three variants of CIDR-la at the same time (Gratepanche et al., 2003). These 
observations suggest that a CIDR-la vaccine is feasible. However, the implications of 
the finding that malaria non-exposed donors have pre-existing anti-CIDR-la responses 
are not known. Such responses may play a role in protection or even immunopathology. 
This studies aims to characterize the nature of cellular responses to CEDR-la as the first 
step to help understand why non-exposed donors can have pre-existing anti-CIDR-la 
CD4 T cell proliferative and cytokine responses.
Specific objectives
(1) investigate the phenotypes of peripheral blood cells that produce IL-10 and IFNy in 
response to activation with CIDR-la
(2) determine whether cellular responses to CIDR-la from different P/EMP1 variants are 
the same i.e. compare in vitro proliferation and cytokine responses elicited by CD36 
CIDRa binders to those elicited by non-binders
(3) study the phenotype of T cells (naive and memory phenotypes) activated in the 
presence IL-10 and the functional importance of such responses in an endemic area
(4) determine whether these T cell responses are HLA restricted by using anti-class II 
antibodies to block the stimulation
(5) determine whether any of four contiguous synthetic peptides spanning the whole 
CIDR-a protein sequence can reproduce the same responses (as the whole protein) in
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an attempt to locate more precisely where on the 250 amino acid stretch the 
stimulating sequence lies
(6) determine which sub-population of peripheral blood DCs responds to CIDR-la and 
the kinetics of these responses
(7) determine whether the CIDR-a protein associated with a particular parasite binding 
phenotype elicits the same dendritic cell responses as the erythrocytes infected with 
the parasite isolate that expresses that CIDR-a
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CHAPTER 2
MATERIALS AND METHODS 
2.1 General
This chapter describes all the methods used in the course of this project. A full list 
of reagents, equipment, and consumables used, protein and DNA sequences can be found 
in the appendix.
2.2.0 Antigen preparation
2.2.1 Expression and purification of recombinant proteins
Source of genomic DNA (gDNAI
DNA extracted from the A4 TRES laboratory isolate for amplification of A4 var 
CIDR-la, and FCR3 varCSA CIDR-la was a kind gift from Dr. Sue Kyes (University of 
Oxford, UK). EXON 2 and Malayan CIDR-la were cloned as explained elsewhere 
(Allsopp et al., 2002).
Polymerase chain reaction (PCR^ amplification of FCR3varCSA CIDR-la and A4var 
CIDR-la genes
Target regions of FCR3varCSA CIDR-la and A4 var CIDR-la were amplified 
from gDNA using PCR. Primers were designed using multiple sequence alignments to 
ensure that the chosen sequences were in variable regions of the gene, and unlikely to be 
conserved in other CIDR-la variants. Primers (see table 3.1 for a list of all the primers 
used) were designed to include a restriction site at each end of the resultant product. The 
different reactions were briefly optimized by varying cycle times and magnesium 
chloride concentration. Approximately lOng of genomic gDNA was mixed with PCR
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buffer (8mM Tris pH 8.3,40mM potassium chloride, 0.2mM each of dATP, dCTP, dTTP and 
dGTP, 1U of Taq polymerase, 2pM each primer, 0-3mM magnesium chloride). Reactions 
were performed in 50pl volumes. Mixtures were overlaid with equal volumes of mineral 
oil.
Separation of DNA fragments
Plasmid DNA extracted from bacterial cells or DNA fragments produced in 
diagnostic digests was separated and sized by agarose gel electrophoresis. Gels were 
poured using between 0.8-2.0% (W/V) agarose in 0.5 X TBE (1 X TBE is 6g Tris, 5.5g 
orthoboric acid 4ml 0.5M EDTA Ph 8 made up to 1 litre with dH20). Samples were 
mixed with equal volumes of loading buffer (30% (v/v) glycerol, lOnM EDTA at pH 8.0, 
0.25% (w/v) xylene cyanol and 0.25% bromophenol blue) immediately prior to loading. 
Gels were run in 0.5 X TBE for approximately 1 hour. On completion, gels were stained 
for 20 minutes in 0.5pg/ml Ethidium bromide in dH20 before UV visualization. 
Fragment sizes were estimated by comparison to appropriate molecular weight markers 
run in adjacent lanes.
Gel purification of DNA
To purify specific DNA fragments from PCR reaction digests, samples were
electrophoresed on 1.4 -2.0% (V/V) low melting point agarose gels in TAE (40mM Tris-
Acetate, ImM EDTA) buffer. Samples were prepared as described previously, and gels
were run at 40V for 1 hour at 0°C. Gels were stained with ethidium bromide as
previously described and bands visualized under long wavelength UV transillumination.
Selected regions of the gel were excised using a scalpel, and transferred to tubes. Slices
of gels were prepared for agarose digestion by addition of EDTA to 10mM and Sodium
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chloride to lOOmM before being melted at 70°C. Samples were cooled to 40°C and 
agarose added at lU/lOOpl volume. Samples were incubated for 2 hours before phenol 
extractions were performed. Equal volumes of phenol were added and tubes were 
vortexed. Micro centrifugation was used to separate the phases, and the aqueous phase 
was transferred into a clean tube. The phenol phase was extracted with an additional 
volume of TE, and the pooled aqueous phases treated with 1/10th volume of 3M sodium 
acetate and 2.5 volumes of ethanol. DNA was precipitated for 30 minutes at 4°C and then 
pelleted by microfugation at 20000g for 15 minutes. DNA pellets were washed in 70% 
ethanol and resuspended in TE buffer.
Restriction digests
Purified DNA vector and PCR products were prepared for ligation by restriction 
digestion. Plasmids extracted from transformed bacteria were screened by restriction 
enzymes to verify the presence of the insert. Table 2.1 shows the enzymes used and their 
respective buffers as recommended by manufacturers.
Table 2.1: Enzymes for restriction digests and their buffers
Enzyme Buffer
Not 1 (Promega, UK) H (Promega, UK)
Ecor 1 (Promega, UK) H (Promega, UK)
PGEX6P.1 vector DNA was digested for 4 hours at 37°C with 2U enzyme per pg of 
DNA while PCR products were incubated for 4 -  12 hours with 10U of enzyme per pg of 
DNA. For phosphatase treatment, 0.03U Calf Intestinal Phosphatase (CIP) was added per
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1 ng of DNA for the last hour of restriction digest treatment. Following digestion, DNA 
was purified by gel electrophoresis as previously described.
Ligation
Plasmids and amplified PGR DNA products were prepared as described above. 
For each construct, lOOng DNA was then incubated with 1:1 molar ratio of vector: insert 
DNA. Controls included vector DNA alone and insert DNA alone. Ligation reaction 
buffer was 50mM Tris-Hcl pH 7.5, 10mM MgCL, K W  DTT, ImM ATP, 25pg/ml BSA and 
200U T4 DNA ligase. Samples were incubated at 16°C for 4 -  16 hours.
Transformation and expression of DNA constructs
Routine culturing of bacterial cells was performed by using Luria-Bertani (LB) 
medium and LB-agarose plates (medium supplemented with 15g agarose per litre). In 
these experiments involving PGEX plasmids, ampicillin was added to a final 
concentration of lOOpg/ml from a lOmg/ml stock in 50% ethanol (Smith and Corcoran, 
1990). All cultures were grown in a shaking incubator at 280 rpm and 37°C.
Bacteria strains
Two strains of E. coli were used. Strain DH5a was used for cloning and for initial 
expression experiments. The BL21 protease deficient E. coli strain was thereafter used 
for protein expression.
Sequencing
The DNA inserts from 10 clones from each of the two CIDR-la were recovered 
from DH5a bacteria after expansion using a miniprep kit (Qiagen) after a restriction 
digest. The DNA was then, quantified by spectrophotometry, pelleted and dried in
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eppendorf tubes before being sent off for sequencing. Sequences were generated and 
verified by MWG Biotech (Germany).
Transformation of competent E. coli bacterial cells
In each case, a vial of E. coli BL21 cells was thawed on ice. 5ng DNA in a 
volume of lpl was added to the cells and mixed gently. The mixture was incubated on ice 
for 30 minutes. The mixture was then incubated for 30 seconds in a 42°C water bath and 
then quickly placed back on ice. 250pl of pre-warmed SOC medium was then added and 
the mixture was then shaken at 225 rpm in a 37°C incubator for 1 hour. 20pl to 200pl of 
the transformation reaction was then plated on two LB plates containing ampicilin to 
ensure well-spaced colonies on at least one plate. The plates were then incubated 
overnight at 37°C.
Storage of transformed bacterial cells
For immediate use, bacteria were grown overnight in LB medium at 37°C before 
being plated on LB agarose. These plates were grown overnight at 37°C and then stored 
for up to one month at 4°C. Longer term cultures were stored at -80°C after the addition 
of glycerol to 20% (V/V) to overnight culture medium.
Expression of recombinant proteins
The GST-expression system is based on an enzyme from Schistosoma japonicum. 
This enzyme retains its function following bacterial expression and has the ability to bind 
reduced glutathione (Smith et al., 1986). This ability to bind reduced glutathione makes it 
possible to purify GST fusion proteins by affinity chromatography using immobilised 
glutathione (Smith and Johnson, 1988). A simplified map of the PGEX6.1 vector used in
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protein expression in this study is shown in figure 2.1 illustrating the main features of this 
expression system.
Initially, small-scale experiments were done in order to optimize conditions for 
each of the three CIDR-la and EXON 2. After optimization of the procedure, overnight 
cultures were inoculated with bacterial clones, grown overnight and diluted 1:10 in fresh 
medium. The cultures were incubated until the ODgoo reached 0.8 -  1.0 when IPTG was 
added to 0.1 mM final concentration, cultures were then incubated until the OD600 reached
1.6 -  2.0 when the cells were pelleted by centrifugation at 3000g for 15 minutes at 4°C. 
Cells were then resuspended in 50ml of cold IX PBS per litre of culture. Sonication was 
done using a 10mm diameter probe with a total treatment time of 1 minute. TX-100 was 
added to 1% and lysate centrifuged at 3000g for 15 minutes at 4°C. Supernatants were 
collected and 1ml of a 50% slurry of glutathione-sepharose (Amersham Pharmacia 
Biotech, USA) beads added per litre of bacterial culture. Tubes were incubated for 30 
minutes at 4°C on a rotating wheel before the glutathione-sepharose beads were washed 3 
times with 10 volumes of cold IX PBS. The beads were washed further with preScision 
cleavage buffer (50 mM Tris-Hcl ph 7, 140 mM Nacl, ImM DTT). PreScision™ protease 
(Amersham Pharmacia Biotech, USA) was added to the washed glutathione-sepharose 
pellet at 80U per bed volume of the glutathione-sepharose beads and incubated on a 
shaking wheel for 16 hours. Following incubation, the suspension was centrifuged at 
500g for 5 minutes to pellet the glutathione sepharose beads. The eluate containing the 
protein of interest was carefully transferred to a clean tube while the GST portion of the 
protein remained bound to the GST matrix. The presence of the protein of interest was 
revealed by coomasie blue staining on an SDS-PAGE gel.
Figure 2.1
Multiple 
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Map o f the glutathione S-transferase fusion vectors showing the position o f the multiple 
cloning site and main features. The ampicillin resistance gene is shown as Ampr, the lac 
response element lac P, promoter Ptac driving expression o f the glutathione-S- 
transferase gene and multiple cloning-site. This vector includes a preScission protease 
cleavage site for cleaving the desired protein from the fiision product.
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Purification of recombinant proteins bv gel filtration
The recombinant proteins were further purified by low-pressure chromatography 
on the FPLC (Amersham's AKTAPrime system, UK) over a superdex 200 column with 
IX PBS (ph 7.4) as the mobile phase. The fractions corresponding to each of the peaks on 
the FPLC elution profile were pooled and concentrated to 3-5 mis using spin columns 
(Amersham Pharmacia Biotech). The peak containing the recombinant protein of interest 
and its purity were assessed by SDS-PAGE and coomasie blue staining.
Polvmixin B chromatography
An affinity pak detoxi-gel endotoxin-removing gel (No. 20344, Pierce, UK) was 
washed with 5ml of 1% sodium deoxycholate (sigma), 5 ml of water, and 10 ml of IX 
PBS. The pooled protein followed by 3.75 of IX PBS was loaded on the column and the 
flow through collected into a clean 10ml polystylene tube (Becton Dickinson, UK). Using 
PD columns (Bio-Rad, UK) IX PBS was replaced with endotoxin free tissue grade water 
as the protein buffer. Proteins were filter sterilized through a 0.2-pm filter, and stored at 
-80° before use. In order to quantify the amount of endotoxin in CIDR-la and EXON 2, 
endotoxin levels of serial dilutions of the recombinant protein preparations were detected 
and semiquantitated against an endotoxin standard (Sigma) in a Limulus assay (E-Toxate; 
Sigma) following manufacturers instructions.
Quantitation of protein samples
A soluble phase protein assay was carried out using a protein assay kit (Bio-Rad,
UK). This assay used Coomasie Blue to stain proteins in aqueous solution with results
being read by spectrophetometry at 595nm. BSA was used as a standard in this assay.
Briefly, protein samples were diluted in IX PBS and proprietary dye reagent added at a
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1:5 dilution. Standard dilutions of BSA were prepared in parallel in IX PBS. Samples 
were incubated for 5 minutes before absorbance was read and concentrations calculated 
from standard curves.
2.2.2 Other antigens 
Commercial peptide synthesis
Four contiguous peptides spanning the whole of the Mcvarl CIDR-la protein 
region were synthesized commercially (CN Biosciences, UK) according to the sequences 
provided. The peptide sequences are shown in the appendix.
Plasmodium falciparum cultures
The Malayan camp P. falciparum parasites used for DCs stimulations were 
cultured according to standard methods (Trager and Jensen, 1976) using RPMI 1640 with 
albumax (Invitrogen, UK) supplemented with glutamine until they reached the late 
trophozoite stage. These parasites were also grown in the presence of 0.5pg/ml of the 
microplasma removal agent (Serotec, UK) as a preventive measure.
Positive and negative control antigens
Apart from the recombinant EXON 2 protein purified as described above, the 
other negative and positive control antigens used are tabulated in table 2.2.
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Table 2.2: positive and negative control antigens
Antigen Company Catalogue No.
Purified protein derivative 
(PPD)
National Institute for 
Biological Standards, UK
PPDT
Lipopolysaccharide (LPS) Sigma L-8274
Phytohaemaglutinin (PHA) Sigma L9017
Staphylococcal 
Enterotoxin-B (SEB)
Sigma S4881
2.3 Study population (Donors)
The studies reported in this thesis were carried out in two places, one in Europe 
and the other in Africa utilizing samples from malaria-unexposed and malaria-exposed 
donors, respectively.
The National Institute for Medical Research. London. UK
The studies reported in chapters 4 and 5 were carried out with samples from 
healthy malaria-unexposed adult volunteers living in London, United Kingdom. Ethical 
approval was given by the High Barnet Area Health Authority. In addition, buffy coats 
for experiments that involved isolation of BDCA-1 positive myeloid DCs were purchased 
from the National Blood Service, Colindale, North London, UK.
Kilifi District Hospital. Kenya
The study reported in chapter 6 was carried out at the Kilifi district hospital,
situated 60 km north of Mombasa on the Kenyan coast. PBMC were obtained from
Kenyan adult donors who had lived in an area immediately surrounding the
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administrative town of Kilifi since birth. This area has prolonged seasonal P. falciparum 
transmission following the long and short rains with an estimated 10 -30  infectious bites 
per person per year, transmitted by the Anopheles gambiae s.I. complex (Mbogo et a l, 
1995). Ethical approval was given by the Kenya National Ethical Review Committee in 
Nairobi.
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2.4 Fluorescence activated cell sorter (FACS) reagents 
Table 2,3: Antibodies for immunophenotyping cells
Antibody Company Clone
Biotin conjugated mouse anti-human CDwl23 Becton Dickson, UK 9F5
PE conjugated mouse anti-human IL-12 (p40/p70) Becton Dickinson, UK C11.5
PE conjugated Mouse IgGl Immunotec PNIM060
Streptavidin PerCP Becton D ickinson, 
USA
340130
APC conjugated mouse antihuman CD4 Becton Dickinson, UK RPA-T4
Biotin conjugated mouse anti-human CD 19 Pharmingen 555411
FITC conjugated mouse anti-human CD 14 Miltenyi Biotec TUK4
BD Fastlmmune Anti-Human-IFN-YFITC/CD69 PE/CD4 T cell 
perCP-Cy5.5
Becton Dickinson, UK 340962
APC conjugated rat anti-human IL-10 Becton Dickinson, UK JES3-19F1
APC conjugated rat IgG2a Pharmingen 553932
FITC conjugated anti-human BDCA-1 M ilteny i B io tec , 
Germany
AD5-8E7
FITC conjugated anti-human BDCA-3 M ilteny i B io tec , 
Germany
AD5-14H12
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FITC conjugated anti-human BDCA-4 M ilten y i B io tec , 
Germany
AD5-17F6
PE conjugated mouse anti-human CD69 Pharmingen FN50
FITC conjugated mouse anti-human IFN-y Pharmingen B27
FITC mouse IgGl Immunotec PN0639
APC conjugated mouse anti-human CD45RO BD Biosciences 559865
FITC conjugated mouse anti-human CD45RA BD Biosciences 555488
Mouse anti-human HLA-DR PerCP B ecton D ickinson, 
USA
347364
APC conjugated ant-human CD56 Immunotec PNIM2474
Mouse anti-human CD49d Becton D ickinson, 
USA
340976
Mouse anti-human CD28 Becton D ickinson, 
USA
340975
CD45RO Microbeads M ilten y i B io tec , 
Germany
130-046-001
BDCA-1 (CD 1C) DCs isolation kit Mil teny i  Biotec ,  
Germany
130-090-506
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Table 2.4: Reagents for intracellular staining
Kit/Reagent Company Catalogue number
Brefeldin A Sigma B-7651
Becton Dickinson, France 
FACS lysing solution
Becton Dickinson, UK 349202
BD FACS permeabilizing 
solution 2
Becton Dickinson, UK 340457
Fix and Perm fixation and 
permeabilization kit
Caltag GAS002S-100
2.5 Isolation of Peripheral I Hood Mononuclear Cells (PBMC) from whole blood
Heparinised blood was taken from the donors or buffy coats after obtaining 
ethical consent. This blood was then transferred to 15ml or 50ml sterile Falcon tubes 
(Becton Dickinson, France) according to the volume taken. Tubes were centrifuged at 
600xg for 5 minutes, and the plasma was taken out and frozen for future use. The blood 
was then layered onto an equal volume of Ficoll Lymphoprep™ (Nycomed, Oslo, 
Norway) in 15ml or 50ml Falcon tubes, and centrifuged at 800xg for 20 minutes (without 
break). The peripheral blood mononuclear layer was then collected from the interphase 
by pastette pipette into fresh Falcon tubes. The PBMC were then washed three times in 
RPMI 1640, and counted under a microscope using 0.05% Trypan Blue solution in IX 
PBS (Sigma, UK) using a counting chamber (Sigma, UK). The PBMC were then 
resuspended at the appropriate concentration in complete RPMI 1640 medium (RPMI
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1640 that contained 10% heat inactivated human AB serum, 2mM glutamine, 100 fxg/ml 
streptomycin, 100 p,g/ml penicillin, and 10 mM HEPES (Gibco))
2.6 Magnetic cell sorting (MACS)
In certain experiments, it was necessary to use supermagnetic beads coated with 
MAbs to either deplete or positively select for particular cell phenotypes. In all these 
cases, a powerful magnet fitted with the necessary adapters (superMACS, Miltenyi 
Biotec, Germany) was used according to the manufacturer’s protocol.
BDCA-1 (CD1C1 dendritic cell isolation (chapter 41
Positive selection of BDCA-1 positive myeloid DCs was done using a magnetic 
labeling system (kit) according to the manufacturers protocol (Miltenyi Biotec, 
Germany). This isolation was done in two steps. Firstly, BDCA-1 expressing B cells were 
magnetically labeled with CD 19 microbeads and subsequently depleted by separation on 
a MACS column (Miltenyi Biotec, Germany), which is placed in a magnetic field. In the 
second step, BDCA-1 blood DCs in the B cell depleted flow through fraction are indirect 
magnetically labeled with biotin-conjugated BDCA-1 antibody and anti-biotin 
microbeads. Upon separation, the labeled BDCA-1 blood DCs are retained in the column 
and are eluted after removing the column from the magnetic field.
Briefly, PBMC were resuspended in staining buffer at 108 cells per 200pl. To deplete B
cells, lOOpl of each of FcR blocking reagent, CD 19 microbeads and BDCA-1 biotin
antibody per 10 cells was added, mixed and incubated for 15 minutes at 4 C. The cells
were then washed in 20 volumes of wash buffer and then resuspended in 500pl of the
wash buffer per 108 cells. The cell suspension was then applied to an LD column
(Miltenyi Biotec, Germany) equilibrated with wash buffer and placed in a strong
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magnetic field. The flow-through collected was devoid of B cells as confirmed by flow 
cytometric staining.
To positively select BDCA-1 positive DCs, the flow-through collected above was 
centrifuged and resuspended in 400pl per 108 cells and incubated at 4°C in the presence 
of lOOpl of anti-biotin microbeads. The cells were washed as above and then resuspended 
in a final volume of 500pl and then applied in to an LS column places in a powerful 
magnetic field. BDCA-1 positive DCs were then flushed out of the column into a 15ml 
Falcon tube using a plunger. This positive selection step was repeated to increase the 
purity of the BDCA-1 DCs collected. The purity of the isolated DCs was assessed by 
flow cytometry.
2.7 PBMC and Whole blood activation cultures and cytokine detection
Detection of cytokines in antigen-activated cells was done as described elsewhere
(Becton Dickinson, France, application notes). Briefly, sodium heparinized venous blood
was aliquoted into 15ml polypropylene tubes at 0.5 ml per tube. The costimulatory
monoclonal antibodies (MAbs) CD28 and CD49d (Becton Dickinson, France) were
added to a final concentration of lp,g/ml and either CIDR-la or EXON2 or
staphylococcal enterotoxin B (SEB, Sigma) was added at optimal concentrations (5pg/ml
for both CIDR-a and EXON2 and lpg/ml for SEB). The tubes were incubated upright in
a humidified 37°C, 5% CO2 incubator for a total of 7 hours, with the first two hours in the
absence of Brefeldin A (BFA, Sigma). The protein transport inhibitor, BFA (lO^i/ml) was
included for the last 4 hours of activation. After 6/7 hours, 50 \il of 20 mM ETDA
solution in PBS was added to the whole blood culture. The tubes were then vortexed
vigorously and incubated for 15 minutes at room temperature after which 100  [xl of the
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activated blood was aliquoted into 5-ml polystyrene tubes for further processing. Blood 
samples were then lysed and fixed withlml of X 1 Becton Dickinson (BD) FACS™ 
lysing solution for 10 minutes at room temperature and then washed twice with XI PBS 
with 0.5% bovine serum albumin and 0.1% sodium azide (wash buffer).
Surface staining was done by incubating the cells with biotinylated mouse anti-human 
CD4 and R-PE conjugated mouse anti-human CD69 antibodies for 30 minutes in the dark 
and then for another 30 minutes with streptavidin PerCP. Cells were subsequently 
resuspended in 0.5 ml permeabilizing solution (BDIS, Becton Dickson Immunocytometry 
Systems) for 10 minutes in the dark at room temperature. After permeabilization, cells 
were washed once and intracellular staining was performed for 30 minutes in the dark 
using FITC and APC conjugated mouse anti-human IFNy and IL-10, respectively.
Four-color flow cytometric analyses were performed on the FACSCaliber™ flow 
cytometer (BDIS). Data were acquired using CELLQuest™ (BDIS), collecting 50000- 
gated CD4+ events. Data were displayed in two color dot plots using CELLQuest to 
measure both the proportions of CD69+ and double positive (CD69+ and cytokine) cells. 
Side scatter and FL3 (CD4 PerCP) gating were used to exclude any CD4+ monocytes 
during data analysis.
2.8 PBMC Proliferation assays
Peripheral blood mononuclear cells (PBMC) were separated over Ficoll-paque 
(Phamarcia Biotech) by use of standard procedures.
PBMC were labeled with Carboxyfluorescein Diacetate Succinimidyl Ester (CFSE,
Molecular Probes, Netherlands) as described elsewhere (Parish, 1999). Briefly, the cells
were washed twice in sterile PBS, pelleted, and re-suspended at 107 /ml of 5pM CFSE in
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pre-warmed PBS at 37°C in the dark. Dye incorporation was stopped by adding twice the 
volume of 100% human AB serum (North London, Blood Transfusion Service). Cells 
were washed 3 times and dye incorporation was assessed by flow cytometry.
PBMC were plated out at 2 X 105 cells/well in a 96 well U bottomed plate (Nunclon; 
Gibco) and cultured in a final volume of 200 pi of complete RPMI 1640. The CIDR-a 
and EXON2 fragments were used at a final concentration of 0.25 pg/ml. Purified Protein 
Derivatives (PPD) at 10 pg/ml and Phytohaemagglutinin (PHA) (Sigma) at 2.0 pg/mL 
were used as positive and viability controls, respectively. Each condition was set out in 
triplicate. Plates were incubated at 37°C, 5% CO2, 95% air in a humidified atmosphere 
for 7 days. The proliferative responses of CD4+T cells were determined by flow 
cytometry. Supernatants were removed for the measurement of cytokines before 
cytometric analysis.
Cells were then washed in sterile PBS containing 0.5% bovine serum albumin 
(BSA), 5.0 mM EDTA pH 8 and 0.01% sodium azide (Sigma) and incubated with the 
appropriate combinations of APC, PE and PerCP conjugated antibodies for 30 minutes. 
Excess antibody was removed with PBS and the cells fixed 1% paraformaldehyde in 
PBS. All antibody labeling was carried out in situ in the culture plates.
Flow cytometry was performed either on a FACscalibur using Cell Quest
software (Becton Dickinson) or on a Coulter EPICS XL with XL system II in London
and Kilifi, respectively. Cell division was determined from the proportion of cells with
reduced fluorescence intensity of CFSE as shown in figure 3. Events were acquired for a
given length of time (1 min) thus permitting the relative numbers of recovered viable
cells within each well to be determined. Analysis using the APC-, PE-, PerCP-,
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conjugated antibodies allowed the proportions of the different cell subsets within the 
dividing (low CFSE fluorescence) and non-dividing (high CFSE fluorescence) 
populations to be determined. A donor was considered to have responded by CD4 T cell 
proliferation if the mean number of dividing cells in triplicate wells, containing an 
antigen exceeded 2  times the mean value of triplicate wells without antigen.
2.9 Determination of cytokine concentrations by Enzyme Linked immunosorbent 
assay (ELISA)
Supernatants from the PBMC cultures were tested for the presence of cytokines 
using the OTEIA™ sets (Pharmingen/ Becton Dickinson, Oxford, UK) for IFN-y, IL-10, 
IL12p70 and IL-4 and a Human IL-18 ELISA kit (Medical and Biological Laboratories 
Co., LTD., Japan) following the manufacturers instructions. The cytokines tested for and 
kits used are listed in table 2.3. Briefly, microwells were coated with lOOpl of the capture 
antibody diluted in 0.1 M carbonate buffer (pH 9.5) and incubated at 4°C overnight. The 
following day, the wells were washed three times with IX PBS with 0.05% Tween-20 
and then incubated with 200pl per well of the assay diluent (IX PBS with 10% fetal calf 
serum) for 1 hour at room temperature. After washing three times, the cytokine standard 
and samples were added in duplicates and triplicates, respectively and incubated for two 
hours at room temperature. The plates were then washed for 5 times and lOOpl per well 
of the working detector (detection antibody + streptavidin-HRP reagent) added. The 
plates were then incubated in the dark for 1 hour at room temperature after which they 
were washed 7 times. lOOpl of the substrate solution (tetramethylbenzidine and hydrogen 
peroxide) was then added and incubated in the dark for 30 minutes after which the 
reaction was stopped by the addition of 2N sulphuric acid. Absorbance was read at 450
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nm. The concentration of the cytokines was determined from the averages of 
duplicate/triplicate wells using a standard curve.
Table 2,5: ELISA sets for cytokine detection
Cytokine ELISA set
Human IL-10 Cat. No. 555157 (Becton Dickinson, UK)
Human IFN-y Cat. No. 555158 (Becton Dickinson, UK)
Human IL12p70 Cat. No. 555183 (Becton Dickinson, UK)
Human IL-4 Cat. No. 555194 (Becton Dickinson, UK)
Human IL-18 Cat. No. 7620 (Medical and Biological 
Laboratories Co., LTD., Japan)
2.10 Denditic cell assays
Dendritic cell assays in whole PBMC
IX106 PBMC were incubated with medium only, EXON2 (5p,g/mL), CIDR-a (5 
Hg/mL) and LPS (l[Ag/mL) in a final volume of 500pl in 48 well microtiter plates. BFA 
was added 4 hours before staining the cells for flow cytometry.
Three different sub-populations of dendritic cells were identified in whole PBMC 
by surface staining of the cells with anti-BDCA-1 FITC and CD 19 PerCP, anti-BDCA-2 
and CD 123 PerCP, and anti-BDCA-3 FITC and CD 14 PerCP (Dzionek et ah, 2000; 
Dzionek et al., 2001). Cells were fixed and the permeabilized for intracellular staining by 
using the Fix and Perm cell permeabilization kit (Caltag Laboratories, USA) according to 
the manufacturers instructions. Intracellular staining for IL-10 and IL-12 was done using
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APC anti-human IL-10 and PE anti-human IL-12, respectively. 4X105 cells were 
acquired per sample on the FACscalibur.
Dendritic cell assays in isolated BDCA-1 DCs
104-105 BDCA-1 positive DCs were incubated with medium only, EXON2 
(5pg/mL), CIDR-a (5 pg/mL), Malayan camp P. falciparum schizonts (30 schizonts/DC) 
and LPS (lpg/mL) in a final volume of 500pl in 48 well microtiter plates. For those 
experiments where cytokine induction was assessed by flow cytometry, BFA was added 
4 hours before harvesting and staining the cells. In this case, cells were harvested, stained 
and examined for IL-12 and IL-10 induction by flow cytometry on a FACscalibur after 6 
and 12 hours post-stimulation. Intracellular staining was done as described above. 
Otherwise, supernatants for cytokine measurement by ELISA were harvested after 12 and 
24 hours post-stimulation in cultures without brefaldin A.
2.11 Data analysis
After acquisition, flow cytomteric data was further analysed by Flowjo software 
version 4.3 (Treestar, Inc., USA). Flow cytometry and ELISA data were stored and 
formatted in Mirosoft Excel (Microsoft Corporation, USA) and all the graphs shown in 
chapters 4, 5 and 6 were plotted in GraphPad software, (GraphPad Software Inc., USA). 
Where appropriate, statistical analyses were done using Stata version 8.0 (Stata 
Corporation, USA).
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CHAPTER 3
EXPRESSION AND PURIFICATION OF RECOMBINANT PROTEINS FROM 
THE EXON 2 AND CIDR-la DOMAINS OF PFEMP-1
3.1 Introduction
The Plasmodium falciparum erythrocyte membrane protein (PfEMP)-l binding
region consists of multiple receptor like domains called Duffy binding like (DBL)
domains and cysteine rich interdomain regions (CIDR). These adhesion domains can be
grouped by sequence similarity (Smith et al., 2000) into seven types of DBL domains (a,
la , p, y, b, e and x) and four types of CIDR domains (a, a i, P and y). See figure 1.7 in
chapter 1 section 1.8.2 illustrating the domain structure of PfEMP-1. CIDR-la has been
described as the CD36 binding domain and contains a conserved cysteine rich motif
(Baruch et al., 1999; Miller et al., 2002). Most P. falciparum field isolates bind to CD36
(Newbold et al., 1997) making CIDR-la an attractive anti-adhesive vaccine. In addition,
the surface location of PfEMP-1 on the infected red blood cell, as described in chapter 1
section 1.8.2., means that CIDR-la is exposed to the immune system making the Pf-
iRBC susceptible to antibody attack. Work to develop a CIDR-la based vaccine is
ongoing and several animal immunization studies have reported some encouraging
progress (Baruch et a l , 2002a; Baruch et al., 2003; Gratepanche et al., 2003). Previously,
it was shown that both malaria exposed and non-exposed humans make both CD4 T cell
proliferative and cytokine (interleukin-10 and IFN-y) responses to a 250 amino acid
recombinant protein fragment of CIDR-a expressed from the Malayan camp (Me) varl
gene (Allsopp et al., 2002). In order to characterize these responses further, CIDR-la
was cloned, expressed and purified from a 250 amino acid segment from the FCR3
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varCSA CIDR-la and a4 var CIDR-la. Mcvarl CIDR-la and EXON 2 were expressed 
and purified from constructs cloned previously in the lab.
3.2 Materials and Methods 
Sequences
Three gene sequences of CIDR-la were obtained from the Malayan Camp 
laboratory isolate me varl gene (accession number Y13402), the A4TRES laboratory 
isolate for the A4var gene (accession number L42244) and FCR3. varCSA gene (accession 
number AJ133811). Whilst me varl and a4var  CIDR-las are CD36 binders, 
FCR3 .varCSA is not. An extra gene segment corresponding to a 250 amino acid fragment 
of the intracellular EXON2 region was obtained from the A4 var gene (accession number 
AJ413950) isolated from the A4TRES laboratory isolate for expression and purification 
of a negative control protein for the CIDR-la experiments conducted in malaria- 
unexposed donors. As shown previously (Allsopp et al., 2002), malaria-unexposed 
donors do not make cellular responses to this region of PfEMP-1.
Polymerase chain reaction (PCR)
Polymerase chain reaction was used to generate a 717 fragment of the EXON2 domain 
coding for 239 aa, a 702 bp fragment from the Me varl CIDR-a region coding for 234 
aa, a 709 bp fragment from the A4var CIDR-la region coding for 236aa and a 710 bp 
fragment from the FCR3.varCSA CIDR-la coding for 238aa. The primers used for these 
amplifications are shown on table 3.1.
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Table 3,1 Primer sequences
Forward primer Reverse primer
Mcvarl CIDR- 
la
5' CGGGAATT CGAAGAC AAA 
ATTATGTCCTATAATGC3'
5' CGGGAATTCCTAATCCGTC 
TTTTCCTCCTGG3'
A4var CIDR-la 5'AGCTGCGGCCGCTTACAA
GGATCCTTTGAATCACCAAT
ACATTGG3'
5'AAAGCTGAATTCAAAGTG 
AAAAAACAAAAGACATTCA 
AT AATTTTTTT3'
¥CR3varCSA
CIDR-la
5 ’ AGCTGCGGCCGCTTACGA 
TTAGAATGTTTTATCATTAT 
CTAC3'
5' AAAGCTGAATTCGATAAT 
CCTAATATCATTTCATAATT 
TTTTT3
EXON 2 5'CCGGAATTCATATATGTAC 
CAGGTAGTCC3'
5' CCGGAATTCTTAGTC ACC A 
CTATGTGTCTCA3'
Cloning
Sequences were verified (MWG Biotech) and cloned into PGEX-6P1 (Pharmacia 
Biotech) as described in section 2.2.1 (chapter 2), resulting in glutathione S transferase 
(GST) fusion proteins. See figure 2.1 in chapter 2 for a map showing the main features of 
PGEX vectors.
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3.3 Results
Expression and Purification of Recombinant Proteins
The two CIDR-la gene segments, FCR3 varCSA CIDR-la 2lvA A 4 var CIDR-la, 
were successfully cloned into the PGEX-6P1 expression vector. Protease deficient E. coli 
B21 bacteria strain was successfully transformed with these constructs. Me varl CIDR- 
l a  and EXON 2 were grown up from glycerol stocks that were cloned into the same 
vector using the primers described above. Single colonies were picked and grown in LB 
broth and protein expression induced with IPTG resulting in the expression of GST 
fusion proteins as explained in chapter 2. Upon sonication of the bacterial cells, the 
extract was incubated with glutathione-sepharose 4b beads. Glutathione-sepharose beads 
were then washed with preScision cleavage buffer. The fusion proteins were then cleaved 
off GST and eluted by the use of preScision protease cleavage according to the 
manufacturer’s instructions. The bacterial extract, various washes (from the beads) 
collected after each step of the purification process and the eluted GST were analysed on 
an SDS-PAGE gel. Staining with coomasie blue revealed a protein of the expected size in 
the case of me varl (approximately 27531 Da) and A4 var CIDR-la (approximately 
27531 Da), and EXON 2 (27009 Da) in the fractions collected after preScision protease 
cleavage. For EXON 2, me varl CIDR-la and A4 var CIDR-la, recombinant proteins of 
the expected molecular weight were expressed and purified. An example of a successful 
purification of CIDR-la is shown in figure 3.1. FCR3 varCSA CIDR-la could not be 
purified, as it was insoluble. Attempts to solubilize this protein with sarkosyl detergent 
did not help, as the denatured protein lost its ability to bind bind glutathione sepharose
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beads. A representative protein gel showing the results for FCR3 varCSA C ID R -la 
purification after treatment with sarkosyl is shown in figure 3.2.
In order to use recombinant proteins for cellular immunological assays, it’s 
important to make sure that there are no bacterial contaminants. Further purification of 
the CIDR-la and EXON 2 proteins was done by gel and polymixin-b chromatography.
Figure 3.1
m o le c u la r  w e ig h t  m a r k e r
C D IR -la
Representative coomasie blue stained SDS-PAGE gel showing Me varl CIDR-la protein 
after prescision protease cleavage from Glutathione sepharose (GST); lane 1 is the 
bacterial sonicate; lane 2 is the bacterial sonicate after incubation with GST beads; lane 
3 is GST beads wash before prescision protease cleavage; lane 4 is the GST containing 
fraction; lane 5 is a spin-column flow through after CIDR-1 a protein concentration; lane 
6 is CIDR-la under reducing conditions; lane 7 is CIDR-la under non-reducing 
conditions and lane 8 is the molecular weight marker (kDa).
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Figure 3.2
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Representative coomasie blue stained SDS-PAGE gel showing the results fo r  
FCR3varCSA CIDR-la protein expression. This gel was run after the prescision 
protease cleavage step; lane 1 is the bacterial sonicate, lane 2 is the bacterial sonicate 
after the incubation with glutathione sepharose beads, lanes 3 - 5  represent the various 
GST bead washes before prescision protease cleavage, lane 6 is GST, lane 7 is FCR3 
varCSA CIDR-la under reducing conditions, lane 8 is FCR3 varCSA CIDR-la under 
non-reducing conditions and lane 9 is the molecular weight marker (kDa).
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Chromatographic purification of CIDR-la and EXON 2
In each case, the recombinant protein fragment recovered from the GST 
purification columns was concentrated to 3-5ml and purified further by size exclusion by 
running it through a superdex 200 column on an FPLC with PBS (pH 7.4) as the mobile 
phase. Fractions corresponding to the various peaks on the elution profile were collected 
and analysed on an SDS-PAGE gel to determine the peak that contained the protein of 
interest. However, in most cases there was only one dominant peak, as shown in figure 
3.3, which corresponded to the protein of interest. Mass spectrometry confirmed the 
presence of signals in the region of the expected molecular weight of CIDR-la and 
EXON 2 to be 27531 and 27009 Da, respectively. Figure 3.4 shows an example of 
CIDR-la after gel purification. CIDR-la was revealed as a single band as opposed to the 
multiple bands seen before the protein was gel purified, figure 3.1.
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2 ml fractions numbered 1 - 50 
Representative chromatogram showing the elution profile for CIDR-la on a superdex
200 column by Pharmacia FPLC (Fast Performance Liquid Chromatography). 2ml
fractions corresponding to the main peak were collected, pooled together and
concentrated to 5 mis before polymixin B chromatography was done.
Figure 3.4
1 2 3 4 5 6  7  8  9
m olecu la r w e ig h t m ark e r  
11 6
5 5 .6
4 2 .7
3 4 .4
--------------C ID R -la
2 7
-------------G ST
20
1 4 .3  
6 .5
Representative coomasie blue stained SDS-PAGE gel showing Me varl CIDR- 
l a  protein after gel filtration: lane 1 is the bacterial lysate collected after sonication; 
lanes 2, 3, 4 and 5 are other fractions apart from the main peak on the FPLC gel 
filtration profile; lane 6 is GST collected after prescision protease cleavage step; lane 7 
is CIDR-la after gel filtration under reducing conditions; lane 8 is CIDR-la after gel 
filtration under non-reducing conditions and lane 9 is the molecular weight marker 
(kDa).
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Polvmixin B affinity chromatography
All the FPLC fractions corresponding to the recombinant protein of interest in the
i
FPLC elution profile were pooled and concentrated. An affinity pak detoxi-gel 
endotoxin-removing gel No. 20344 (pierce) was washed with 5ml of 1% sodium 
deoxycholate (sigma), 5 ml of water, and 10 ml of IX PBS. The pooled protein followed 
by 3.75 of IX PBS was loaded on the column and the flow through was collected. This 
process was repeated three times for each recombinant protein preparation. Using PD 
columns IX PBS was replaced with endotoxin free tissue grade water as the protein 
buffer. Proteins were filter sterilized through a 0.2-pm filter, and stored at -80° before 
use. In order to quantify the amount of endotoxin in CIDR-la, endotoxin levels of serial 
dilutions of CIDR-la preparations were detected and semiquantitated against an 
endotoxin standard (Sigma) in a Limulus amoebocyte assay (E-Toxate; Sigma) following 
manufacturers instructions. The endotoxin level was found to be 0.10 EU/ml determined 
by multiplying the inverse of the highest dilution of CIDR-la found to be positive by the 
lowest concentration of an endotoxin standard found positive.
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3.4 Discussion
The work presented in this chapter was aimed at generating sufficiently pure 
recombinant proteins for use as antigens in the experiments investigating immune 
responses to CIDR-la as presented in the next three chapters. The CIDR-la gene 
sequence is highly variable but the respective resultant proteins are functionally 
conserved. As described in chapter 1, CIDR-la is the CD36 binding domain of PfEMP- 
1. However, a few CIDR-la variants that are expressed on parasites that bind CSA 
(chondroitin sulphate) do not bind CD36. CIDR-la-CD36 interactions have been 
implicated in the inhibition of maturation of human monocyte derived DCs reported 
previously (Urban et al., 1999; Urban et al., 2001b) (see chapter 1). Therefore, in 
addition to characterising cellular responses to CIDR-la, the studies presented in this 
thesis aimed at comparing DC stimulations by CD36 binding CIDR-las with those that 
do not. Three CIDR-la variants from the same region of PfEMP-1, two of which are 
CD36 binders (me varl and A4 var) and one non-CD36 binder (FCR3 var CSA) were 
identified and cloned as described in chapter 2 and the introduction to this chapter.
Two of these CIDR-la gene variants and the EXON 2 gene were successfully 
cloned into PGEX6P1 and GST fusion proteins expressed and purified. GST fusion 
proteins were purified from E coli BL21 protease deficient cells transformed with these 
constructs. A third CIDR-la construct, FCR3.varCSA CIDR-la was successfully cloned 
but its respective protein could not be purified because it was insoluble. The detergent, 
sarkosyl, was used to solubilize this protein. However, the denatured protein failed to 
bind glutathione sepharose beads, which means that the solubilized protein could not be 
purified. There other ways of improving recombinant protein solubility including
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reducing the number of cysteines around the primer boundaries that could have been 
used. In addition, altering the culturing conditions in which the expressing bacteria is 
grown and especially lowering the temperature may aid the expression of a soluble 
protein. It is also worth changing the expression system and expressing the protein in 
mammalian or insect cells. Even though the A4 var CIDR-la was expressed, it was 
produced in low amounts and was too unstable to successfully purify it in large enough 
quantities that could be used in these studies. This protein is known to degrade rapidly 
during purification, with time and storage (Britta Urban, Claire Mackintosh, personal 
communication). For these reasons, only one variant of CIDR-la, the me varl variant 
was available for use in the experiments described in the next three chapters. Therefore, 
unless otherwise stated, the results presented in the next three chapters will be based on 
me varl CIDR-la experiments.
Since LPS and other bacterial products can stimulate DCs and other APC cells via 
TLRs and/or other receptors on the surface of these cells, EXON 2 was purified for use as 
a negative control for CIDR-la for all experiments involving malaria-unexposed donors. 
Previously, it was shown that unlike malaria exposed donors, malaria-unexposed donors 
do not respond to this EXON 2 domain of PfEMP-l by CD4 T cell division and cytokine 
production (Allsopp et al., 2002). This made EXON 2 an excellent control for 
contamination in CIDR-la since the two proteins were expressed in the same system and 
purified in exactly the same way. In addition, both CIDR-la and EXON 2 recombinant 
proteins were taken through thorough purification protocols in order to get rid of bacterial 
contaminants from the final products. As discussed in section 3.3, the desired proteins 
were cleaved off GST by using preScision protease™ and then purified further by gel
filtration (FPLC) and polymixin B chromatography resulting in reasonably pure 
recombinant proteins. For both proteins endotoxin contamination, determined by the E- 
Toxate limulus based assay was found to be negligible (as shown in section 3.3).
108
CHAPTER 4
DENDRITIC CELL RESPONSES TO THE CIDR-la DOMAIN OF PfEMP-1 IN 
MALARIA UN-EXPOSED DONORS
4.1 Introduction
Dendritic cells (DCs) are central to the induction of immune responses to 
pathogens infecting the human host because they phagocytose and transport antigen from 
the periphery to lymphoid tissues in response to microbial products and inflammatory 
signals. In the T cell zones of secondary lymphoid organs, they initiate primary immune 
responses by activating naive T cells as well as boosting memory responses. DCs also 
regulate the immune responses by producing cytokines. Several DC-derived cytokines 
mainly IL-10 and/or IL12 and IL-18 have been reported to have a role in malaria (see 
section 1.6.2) (Singh et a l . , 2002; Stevenson et a l ., 2001). CD4 T cells and antibodies 
have been shown to protect immunized animals from infection (Collins et a l . ,  1994; 
Hirunpetcharat et al. ,  1997; Hoffman et al.,  1989; Hoffman et a l ,  1994; Rodrigues et a l. ,  
1993; Siddiqui et a l. ,  1987) and there is ample evidence that antibodies play a role in 
protection against malaria in people living in endemic areas (Bull and Marsh, 2002; 
Cohen et al.,  1961; Edozien et al. ,  1962; McGregor and Carrington, 1963; Sabchareon et 
a l . ,  1991). It is expected therefore that such protective antibody responses would be 
induced by DCs and macrophages presenting malarial antigens to CD4 T cells, which in 
turn provide help to B cells.
Of particular relevance to P. falciparum infections in humans is the expression of 
CD36 on some populations of DC. This molecule, thought to be responsible for 
recognition and uptake of apoptotic cells (Albert et a l, 1998), is also implicated in
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modulating immune responses to Plasmodium falciparum-infected red blood cells (Pf- 
iRBC) via its ligation on monocyte-derived DCs (Urban et al., 2001b). DC-Pf-iRBC 
interaction is most likely mediated by the CIDR-la domain of PfEMPl on the surface of 
Pf-iRBC (Urban et al., 1999; Urban et al., 2001b). Alternatively, DC may interact with 
Pf-iRBC via TLRs. However, as already stated in chapter 1, the role of TLRs in malaria 
is only beginning to be investigated. A recent report indicated that Pf-iRBC might have a 
ligand for TLR9 (Pichyangkul et al, 2004).
There are several DC sub-populations that differ in phenotype, function and 
localization in various microenvironments in the human body. Three distinct sub­
populations of human peripheral blood DCs can now be easily distinguished by using 
monoclonal antibodies against novel blood DC antigens (BDCA) (Dzionek et al., 2000; 
Dzionek et al., 2001). BDCA-2 and BDCA-4 are specifically expressed on plasmacytoid 
(lymphoid) BDC (CDllc'CD123bigh). BDCA-1 (CDlc) and BDCA-3 discriminate 
between two sub-populations of human blood DCs, which are phenotypically of myeloid 
origin: BDCA-1 (CDlc) is expressed on CDllch,ghCD123low and BDCA-3 on previously 
not well described, CDllclow and CD 123" BDCs. These antibodies, when conjugated to 
fluorochromes, allow us to identify and enumerate the blood DC sub-populations by flow 
cytometry. They have also been conjugated to immunomagnetic beads allowing for the 
isolation of BDCA-1, BDCA-2/BDCA-4 and BDCA-3 positive DCs. In this chapter they 
have been used to: 1) identify the three DCs sub-populations in both whole blood and 
PBMC in an intracellular cytokine staining assay optimized for IL-10 and IL-12 detection 
and 2) for isolation of BDCA-1 positive DCs. In short, this study has used anti-BDCA
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antibodies to analyse cytokine responses of DC to CIDR-la, the CD36 binding domain 
of PfEMP-1 on the surface of P. falciparum infected red cells.
4.2.0 Experimental design
4.2.1 Rationale
Anti-CIDR-la responses in CD4 T cell populations from malaria naive donors 
have been reported previously (Allsopp et al., 2002), and are described in more detail in 
chapter 5 of this thesis. In order to understand why the T cells of malaria un-exposed 
donors are activated by this malarial antigen, it is necessary to investigate the interaction 
of CIDR-la with DCs. DCs are the main APCs in the human body and unlike other 
APCs, they have the ability to induce primary as well as secondary responses (Liu, 2001). 
In order to stimulate T cells, DCs up-regulate surface expression of co-stimulatory 
molecules such as CD80, CD86 and CD40, which are required for T cell activation in 
addition to TCR ligation by HLA molecules (as described in chapter 1, section 1.6.2 and 
figure 1.5). In addition, DCs produce cytokines that can drive T helper cell deviation into 
either TH1 or TH2. DC-derived cytokines include the pro-inflammatory and anti­
inflammatory IL12p70 and IL-18, and IL-10 cytokines, respectively. The previously 
observed response of CD4 T cells to CIDR-la in malaria un-exposed donors (Allsopp et 
al., 2002) could be the result of classical antigen-presentation by DCs i.e. uptake, 
processing of CIDR-la within class II pathway and subsequent presentation of peptides 
on MHC class II for recognition by specific T cells via the TCR. Alternatively, it is 
possible that DCs may directly interact with CIDR-la through CD36 or even toll-like 
receptors (TLR) resulting in the production of IL-18 and IL12p70 that may in turn 
activate and induce IFN-y transcription in the responding CD4 T and NK cells without
engaging the TCR via MHC class II peptide complex. It has now been demonstrated that 
the presence of these two cytokines is enough to induce IFN-y production in T cells 
(Yang et al., 1999; Yang et a l, 2001). In this chapter, the cytokine response of DCs to 
CIDR-la has been investigated by analysing IL-10, IL12p70 and IL-18 production in the 
two major blood DC sub-populations.
Previous studies have shown that the malaria parasite, P. falciparum, modulates 
monocyte-derived DC responses to pro-inflammatory signals (Urban et al., 1999; Urban 
et al., 2001a). Intact Pf-iRBC can bind directly to CD36 (Udomsangpetch et al., 1997), 
inhibit maturation of DCs and change their phenotype from IL12p70 producing DCs to 
IL-10 producing DCs (Urban et al., 1999; Urban et a l , 2001b). It has also been 
demonstrated that monoclonal antibodies (MAbs) to CD36 and apoptotic cells inhibit 
DCs maturation and function in a similar fashion (Urban et al., 2001b). These 
experiments implicated CIDR-la, the CD36 binding domain of PfEMP-1 (Baruch et al., 
1997; Baruch et al., 1999; Cooke et al., 1998; Gamain et al., 2001b; Miller et al., 2002), 
as the ligand on Pf-iRBC that interacts with DCs. More recently, a similar phenomenon 
has been described in murine malaria whereby Plasmodium yoelii blood stage parasites 
inhibited a protective CD8 T response directed at liver stage parasites (Ocana-Morgner et 
al., 2003). It is therefore important that we understand clearly the interaction of the 
CIDR-la domain with DC as this domain of PfEMP-1 is now being considered as a 
potential anti-malaria vaccine candidate, and there have been some encouraging reports 
indicating that animals immunized with CIDR-la may be protected from disease (Baruch 
et al., 2003; Gratepanche et a l , 2003). The experiments described in this chapter
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investigated whether CIDR-la directly activates peripheral blood DCs and whether their 
activation results in the production of cytokines.
4.2.2 Materials and Methods 
Donors
Healthy malaria un-exposed donors working at the National Institute for Medical 
Research, London, UK were recruited as described in chapter two, section 2.3. Initially, 
ten donors were recruited for time-course experiments investigating at the kinetics of IL- 
10 and IL12p70 production for 24 hours post stimulation by intracellular staining on 
whole PBMC. Another 12 donors were subsequently tested for IL-10, IL12p70 and IL-18 
in isolated BDCA-1 positive myeloid DCs; 6 of them by ELISA for the three cytokines at 
12 and 24 hours post stimulation and the other six by intracellular staining for IL-10 and 
IL12p70 at 6 and 12 hours post stimulation.
PBMC cell cultures
For cytokine detection in blood DCs in whole PBMC, 106 PBMC suspended in 
500 pi of complete RPMI 1640 (constituted as described in chapter 2, section 2.5) per 
well were cultured in 48 well microtitre plates, in the presence of CIDR-la or control 
antigens as described in chapter two, section 2.10. Brefeldin A was included in the 
cultures for the last four hours before the cells were harvested for intracellular cytokine 
analysis by flow cytometry (Picker et al., 1995).
BDCA-1 DC isolation
For the experiments that involved DC isolation, the BDCA-1 isolation kits were 
used according to the manufacturer’s protocol (Miltenyi biotec), briefly described in 
chapter 2, section 2.6.
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Isolated DC cultures
For cytokine detection in isolated DCs by either intracellular staining or ELISA,
105 cells were suspended in 250 pi of complete RPMI1640 (see chapter 2, section 2.5) in 
48 well microtiter plates and stimulated with antigens for 6 and 12 hours. These assays 
were either set up in duplicates whenever sufficient numbers of DCs were recovered.
DC stimulations with Pf-iRBC
In some experiments involving isolated BDCA-1 DCs, Pf-iRBC from the 
Malayan camp parasite isolate at the schizont stage or un-infected red cells were included 
as antigens and negative controls, respectively. In each case 30 Pf-iRBC were added for 
each DC. The parasites were cultured using well-established methods (Trager and Jensen, 
1976) and schizonts purified over a powerful magnetic field as described in chapter 2, 
section 2.2.2.
Surface and intracellular staining
Cells were handled and stained as described in chapter 2, section 2.7. Surface 
staining was done before cell fixation and permeabilization.
Flow cvtometrv
Data were acquired on a FACscalibur™ flow cytometer using Cell Quest 
software (Becton Dickinson). The proportion and number of DCs cells staining positive 
for IL-10 and IL12p70 production were determined by analyzing the collected data using 
flowjo software 4.3 (Treestar, Inc., USA).
Detection of IL-10. IL12p70 and IL-18 bv ELISA
The concentration of IL-10 and IL12p70, and IL-18 produced by isolated BDCA- 
1 DCs was measured using OPTEIA ELISA kits as described in chapter 2, section 2.9
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(Becton Dickinson) and the human IL-18 ELISA kit (Medical and Biological 
Laboratories Co., LTD, Naka-ku Nagoya, Japan), respectively. However, these 
experiments were repeated using intracellular staining for IL-10 and IL12p70 on isolated 
cells since the IL12p70 ELISA did not work.
Data storage and analysis
Data were stored, formatted, and analyzed with Microsoft Excel (Mirosoft 
Corporation, CA, USA). Graphs were plotted in Prism-Graphics (Graph pad software, 
Inc., San Diego, CA, USA).
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4.3.0 Results
4.3.1 Identification of blood DC subsets in human peripheral blood
Three different subsets of DCs in human peripheral blood were identified as 
shown in (figure 4.1). PBMC were analysed for the presence of BDCA-1, BDCA-2 and 
BDCA-3 positives cells in the live gate as illustrated in figure 4.1 a. The average 
percentages of BDCA-1, BDCA-2 and BDCA-3 positive cells were 0.43% (standard 
deviation (STDEV), 0.9) for 7 donors, 0.25% (STDEV, 0.11) for 4 donors and 0.05% 
(STDEV, 0.046) for 5 donors, respectively.
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4.3.2 Myeloid DCs produce IL-10 and IL-12p70 in response to CIDR-la
Intracellular cytokine staining could only be carried out for two of the three 
subsets: the BDCA-1 and BDCA-2 positive DCs. BDCA-3 positive DCs were too few to 
analyse accurately for cytokine production. Isolated PBMC were cultured with CIDR-la, 
EXON 2 (as a similarly prepared, negative control protein), LPS (positive control) and 
medium only (control). DCs from these cultures were then analyzed for IL-10 and 
IL12p70 production by flow cytometery at various time points. CIDR-la and LPS, but 
not EXON 2 and the medium controls induced IL-10 and IL-12 production in the BDCA- 
1 positive sub-population in all the 5 donors (in time course experiments) tested. In 
contrast, BDCA-2 DCs did not produce any of the cytokines tested in response to CIDR- 
l a  and LPS. A representative example of BDCA-1 positive DCs responding to CIDR-la 
and other stimulants is shown in Figure 4.2. In all the 5 donors, IL-10 and IL12p70 
positive BDCA-1 DCs could be detected at 12 hours. At this time point, the majority of 
DCs producing cytokines were producing IL-10 both in response to CIDR-la and the 
positive stimulus, LPS (19.7% and 22.4%, respectively compared with 8.3% and 3.7% 
for the IL12p70 response). However, cytokines produced earlier or later than the chosen 
time point would have been missed in these experiments. In a time course experiment, 
PBMC from 5 donors incubated with EXON 2, CIDR-la, LPS were tested for 
intracellular cytokine production at 3, 6, 18, and 24 hours post stimulation. Only among 
the BDCA 1+ myeloid DC sub-population were cytokines detected upon stimulation with 
CIDR-la but not with the negative control protein (EXON 2) and the medium control. 
As shown in figure 4.3 both IL12p70 and IL-10 were produced but the kinetics of their 
production were different. While the proportion of cells positive for IL-10 continued to
increase throughout the 24-hour culture period, those producing IL12p70 reached a peak 
between 6 and 12 hours but at 24 hours there were no Il-12p70 positive cells. Clearly, 
these results suggest that similar to the response to LPS, CID R-la induces an initial 
IL12p70 response in DCs that is subsequently superceded by IL-10.
Figure 4.2
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A representative response to CIDRl-a by BDCA1 positive DC. A total o f 400,000 cells 
were acquired in each case. A) Live cell gate B) BDCA1 positive myeloid DCs gate. Cells 
were stimulated with C) CIDR-la, D) EXON 2, the negative control protein E) 
Lipopolysaccharide positive control and F) Medium control for 12 hours. In A) and B), 
the numbers shown indicate the percentages o f live cells and myeloid DCs, respectively. 
In C) - F), the numbers in the blue and red rectangular gates indicate the percentages o f  
BDCA-1 + DCs staining positive for IL-10 and !L12p70, respectively.
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Kinetics o f IL-10 and IL-12p70 production by BDCA-1 positive DCs stimulated by a) 
CIDR-la, b) Lipopolysaccharide (LPS) and c) EXON 2 (the control protein). The filled 
and open bars represent the percentages o f cells positive for 1L-I2p70 and IL-10, 
respectively. The error bars are standard errors o f the mean for 5 donors. Stimulations 
were performed in whole PBMC obtained from malaria un-exposed donors. Cells were 
harvested and stained for flow cytometry at 3, 6, 12 and 24 hours. In each case, 400,000 
cells were acquired and the percentage o f BDCA-1 + cells positive for each o f the two 
cytokines determined.
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4.3.3 CIDR-la Induced IL-10, IL12p70 and IL-18 production in isolated BDCA-1 
DCs
In order to determine whether the BDCA-1 cytokine response to CIDR-la is the 
result of a direct interaction between the DCs and CIDR-la without the involvement of 
other cells, BDCA-1 positive DCs were isolated using magnetic beads as described in the 
materials and methods section. A representative isolation is shown in figure 4.4. BDCA-1 
positive DCs were isolated in two steps. Firstly, CD 19 positive B cells were removed 
from PBMC using magnetic beads conjugated with a CD 19 MAb. Secondly, the BDCA-1 
positive DCs were positively selected from the CD 19 depleted PBMC fraction. The 
purity of the isolated DCs was evaluated by flow cytometry. Aliquots of the isolated DCs 
were stained with BDCA-1-biotin, streptavidin-PerCP, CD 19 APC and CD 14 FITC 
antibodies. After isolation, BDCA-1 positive DCs were expected to stain for BDCA-1 but 
not for CD19. Staining for CD14 was expected to reveal a minor population of BDCA-1 
blood DCs expressing CD 14 to a variable degree (figure 4.4 d). When analyzing purified 
BDCA1 DCs, an average of 1.4% (STDEV, 0.4.) CD 14 positive, BDCA1 negative cells 
were observed for 9 BDCA-1 DC isolates. On average BDCA1 positive cells from 9 
buffy coats were 96.4% (STDEV, 2.0%) pure with 1.1% (STDEV, 1.4) contaminating B 
cells and 2.3% (STDEV, 0.93) contaminating cells whose phenotypes could not be 
determined but included the CD 14 positive cells mentioned above.
The isolated BDCA-1 positive DCs were then cultured with CIDR-la, medium 
alone or control antigens for 6 and 12 hours. Cells harvested after 6 and 12 hours post 
stimulation were tested for IL-10 and IL12p70 production by intracellular staining 
followed by flow cytometry. The purified BDCA-1 DCs produced both IL-10 and
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IL12p70 in response to CIDR-la and LPS, but not to media or EXON 2 controls. 
IL12p70 and IL-10 positive cells could be detected 12 but not 6 hours post-stimulation. 
The percentages of responding BDCA-1 positive DCs from six donors after 6 and 12 
hours of stimulation are shown in figure 4.5.
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Figure 4.4
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Representative plots showing the isolation o f BDCAl positive DCs. DCs were isolated 
from PBMC obtained from buffy coats purchased from the National blood bank (UK) in 
two steps; depletion o f CD 19 positive B cells followed by positive selection o f BDCAl 
positive DCs. The data shown on this plots is gated on a live gate in order to exclude 
dead cells. 100000 cells were analysed in each case. A) Live PBMC before separation B) 
B cell depleted flow through fraction C) Counter staining o f the CD 19 positive B cell 
depleted fraction with CD 14 FITC, D) BDCAl + blood DCs
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Figure 4.5
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IL-12p70 (a), and IL-10 (b) responses in BDCA-1 positive isolated DCs at 6 (open bars) 
and 12 (black bars) hours after stimulation with antigen. Isolated BDCA-1 DCs were 
cultured at 100000 cells per well in the presence o f medium only, EXON 2 (negative 
control), CIDR-la and LPS (positive control). 50,000 cells were acquired on the flow  
cytometer and analysed for cytokine production after staining with antibodies as 
explained in the materials and methods section. The error bars represent the standard 
error o f the mean for 6 donors.
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4.3.4 Isolated BDCA-1 DCs made IL-18 in response to CIDR-la and Plasmodium 
falciparum infected red cells (Pf-iRBC)
In the above experiments, it was not possible to stain for IL-18 intracellularly due 
to the unavailability of appropriate anti-IL-18 monoclonal antibodies (at the time) that 
could be used for this purpose. However, an ELISA kit (MBL) was available for the 
detection of this cytokine in culture supernatants. To find out whether isolated BDCA-1 
DCs could also make IL-18 in response to CIDR-la, cells were cultured in the presence 
of CIDR-la or control antigens for up to 24 hours. The concentrations of IL12p70 and 
IL-10 present in these supernatants were determined by ELISA. In these experiments, 
Malayan Camp parasite isolate Pf-iRBC schizonts and control un-infected red cells were 
included as antigens in order to determine whether the anti-CIDR-la response can be 
reproduced with the intact parasite. Culture supernatants were harvested at 12 and 24 
hours and tested for IL-10, IL-12p70 and IL-18 concentrations using Opteia™ (BD) and 
the human IL-18 kit (MBL), respectively. At these time points, IL12p70 was not detected 
but CIDR-la and Pf-iRBC induced IL-10 and IL-18 production Figure 4.6 shows the 
concentrations of IL-18 and IL-10 from six donors after subtraction of the medium 
control specific values. It is not clear why IL12p70 could not be detected by ELISA in 
culture supernatants after 12 hours of antigenic stimulation and yet the same cytokine 
was detected in BDCA-1 positive DCs by intracellular staining in both whole PBMC and 
isolated DCs at the same time point (figures 4.3 and 4.5). It is possible that the ELISA kit 
used was not sensitive enough.
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Kinetics o f IL-18 (a) and IL-10 (b) production by isolated BDCAl positive DCs 
stimulated by medium only, EXON 2 (negative control), CIDRl-a, Plasmodium 
falciparum Infected red blood cells (Pf-iRBC) at the schizont stage red blood cells (RBC, 
negative control for Pf-iRBC) and LPS. Isolated BDCA-1 positive cells were cultured at 
100000 cells per well and culture supernatants were harvested after 12 and 24 hours o f 
antigenic stimulation. IL-18, IL-12p70 and IL-10 concentrations in the culture 
supernatants were determined by ELISA. The concentrations for the medium controls 
were subtracted from those o f the respective antigens. The error bars represent the 
standard error o f the mean for 6 donors. IL-12p70 was not detected in any o f the 
supernatants and this is most likely due to poor sensitivity o f the ELISA kit used (see 
section 4.4).
126
4.4 DISCUSSION
Blood from volunteers is the most accessible source of human DCs. However, 
low numbers in blood and lack of specific identification markers for human DCs has led 
investigators to rely on DCs derived from monocytes cultured in vitro in the presence of 
GMS-CSF and IL-4 for 5-7 days. Previous experiments involving stimulation of human 
DCs with malaria antigens have therefore been performed on such monocyte-derived 
populations. This gives us information from only one type of DC and not necessarily 
those that would be found in peripheral blood. In addition, in vitro manipulation and 
growth in selected cytokine environments may alter the DCs functionally. It is important 
therefore, to be able to confirm that these in vitro derived DCs give similar responses to 
DCs isolated directly from blood.
Recently, the availability of MAbs to blood DC antigens (BDCA) has greatly 
aided DC research and allowed us to isolate different sub-populations of DC directly 
from blood. As indicated earlier, (section 4.1) three subtypes of DCs can be identified in 
human blood using these antibodies: BDCA-1 and BDCA-3 myeloid DCs, and BDCA- 
2/4 positive plasmacytoid DCs {Dzionek, 2001 #215; Dzionek, 2000 #216. The current 
study investigated cytokine responses of blood DCs to CIDR-la (and Pf-iRBC) either in 
whole PBMC cultures or in purified blood DCs subsets by intracellular staining and 
ELISA assays.
An alternative set of peripheral blood DC markers exists. However, even though 
they stain the corresponding phenotypes of cells as the BDCA markers {Dzionek, 2001 
#215; Dzionek, 2000 #216}, these markers were not suitable for the experiments that 
involved detecting cytokines by four-colour flow cytometry in PBMC since they must be
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used in combination with at least two other antibodies. This reduces the number of 
cytokines that can be detected at any one time. These markers, the IL-3Ra (CD 123) 
specific for plasmacytoid DCs (Olweus et al., 1997) and C D llc for myeloid DCs 
(O'Doherty et al., 1994) are also found on various other cell types. Both, the anti-CD 123 
antibody and the CDllc antibody have to be used together with a cocktail of antibodies 
specific to lymphocyte, monocyte and granulocyte-lineage markers (lineage marker 
cocktail) conjugated to a single fluorochrome, and an anti-HLA-DR antibody conjugate 
to a different fluorochrome to detect DCs that are either CDll-CD123+HLA-DR+lin- 
(plasmacytoid DCs, BDCA-2+) or CD11C+CD123-HLA-DR+Iin- (myeloid DCs, 
BDCA-1+).
The cytokine response to CIDR-la domain of PfEMP-l in whole PBMC was 
investigated among the BDCA-1 and BDCA-2 positive DC sub-populations. BDCA-3 
positive myeloid DCs were too scarce to be analysed for cytokine production. Whilst 
BDCA-1 positive DCs responded by making IL-10 and IL12p70, BDCA-2 positive DCs 
did not respond with production of these two cytokines. BDCA-2 positive DCs 
disappeared from culture with time and were not detectable after 6 hours supporting 
previous observations that BDCA-2 expression is down regulated in vitro on CD llc- 
CD123+ DCs (Dzionek et al., 2000). For BDCA1+ DCs, the kinetics of IL-10 and 
IL12p70 production were different with the percentage of IL12p70 positive cells 
increasing to a peak at around 9 hours and then falling rapidly. On the other hand, the 
percentage of IL-10 positive cells increased throughout the 24-hour culture period. This 
difference in kinetics highlights the need for time course experiments when studying the 
production of these two cytokines by DCs. Single time point investigations after 12 hours
in culture would detect little if any IL12p70 production while both cytokines will be 
detected at earlier time points. This point is well illustrated in figure 4.3 and this 
difference in kinetics may well explain why different studies investigating Pf-iRBC 
interactions with DCs have reported conflicting results on cytokine production. In one 
study, DCs exposed to P. falciparum infected red cells were found to secrete IL-10 rather 
than IL12p70 in response to LPS and their ability to activate T cells in an allogeneic 
mixed lymphocyte reaction or to activate memory CD4 T cells was markedly reduced 
(Urban et al., 1999). These DCs also failed to mature in response to LPS as evidenced by 
failure to up-regulate costimulatory markers. Similar observations have been reported 
with in vitro and in vivo studies with P. yoelii in mice (Ocana-Morgner et al., 2003). On 
the other hand, purified haemozoin, the insoluble residue of P. falciparum  that 
accumulates in phagocytes induces DC maturation, as evidenced by the up-regulation of 
activation markers and marked IL-12 production; haemozoin did not alter LPS induced 
IL-12 production (Coban et al., 2002). In addition, Pf-iRBCs have been reported to 
induce IL12p70 production by PBMC adherent cells in vitro of naive donors within 18 
hours (reviewed in (Stevenson and Riley, 2004)). The kinetics of IL12p70 and IL-10 
production observed over a 24-hour period in the current study suggests that an initial, 
but transient, period of conventional APC/DC interaction may be followed by a 
refractory period during which pro-inflammatory cytokines are not secreted. It is 
therefore likely that different studies will report different results depending on the time 
point at which cytokine measurements were made.
These BDCA-1 responses to CIDR-la cannot be explained by endotoxin 
contamination of the recombinant protein. As explained in chapter 3, recombinant CIDR-
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l a  was subjected to thorough purification protocols including gel purification and 
polymixin-B chromatography. The amount of endotoxin in the final CIDR-la 
preparation was quantified against an endotoxin standard (Sigma) in a Limulus 
amoebocyte assay (E-Toxate; Sigma). The endotoxin level was found to be negligible 
(less than 0.10 Eu/mL, approximately 5pg/ml) as indicated in chapter 3. Even though 
human cells can respond to low levels of endotoxins, the lowest published level reported 
to induce cytokine production in human is 2 EU/mL (approximately 100 pg/ml) 
(Matthews et al., 2000). In the current study, at least 50 ng/ml were required to induce 
IL-10 and IL12p70 production in PBMC. It is therefore unlikely that the presence of LPS 
could account for the cytokine induction by CIDR-la. Furthermore, in all the above 
experiments and those that will be presented in the chapters that follow, EXON 2, a 
recombinant protein from the intracellular domain of PfEMP-1 purified exactly in the 
same way as CIDR-la was included (at the same concentration as CIDR-la) as a control 
for contamination. This segment is not known to induce cytokine responses in PBMC 
from malaria un-exposed donors (Allsopp et al., 2002) and in the current study; it did not 
induce cytokine production in DCs. In addition, P. falciparum infected erythrocytes 
grown in the presence of mycroplasma removal agent™ that prevents contamination in 
cell cultures induced IL-10 and IL-18 production in a similar fashion to CIDR-la 
suggesting that the native PfEMP-1 (or may be another) protein on the Pf-IRBC surface 
could induce the same responses as recombinant CIDR-la.
In order to elucidate whether these responses involved a direct interaction 
between BDCA-1 positive DCs and CIDR-la, BDCA-1 positive DCs were isolated from 
PBMC using immunomagnetic beads conjugated with an anti-BDCA-1 monoclonal
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antibody. These cells were stimulated with CIDR-la and Pf-iRBC, and control antigens. 
Culture supernatants were harvested after 12 and 24 hours and tested for IL-10, IL12p70 
and IL-18 by ELISA. Unfortunately, the IL12p70 could not be detected by ELISA, which 
may be due to poor sensitivity of the assay rather than its absence since this cytokine was 
detected when the experiment was repeated by intracellular staining. The stimulation of 
BDCA-1 positive DCs to make IL-10, IL12p70 and IL-18 by CIDR-la suggest that 
CIDR-la directly interacts with, and activates myeloid DCs.
However, the induction of cytokine production by DC in malaria is not limited to 
P. falciparum infected red cells. DCs, being the most important APCs (as explained in 
chapter 1), interact with other Plasmodia sp. and indeed other pathogens. P. chabaudi 
infected red cells have also been reported to induce upregulation of costimulatory 
molecules and the production of pro-inflammatory cytokines including IL-12, IL-6 and 
TNF by bone marrow derived DCs in mice (Langhome et al., 2004; Seixas et al., 2001). 
In addition, Myd88 knock out (KO) mice infected with P. berghei were shown to have a 
decreased production of endogenous IL-12 and less severe pathology than wild type mice 
(Adachi et al., 2001). This study suggested that IL-12 induced via the Toll/IL-1 receptor 
(TIR) signaling pathway (which contains Myd88 as a cytoplasmic adaptor common to 
TLR signaling) is involved in the pathogenesis of P. berghei malaria in murine malaria. 
Various microbial organisms have also been reported to induce the upregulation of 
costimulatory molecules and production of IL-2 and IL-12 in DC (Granucci et a l, 2001; 
Granucci et al., 2004), and similar results have been reported with protozoan parasites 
including Leishmania major (Gorak et al., 1998; Granucci et al., 2001; Granucci et a l,
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2004; von Stebut et al., 1998) and Toxoplasma gondii (Aliberti et al., 2004; Del Rio et 
al., 2004; Granucci et al., 2001; Granucci et al., 2004).
The detection of IL-10 and IL-18 in response to Pf-iRBC as well as CIDR-la 
suggests that the Pf-iRBC might interact with DCs via CIDR-la. That CIDR-la might 
interact with DCs via the scavenger receptor, CD36, has been suggested previously 
(Urban et al., 1999; Urban et al., 2001b). However, whether Pf-iRBC stimulate BDCA-1 
DCs to make cytokines by binding to CD36 is not known. Stimulation of monocyte- 
derived DCs with anti-CD36 monoclonal antibodies had the same effect as apoptotic 
cells, Pf-iRBCs and CIDR-la, all of which are known to interact with CD36 (Urban et 
al., 2001b). Alternatively, CIDR-la and Pf-iRBC may interact with BDCA-1 DCs via 
TLRs. While major advances have been made in the assignment of individual TLRs to 
defined roles in bacterial infections (Takeda and Akira, 2004), such identification has 
only begun to emerge in protozoan parasites (Teixeira et al., 2002). A recent study 
demonstrated that P. falciparum schizonts or schizont extract could activate human 
plasmacytoid DCs (PDC) by inducing CD86 expression and IFN-a synthesis 
(Pichyangkul et al., 2004). The P. falciparum schizont stimulated PDC elicited a poor T 
cell response, but promoted y8T cell proliferation and IFN-y production, and these 
stimulatory effects could be reproduced with murine DC and required the TLR-9-myd88 
signalling pathway. In addition, the study by Adachi and colleagues on Myd88 KO mice 
demonstrated that signaling via the TIR pathway was critical for the production of P. 
6erg7ze/-induced IL-12 (Adachi et al., 2001). These two studies demonstrated that 
Plasmodium sp. could interact with DC via TLR resulting immune regulation and 
immunopathology in malaria infections. Candidate TLR agonists in P. falciparum include
PfEMP-1 (CIDR-la) and other variable surface antigens since intact Pf-iRBCs can 
activate DCs as shown in the current study. In addition, malaria 
glycosylphosphatidylinositol (GPI), purified from the main surface proteins of the 
merozoite stage (MSP-1 and MSP-2) of P. falciparum have been identified as a potential 
TLR2 agonist (Naik et al., 2000; Schofield and Hackett, 1993). GPI anchors and 
unmethylated DNA from other protozoan parasites have pro-inflammatory activities that 
have been associated with TLRs previously (reviewed in (Gazzinelli et al., 2004)). GPI 
anchors derived from either the trypomastigote or epimastigote stages of Trypanosma 
cruzi has also been identified as a TLR2 agonist (Gazzinelli et al., 2004). Similarly, GPI 
purified from the variable surface glycoprotein (VSG) of Trypanosma brucei and 
lipophosphoglycan (LPG) from Leishmania major have a pro-inflammatory activities 
associated with TLR2 (Gazzinelli et al., 2004). Unmethylated DNA derived from 
Trypanosma brucei and Trypanoma cruzi were identified as agonists for TLR9 on 
macrophages (Gazzinelli et al., 2004). More studies on the involvement of TLR in 
falciparum malaria will help identify the specific TLRs on DCs that interact with Pf- 
iRBC and their respective parasite-derived agonists.
Taken together, these data suggests that Pf-iRBC and CIDR-la, the CD36 
binding domain of PfEMP-1, induce IL-10, IL12p70 and IL-18 production in BDCA-1 
but not BDCA-2 positive DCs. Even though the upregulation of costimulatory molecules 
and IL-2 production by DC were not investigated in the current study, the production of 
cytokines suggest that CIDR-la and Pf-iRBC activated BDCA-1 DCs. Such activated 
DCs loaded with antigen and producing pro-inflammatory cytokines will then activate 
antigen specific T cells. CD4 T cells activated in the presence of IL-12 and IL-18 will
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proliferate and the progeny differentiate into TH1 cells, which secrete IFN-y, an effector 
cytokine that can activate macrophages to release nitric oxide that can kill 
microorganisms (Akira, 2000). In addition, IFN-y can also induce isotype switching on B 
cells that results in the secretion of strongly opsonizing antibodies (Janeway et al., 1999).
As discussed in chapter 1 (section 1.6.2), the appropriate induction of a TH1 response is 
required for the elimination of intracellular pathogens and involves macrophage 
activation, production of complement fixing and opsonising antibodies (Robinson and 
O’Garra, 2002). In contrast, IL-10 is capable of inhibiting the synthesis of several 
cytokines from different cells (Conti et a l, 2003) and is perhaps responsible for the lack 
of maturation of Pf-iRBC exposed DCs reported previously (Urban et al., 1999). For 
example, IL-10 inhibits NK cell activity, the production of Thl cytokines, cytokines 
generated by PBMC, and macrophage activity (Conti et al., 2003).
Induction of IL12p70 and IL-18 production by Pf-iRBC on DCs, if it happens in 
vivo, may be responsible for the induction of some of the IFN-y production seen in 
patients with acute malaria illness. In humans, low levels of IL12p70 (Luty et al., 2000; 
Perkins et al., 2000) and IL-18 (Malaguamera et al., 2002) are associated with severe 
malarial pathology. However, in prospective epidemiological studies, IL12p70 
production is inversely associated with the risk of infection and positively associated with 
haemoglobin concentration (suggesting a protective effect against malaria anaemia), and 
IFN-y and TNF production (Dodoo et al., 2002).
These findings may have implications on the development of a CIDR-la based 
vaccine. The induction of IL12p70 and IL-18 production in BDCA1+ DCs can mediate 
either protective or pathological mechanisms. As discussed above, the induction of pro-
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inflammatory cytokine production is a prominent feature of acute malaria and these 
cytokines, particularly lymphotoxin-a (Engwerda et al., 2002); IL12p70 (Luty et al., 
2000; Perkins et al., 2000) and IL-18 (Malaguamera et al., 2002) have been associated 
with pathology. On the other hand, IFN-y production has been associated with protection 
(Gramzinski et a l, 2001; Mohan et al, 1997; Schofield et al., 1987; Seguin et al., 1994). 
A CIDR-la based vaccine will have to strike a balance between the induction of pro- 
inflammatory and anti-inflammatory cytokines in such a way that only the protective 
benefits of the cytokine response are manifested.
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CHAPTER 5
CD4 T CELL RESPONSES of MALARIA NAIVE DONORS TO the CIDR-la 
DOMAIN of PfEMP-1
5.1 Introduction
There is longstanding evidence for the presence of malaria specific T cells in most 
adults prior to any exposure to P. falciparum exposure. However, this phenomenon is not 
unique to malaria, as T cells from non-exposed donors have been shown to respond to 
other parasites including Leishmania (Kemp et a l , 1992) and Trypanosma cruzi 
(Piuvezam et al., 1993). The presence of such pre-existing anti -Plasmodium T cells has 
been described in malaria un-exposed individuals for a crude extract of P. falciparum (Pf- 
iRBC extract), circumsporozoite protein (CSP), MSA1, MSA2, and SERA (Dick et al., 
1996; Good, 1991, 1994; Goodier et a l, 1992). These T cells can be present in high 
frequency (Zevering et a l, 1992) and are thought to have arisen through previous 
exposure to other environmental organisms that share common epitopes with P. 
falciparum (Currier et al., 1992; Currier et al., 1995; Good, 1994). Earlier reports had 
suggested that malaria parasites were mitogenic for human T cells (Ballet et a l, 1981; 
Gabrielsen and Jensen, 1982; Greenwood and Vick, 1975; Greenwood et a l, 1979; 
Strickland, 1978; Wyler et a l, 1979). However, it was later suggested that malaria 
parasites specifically stimulate T cell clones, and malaria-specific clones from non­
exposed donors are major histocompatibility complex (MHC)-restricted, unlike 
mitogenic and super-antigenic responses (Chizzolini and Perrin, 1986; Currier et al., 
1995; Good et a l, 1990). Previous studies have reported MHC class II restricted
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responses in naive donors to certain malaria proteins and T cells that responded to the 
parasite expressed the activation marker CD45RO (memory) (Currier et a l, 1992; Good 
and Currier, 1992). However, there is also reported evidence of CD45RA (naive) T cells 
responding to CSP peptides (Fern and Good, 1992) and intact Pf-iRBC (Goodier et al., 
1992) indicating that both memory and naive T cells may be stimulated by P. falciparum 
antigens. Since these responses occur in naive donors who can succumb to a malaria 
infection, they may not be protective but may be preferentially expanded upon malaria 
exposure (Good et al., 1993). It has been suggested that their presence may have the 
potential to skew the repertoire of P. falciparum reactive T cells towards the cross­
reactive epitopes (Good et al., 1993). They may also be responsible for the initiation of 
the inflammatory response to malaria in non-immunes, which may in turn contribute to 
the pathology of disease (Good and Currier, 1992; Good, 1994).
It has been demonstrated that the active component of the Pf-iRBC that induces 
proliferation in memory CD4+ T cells is membrane-bound (Dick et al., 1996). A 
candidate membrane-derived antigen could be the variable surface antigens (VSA) such 
as PfEMP-1. Previously, it was shown that a recombinant protein fragment of the CIDR- 
l a  domain of PfEMP-1 stimulated CD4 T cells in both malaria-exposed and non-exposed 
donors to proliferate, and supernatants collected from PBMC cultures contained IL-10 
and IFN-y (Allsopp et a l, 2002). CIDR-la is now a potential anti-adhesive vaccine 
candidate (Baruch et a l, 1997; Baruch et a l, 2002a) and it is important to understand 
how such a vaccine will interact with the pre-existing CIDR-la specific CD4 T cells.
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5.2.0 Study design
5.2.1 Rationale
This study is an extension of a previous study that showed that CD4+ T cells from 
both malaria exposed and unexposed donors responded to CIDR-la by proliferation. In 
addition, IL-10 and IFN-y were measured in PBMC culture supernatants (Allsopp et al., 
2002) although the cell phenotypes making IFN-y and IL-10 were not determined. 
Information on the nature and kinetics of these responses would help us to understand 
how the parasite interacts with these CD4 T cells, and how their presence might affect the 
function of CIDR-la based vaccine. As suggested in chapter 1 (section 1.6.3), such pre­
existing CD4 T cells may be protective or even involved in pathogenic mechanisms. 
Boosting the pre-existing CIDR-la specific response could therefore either boost the 
protective response or exacerbate the malarial disease.
CIDR-la specific T cell responses in malaria-unexposed donors could be induced 
if the CIDR-la domain of PfEMP-1 contained a mitogen, a super antigen or epitopes that 
are shared with other common environmental microorganisms. More recently, it has been 
demonstrated that CD4 T cells can respond to the cytokine environment (independently 
of T cell receptor (TCR) recognition), particularly IL-12 and IL-18 by making IFN-y 
(Chakir et al., 2003; Yang et al., 1999; Yang et al, 2001) (see chapter 1, section 1.6.2 for 
details). The possibility that these cytokines induce IFN-y production in P. falciparum 
malaria has been suggested previously (Artavanis-Tsakonas and Riley, 2002). These two 
cytokines are produced by dendritic cells that could interact with P. falciparum through 
pattern recognition receptors like TLRs or the scavenger receptor, CD36 (Urban et al.,
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2001b). This study examined the nature of CIDR-la specific responses in malaria un­
exposed donors. More precisely, it was an attempt to 1) locate where within the 
recombinant CIDR-la protein the stimulating sequence lies by using contiguous 
peptides, 2) to investigate whether these responses are MHC class II restricted, and 3) 
whether they are dependent on recognition of CIDR-la peptides by TCR.
5.2.2 Materials and methods 
Donors and blood sampling
Sixty healthy adult volunteers working at the National Institute for Medical 
Research, London, UK were recruited into the study for the assessment of CIDR-la 
specific CD4 T cell responses in malaria-unexposed donors. A detailed travel history was 
taken from each of these donors to confirm that they had never been exposed to malaria. 
All experiments involving humans followed the guidelines of conduct of clinical research 
of the UK government and were performed after informed consent was obtained from the 
volunteers. Ethical clearance was granted by the High Barnet Ethical Committee in North 
London. For each of these donors, 20 mis of blood was collected in heparinized 
vaccutainers. PBMC were isolated as explained in chapter 2, section 2.5. The CD4 T cell 
response was investigated in two ways: intracellular staining for IFN-y and IL-10 
production in activated CD4 T and NK cells identified by CD69 expression by multi­
parameter flow cytometry, and proliferation revealed by CFSE dilution (by flow 
cytometry) combined with cytokine detection by ELISA.
Measurement of CD69 expression and IFN-y production in short activation (7-hour) 
assays
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Briefly, 1 X 106 PBMC suspended in 500 |xl of complete RPMI 1640 per well, or 
500 pi of heparinized blood were plated in 48 well plates and stimulated with medium 
only (medium control), EXON 2 (negative control protein), CIDR-la at a final 
concentration of 5 pg/ml, and SEB at a final concentration of 1 pg/ml as the positive 
control. See chapter 2, section 2.7 for details. The cells were harvested after 7 hours of 
culture and stained for surface expression of CD4 and CD69, and intracellular IFN-y and 
IL-10 production as described in chapter 2, section 2.7. Data were acquired on a Becton 
Dickinson flow cytometer using Cell Quest software (Becton Dickinson, France). 
Proliferation
PBMC were stained with CFSE and plated out at 2 x 105 cells/well in a 96 well 
U-bottomed plate (Nunclon; Gibco) in 200pl complete RPMI 1640 as described in 
Chapter 2, section 2.8. Cells were then stimulated with medium only (medium control), 
EXON 2 (negative control) and Malayan camp CIDR-la recombinant protein (prepared 
as described in chapter 3) at a final concentration of O.lpg/ml, PPD at lOpg/ml (positive 
control) and PHA at 2.0pg/ml (control for cell viability). The numbers of CD4 T 
lymphocytes dividing in response to the various stimulations were determined by flow 
cytometry as described in chapter 2, section 2.8. Supernatants were harvested and stored 
at -70°C for the measurement of cytokines before cytometric analysis.
Detection of cytokines bv ELISA
Supernatants from PBMC cultures were tested for the presence of IFN-y and IL- 
10 by use of OPTEIA™ ELISA kits according to the manufacturer’s instructions and as 
described in chapter 2, section 2.9 (Becton Dickinson, France). The sensitivities of the 
ELISA assays were 4 pg/ml in each case.
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Flow cvtometrv
CD69 expression, intracellular IFN-y and IL-10 cytokine staining and 
proliferation data were acquired on a FACscalibur™ using Cell Quest software (Becton 
Dickinson). The proportion and number of CD4 T cells staining positive for CD69 
expression, IFN-y and IL-10 production, and cell division were determined by analyzing 
the data using Flowjo software (Treestar Inc., Ashland, CA, USA).
Data analysis
Data were stored, formatted, and analyzed with Microsoft Excel (Mirosoft 
Corporation, CA, USA). Graphs were plotted in Prism-Graphics (Graph pad software, 
Inc., San Diego, CA, USA) and Stata version 8 computer softwares. Correlations between 
different variables where appropriate, were tested by Pearson correlation in Stata.
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5.3.0 Results
5.3.1 C ID R -la activates CD4 T and NK cells from malaria naive-donors to 
express CD69 and produce IFN-y
Heparinized blood or PBMC from healthy donors were stimulated in vitro for 7 
hours with 5 pg/ml of CIDR-la protein. During this time, a proportion of CD4 T and NK 
cells had up-regulated the expression of CD69 and some cells produced IFN-y. The 
frequency of responding CD4+ T and NK cells was determined by the combined flow 
cytometric analysis of CD69 expression, and intra-cellular IFN-y or IL-10 induction in 
CD4 T and CD56 NK cells, separately. Figure 5.1 is a representative example of a typical 
responder. In this donor, nearly 50% of the total number of CD4 T cells expressed CD69 
and 4% produced IFN-y in response to CIDR-la. Similarly, CIDR-la also activated a 
proportion of CD56 positive NK cells and they produced IFN-y. Figure 5.2 is a 
representative example of a responder showing the NK cell response. In this donor, more 
that 63% of the total number of NK cells expressed CD69 and 12% produced IFN-y.
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Figure 5.1
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CIDR-la specific CD4 T cells were detected directly from PBMC 7 hours after antigen
stimulation by flow cytometry. Cells were gated on CD4 T cells (a). Specifically activated 
CD4 T cells were identified as being CD69+ (b-fi. Some o f these activated CD4 T cells 
produced IFN-y. The percentages o f the total number o f CD4 T cells responding by CD69 
expression and IFN-y are shown in the upper left and right quadrants, respectively. 
CIDR-la and the positive control, Staphylococcal Enterotoxin B (SEB) induced CD69 
expression and IFN-y production (b and d). There was negligible CD69 expression and 
no IFN- y production in the EXON 2 and media controls (c and e). Mouse IgGl PE and 
mouse IgGl FITC were use as isotype controls on CIDR-la activated cells (f).
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CIDR-la specific CD56+ NK cells were detected directly from PBMC 7 hours after 
antigen stimulation by flow cytometry. Cells were gated on CD56+ NK cells (a). 
Specifically activated CD56+ NK cells were identified as being CD69+ (b - f). Some o f 
these activated CD56+ NK cells produced IFN-y. The percentages o f the number o f  
CD56+ NK cells responding by CD69 expression and IFN-y are shown in the upper left 
and right quadrants, respectively. CIDR-la and the positive control, staphylococcal 
enterotoxin B (SEB) induced CD69 expression and IFN-y production (a and d). There 
was negligible CD69 expression and no IFN- y production in the EXON 2 and media (c 
and e) controls.
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The measurement of CD4 and NK cell activation (CD69 up-regulation) by this assay was 
reproducible among responders since similar results were obtained when the same donors 
were tested in several independent experiments as shown in figure 5.3. Data from three 
separate experiments are summarized for each of two donors. Although the percentage of 
CD4 T cells positive for IFN-y production was more variable, each of these two donors 
responded each time. The coefficients of variation for donors a and b were 2.30 and 3.00, 
and 3.90 and 2.40 for CD69 expression and IFN-y production, respectively.
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Reproducibility o f CD69 up-regulation andIFN-y induction in CD4 T cells by CIDR-la 
(in responders). CD4 T cells were gated on a side scatter vs CD4 T cell-PerCP density 
plot as shown in figure 5.1. The frequencies o f CD69 and IFN- y expressing CD4 T cells 
after PBMCs from two donors (A) and (B) were incubated with CIDR-la for 7 hours are 
shown on the y-axis. Data from three separate experiments are shown in each case i.e. 
each green or red bar represents data from a single experiment. The green and red bars 
represent the proportions o f CD4CD69+ and IFN- y positive cells, respectively.
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Donors were considered positive if the proportion of CD4+ T or NK cells 
expressing CD69, or CD69 and cytokine production (separately) was at least three fold 
above the medium control. Figure 5.4 shows a summary of the results from 23 
individuals tested for CD4 T cell activation in the whole blood assay. 89% of the donors 
responded by CD69 up-regulation and 56% by both CD69 expression and IFN-y 
production. All of the 10 donors analyzed for NK cell activation expressed CD69 in this 
population of cells and produced IFN-y as shown in figure 5.5. All IFN-y producing CD4 
T and NK cells were also CD69 positive.
CIDR-la specific CD4 T cells were also analyzed for IL-10 production after 
seven hours of culture by intracellular cytokine staining. IL-10 was not detectable in CD4 
T cells stimulated with either CIDR-la or SEB at this time point.
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Proportion o f malaria naive donors responding to CIDR-la by CD69 up regulation (a) 
or production o f IFN-y (b) in whole PBMC cultures. CD4 T cells were gated as described
and 5.1. A response was considered positive when the proportion o f CD69 or IFN-y 
positive cells was 3 fold above the medium control (a 3-fold cut-off was preferred for use 
in this assay because o f clustering around the 2-fold cut-off used with the 7-day 
proliferation assay). Each o f the dots represents a single donor (n = 23). 20 and 13 o f 23 
donors responded by CD69 up regulation and IFN-yproduction, respectively.
in figure 5.0. CD69 and IFN-y positive cells were identified as described in figures 5.0
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Proportion o f malaria naive donors whose CD56+ NK cells responded to CIDR-la by 
CD69 up regulation (a) or production o f IFN-y (b) in whole PBMC cultures. CD56+ NK 
cells were gated as described in figure 5.1. CD69+ and IFN-y positive cells identified as 
described in figures 5.0 and 5.1. A response was considered positive when the proportion 
o f CD69 or IFN-y positive cells was three fold above the medium control. Each dot 
represents the response o f a single donor (n = 10). All o f the 10 donors responded by 
CD69 up regulation while 9 responded by IFN-yproduction.
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Stimulation with EXON 2 and SEB were carried out as negative and positive 
controls, respectively. In neither CD4 T nor NK cells did the negative control antigen 
induce CD69 expression or any relevant cytokine induction, where as CIDR-la and SEB 
readily stimulated both cell types.
Taken together, these data demonstrated the presence of CIDR-la reactive CD4 T 
and CD56 NK cells in the peripheral blood of malaria naive individuals. Moreover, 
specifically activated CD4 T and NK cells were shown to produce IFN-y.
5.3.2 Assessment of CD4 T cell response to CIDR-la by cell division
As described in chapter 2, CD4 T cell division in response to CIDR-la and 
control antigens was revealed by dilution of the fluorescent dye, CFSE. CFSE-labeled 
PBMC from healthy malaria unexposed adults were stimulated with CIDR-la and 
control antigens for 7 days after which CD4 T cell proliferation was assessed by flow 
cytometry as described in figure 5.6. EXON 2 and PPD were used as negative and 
positive control antigens, respectively, while PHA-stimulated cells were included as a 
control for cell viability.
A positive response was defined as one where the numbers of divided CD4 T cells 
were above 2 stimulation indices of triplicate or duplicate wells as described in chapter 2. 
Figure 5.7 shows a summary of results from 34 individuals.
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Figure 5.6
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A representative example o f a CIDR-la specific CD4 T cell response. PBMC from a 
normal healthy donor were cultured in the presence o f CIDR-la fo r  7 days and 
thereafter analysed for CD4 T cell division by flow cytometry. Dead cells were excluded 
by drawing a live gate (A). CD4 T cells were then gated on from among the live cells on a 
side scatter vs CD4 density plot (B). CD4 T cells were then analysed for cell division as 
shown in (C) -(D) for CIDR-la, PPD, EXON 2 or vector (negative control) and media 
controls. Divided CD4 T cells were identified as those with reduced CFSE fluorescent 
intensity on the x-axis o f similar histograms as those shown above. The numbers shown 
are the percentages o f CD4 T cells in the respective gates.
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Figure 5. 7
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Proportions o f malaria naive donors responding to CIDR-la by CD4 T cell proliferation 
(n=34) (a), IFN-g (n=33) (b) and IL-10 (n=33) (c) production after 7 days o f PBMC 
cultures. To determine the number o f divided CD4 T cells by flow cytometry, cells were 
gated on a CD4 T Cell gate and the number o f divided cells were identified as those with 
reduced CFSE fluorescence intensity as described in figure 5.6. The concentrations o f 
IFN-y and IL-10 in culture supernatants were determined using ELISA. In these 
experiments EXON 2 was used as a negative control and in all cases, the medium control 
value was subtracted from the antigen specific value. Each dot represents data from a 
single individual. Cytokine responses that were 2 fold above the medium control, and 
proliferative responses o f above 2 stimulation indices were considered positive. 8 out o f 
34 individuals had proliferative stimulation indices o f over 2, 18/33 and 16/33 
individuals had concentrations above 2 folds o f the medium control for IFN-y and IL-10, 
respectively.
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Figure 5.8
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Relationship between the numbers o f divided CD4 T cells and the percentage o f CD69 
positive (activated) CD4 T cells after incubation of PBMC with CIDR-la for 7 days and 
7 hours, respectively (n=14). Generally, all those that responded by cell division also 
responded by CD69 expression. However, more donors responded by CD69 expression 
than cell division.
Of these 34 donors, 8 gave a positive proliferative response. However, when 14 
individuals were tested with both the CFSE based proliferation and the 7-hour activation 
assays, it was clear that whilst most of the donors responded by CD69 expression, only 4 
out of the 14 responded by cell division (Data shown in figure 5.8). There was therefore 
no association between CD69 expression and cell division in response to CIDR-la.
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5.3.3. IL-10 production in the 7 days PBMC cultures excluded cell division
PBMC culture supernatants were harvested from the 7-day proliferation assays. 
The amounts of IFN-y and IL-10 in these cultures were measured using BD OPTIA Kits 
according to the manufacturer’s instructions (Becton Dickinson, France). Supernatants 
were tested in duplicates and the mean cytokine concentrations calculated in pg/ml. 
Individuals were considered positive if the cytokine concentration was two fold over the 
no antigen (medium) control. As shown in figure 5.7, 18 and 16 out of 33 donors tested 
were positive for IFN-y and IL-10 production, respectively. In general, there was no 
association between IL-10 production and CD4 T cell proliferation (see figure 5.9) 
(spearman’s rho coefficient = 0.4, p = 0.15). Some individuals responded by IFN-y 
production and no cell division (figure 5.9). There was a positive association between 
IFN-y production and the number of divided CD4 T cells though it wasn’t statistically 
significant (spearman’s rho coefficient = 0.5, p = 0.09). There was an unexpected positive 
association between IFN-y and IL-10 concentrations as shown in figure 5.9 (spearman’s 
rho coefficient = 0.62, p = 0001). IL-10 is an anti-inflammatory cytokine and its presence 
would be expected to antagonise IFN-y production. Perhaps the fact these two cytokines 
are coming from different cell phenotypes and may be with different kinetics of secretion 
explains this association.
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Figure 5.9
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Relationships between the different responses to CIDR-la measured from the 7-day 
proliferation assay. In general, there was no association between IL-10 production and 
CD4 T cell proliferation, spearman’s rho coefficient = 0.4, p  = 0.15) (a). There was a 
positive association between IFN-y production and the number of divided CD4 T cells but 
this association was not statistically significant (r2 = 0.25, p  = 0.09) (b). There was an 
un-expectedpositive association between IFN-y production and IL-10 (r2 = 0.38, p  = 
0.001) (c).
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5.3.4 Synthetic peptides did not induce CD69 expression
In order to map the precise sequence within the recombinant CIDR-la protein that 
stimulates the responses described above, synthetic peptides were used. Four contiguous 
peptides spanning the whole length of the CIDR-la recombinant protein used in this 
study were ordered from CN Biosciences, Nottingham, UK. These peptides were coded 
CIDR-1, CIDR-2, CIDR-3 and CIDR-4. The amino acid sequences for each of them are 
shown on appendix 5.1. These peptides were used to stimulate PBMC in parallel with the 
recombinant EXON 2 and CIDR-la proteins, medium control and the positive and 
negative controls in both the 7 hour CD69-expression based activation assay and the 7- 
days CFSE based proliferation assay as described in chapter 2.0.
In the 7-hour assay, PBMC from each of five donors were stimulated with the 
four peptides at lOpg/ml, EXON 2 and CIDR-1 at 5fig/ml, SEB at lpg/ml and medium 
(media control) and incubated for seven hours. Brefeldin A was included in the cultures 
four hours before the cells were harvested, stained and analysed by flow cytometry for 
CD69 and IFN-y induction. Figure 5.10 is an example of a representative result from one 
of the 5 donors. Generally, the recombinant CIDR-la and SEB induced CD69 expression 
whilst none of the four peptides induced appreciable levels of CD69 expression (see table 
5.1) suggesting that the whole intact protein was required to stimulate naive T cells.
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Figure S. 10
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Representative flow cytometric plots showing an example o f a CD4 T cell response to the 
CIDR-la recombinant protein, four contiguous synthetic peptides spanning the whole 
length o f the region o f the MC var 1 CIDR-la used in this study and controls. PBMC 
were stimulated with medium only (a), EXON 2 (b), CIDR-1 peptide (c), CIDR-2 peptide 
(d), C1DR- 3 peptide (e), CIDR-4 peptide (f), recombinant CIDR-la (g) and SEB (h). 
PBMC were then incubated in the presence o f brefaldin A as explained in chapter 2. They 
were then analysed by flow cytometry for CD69 expression and IFN-y among CD4 
positive T cells.
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Table 5.1
DONOR % of CD4 T cells positive for CD69 after PBMC culture with:
CIDR-la protein CIDR-1 CIDR-2 CIDR-3 CIDR-4 Medium
1 30.3 2.67 1.7 2.4 1.98 1.56
2 25.9 2.66 2.75 2.73 2.5 2.4
3 24.6 1.1 2.11 1.42 3.04 2.9
4 45.4 3.05 3.61 3.15 3.57 2.07
5 22.2 1.45 1.03 1.04 1.53 1.06
Up-regulation o f CD69 on CD4 T cells by four contiguous synthetic peptides covering 
the whole length o f the recombinant CIDR-la protein used in this study. PBMC from 5 
normal healthy donors were incubated with recombinant CIDR-la and four synthetic 
peptides for 7 hours and thereafter analysed for CD69 expression by flow cytometry. 
CD4 T cells were gated and analysedfor CD69 expression as described in figure 5.1.
5.3.5 Synthetic peptides did not induce CD4 T cell division, IFN-y and IL-10 
production
As described in section 5.3.2, 8 of 34, 18 and 16 of 33 malaria-unexposed individuals 
responded by CD4 T cell proliferation, IFN-y and IL-10 production to the intact CIDR- 
la  protein. In order to map the location of the stimulating sequence (as explained above), 
PBMC from five donors were stained with CFSE and incubated with the four synthetic 
peptides spanning the entire CIDR-la sequence along side CIDR-la, EXON 2 and 
media control (as described in chapter 2.0) for 7 days. The peptides were used at a final 
concentration of 2 pg/ml. The concentrations of IFN-y and IL-10 in the culture 
supernatants were determined by ELISA as described in section 5.2.2. None of the five
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donors gave a positive proliferative response to any of the peptides used but responded to 
the intact recombinant CIDR-la protein and the positive control antigen, PPD. 3 out of 
these 5 donors made IFN-y and IL-10 in response to the intact CIDR-la protein but not 
to the peptides. The concentrations of these cytokines ranged from 10-344pg/ml and 20 - 
157pg/ml for IFN-y and IL-10, respectively. None of the four synthetic peptides induced 
the production of either of these cytokines (data not shown). This observation suggests 
that the intact CIDR-la protein is required to elicit these cytokine responses.
5.3.6 IFN-y produced in response to CIDR-la is not MHC class II restricted
To determine whether the response to CIDR-la in malaria naive donors could be 
the result of an MHC class II/TCR mediated interaction, PBMC were cultured in the 
presence of antigen and varying concentrations of an anti-MHC class II antibody; 0 
pg/ml, 5 pg/ml, 10 pg/ml and 40 pg/ml. Initially, a panel of anti-MHC class II MAbs 
were tested for the ability to bind HLA-DR by flow cytometry and to inhibit a classical 
MHC class II-restricted response. The MAb, L243 (anti-HLA-DR; ATCC, Rockville, 
MD), bound the surface of B cells, and inhibited a classical MHC class II restricted anti- 
PPD CD4 T cell proliferative and IFN-y production response in PBMC from individuals 
who had previously been immunized with BCG (Mycobacterium tuberculosis) in a dose 
dependent manner (as shown in figure 5.11) and was therefore selected for use as a 
positive control in these experiments. However, PPD failed to induce appreciable CD69 
up-regulation and IFN-y induction in the 7-hour assay suggesting that CIDR-la is 
different in the way it interacts with naive T cells. In addition, CD69 expression and IFN- 
y production in response to the super-antigen, SEB, were not inhibited by this antibody in 
4 donors suggesting that L243 does not block the SEB binding epitope on MHC class II.
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For this reason, it was not possible to investigate the MHC class II requirement of CIDR- 
l a  specific responses in the 7-hour assay.
Figure 5.11
a) CD4 T cell diviosion b) IFN-y production
lOO-i
dl6  
d 17 
(144
5 10 15 20 25 30 35 40 45 50
Anti-MHC c la ss  II antibody concentration ng/ml
10 15 20 25 30 35 40 45 50
Anti4\4HC class II antibody concentration (ig/ml
Inhibition o f the CD4 T cell response (a) and IFN-y response (b) to PPD by anti-MHC 
class II MAb, L243. PBMC from normal healthy donors were incubated with PPD, and 
either the anti-MHC class II antibody or the mouse lgG2a isotype control, at different 
concentrations; 0, 5, 10 and 40 mg/ml. They were then cultured for seven days after 
which the cells were analysed for cell division as described in figure 5.6 and IFN-y 
production as described in section 5.2.2. Percent inhibitions were calculated by 
subtracting the L243 associated values from the corresponding values associated with 
the respective concentrations o f the isotype control. Each line represents data from one 
o f three donors.
To investigate the MHC class II requirement for the CIDR-la specific responses 
in the 7-day proliferation assay, PBMC from 7 donors were cultured in the presence of 
increasing concentrations of the MHC class II MAb as already described. None of the 7 
donors responded by CD4 T cell proliferation in control assays. However, they all made 
IFN-y• In contrast to the PPD specific IFN-y response which was inhibited by the anti-
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MHC class II antibody in a dose depended manner, the CIDR-la specific IFN-y response 
was insensitive to L243 in 5 out of 7 donors (figure 5.12). This observation suggested 
that this response, unlike the anti-PPD response is not MHC class II restricted in the 
majority of malaria-unexposed donors. In other words, these responses do not require 
antigen processing and presentation in the context of the MHC class II-peptide complex. 
It is possible that CIDR-la is a T cell super-antigen but this possibility could not be 
evaluated since the anti-MHC class II MAb failed to block SEB induced IFN-y 
production. However, cross reactivity between CIDR-la epitopes with other antigens 
may explain the dose dependent inhibition of IFN-y production when MHC class II 
molecules were blocked in donors d33 and CL (see figure 5.12).
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Figure 5.12
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Inhibition o f the IFN-y response to CIDR-la by anti-MHC class II MAb, L243. PBMC
from normal healthy malaria unexposed donors were incubated with CDIR-la and either 
L243or the mouse IgG2a isotype control at different concentrations; 0, 5, 10 and 40 
mg/ml. They were then cultured for 7 days after which the cells were harvested and 
analysed for CD4 T cell division as described in figure 5.6 and IFN-y production as 
described in section 5.2.2. None o f these donors responded by CD4 T cell division but 
they all produced IFN-y. Percent inhibitions were calculated as described in figure 5.11. 
Each line represents data from one o f 7 donors.
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5.3.7 IFN-y production in response to CIDR-la requires TCR ligation in some 
donors
Antigen activation of CD4 T cells is an important mode of IFN-y induction. 
However, another pathway that is capable of inducing IFN-y transcription that does not 
involve antigen presentation has been suggested (Yang et al., 1999; Yang et al., 2001) as 
described in chapter 1, section 1.6.2. In this pathway IL-12 and IL-18 are thought to act 
in concert to induce IFN-y production by CD4 T cells. Cyclosporin A inhibits TCR 
(antigen) induced IFN-y production, but not IL-12/IL-18-induced IFN-y production, 
biologically discriminating between these two pathways (Yang et al., 1999; Yang et a l, 
2001).
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Figure 5.13
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Inhibition o f the CD4 T cell proliferative response to PPD by cyclosporin A. PBMC from 
4 normal healthy donors were incubated with either PPD plus Opg/ml cyclosporin A (A), 
or PPD plus 100fJLg/ml o f Cyclosporin A (B) and thereafter cultured for 7 days. CD4 T 
cells were then analysed for cell division where divided cells were identified as those with 
reduced CFSE fluorescence intensity as described in figure 5.6. Each horizontal pair o f 
graphs represents data from an individual donor (3 representative donors shown). In 
each graph, the peaks associated with high and low CFSE fluorescence intensities 
correspond to the proportions o f undivided and divided CD4 T cells, respectively. The 
percentages o f divided and undivided CD4 T cells are shown in each case.
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In order to find out whether the CIDR-la specific IFN-y response is TCR 
mediated, PBMC from 6 donors were cultured either in the presence or absence of 
100[xg/ml of Cyclosporin A. PBMC were stimulated with medium control, EXON 2, 
CIDR-la and PPD for the 7 day proliferation assay. Cyclosporin A inhibited both the 
proliferative and IFN-y responses to PPD as shown in figures 5.13 and 5.14, respectively, 
which are known to be TCR mediated confirming that this is a good way of testing 
whether the CIDR-la specific response is TCR mediated. Unfortunately, none of these 6 
donors responded to CIDR-la by cell division but 5 of them responded to CIDR-la by 
IFN-y production. The IFN-y response to the CIDR-la was sensitive to cyclosporin A in 
3 out 5 donors suggesting that this response requires TCR ligation in some donors and 
not others as shown in figure 5.14. Together, these data suggest that the IFN-y response 
to CIDR-la in malaria-unexposed donors is mediated by more than one mechanism. It is 
likely that the cyclosporin A sensitive-IFN-y is made in response to a CIDR-la epitope 
that is cross reactive with a common microorganism in the environment or a super­
antigen while the insensitive IFN-y response might be the result of a bystander effect.
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Figure 5.14
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Inhibition o f IFN-y production in response to PPD (a) and CIDR-la (b) by Cyclosporin
A. PBMC from healthy malaria unexposed donors were stimulated with antigen either in
the presence o f Omg/ml (open bars) or lOOmg/ml (filled bars) o f cyclosporin A. IFN-y
concentration was determined by ELISA as described in section 5.2.2. Data from 6 and 7
responders are shown for PPD and CIDR-la, respectively.
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5.4.0 Discussion
CD4 T cells are important in immunity to malaria, either as effector cells (Pombo 
et al., 2002) or as helper cells for antibody production by B cells (Langhome et al., 
1998b). T cells have also been implicated in expression of disease symptoms in malaria 
infections (reviewed in (Good and Miller, 1989)). As mentioned in the introduction, 
malaria un-exposed individuals normally have pre-existing P. falciparum specific T cells, 
which can be present at high frequencies (Zevering et al, 1992). The function of these P. 
falciparum specific pre-existing T cells in malaria un-exposed individuals is unknown. It 
has been suggested that they may contribute to disease symptoms once a naive individual 
is exposed to malaria for the first time (Good and Miller, 1989; Good, 1994). In this case, 
activated pre-existing T cells accumulating in particular organs may mediate organic 
specific pathology like pulmonary oedema (reviewed in (Good, 1994)). It is also possible 
that pre-existing anti-P. falciparum specific T cells are protective (Good, 1994). This is 
difficult to test in vivo but CD4 and CD8 T cells from malaria un-exposed donors have 
been shown to inhibit P. falcipamm growth in vitro (Fell et al., 1994). These cells may 
represent clones that have expanded in response to other stimulations, and it has been 
speculated that their expansion may be at the expense of non-cross-reactive virgin T cells 
uniquely specific to P. falciparum alone and may skew the immune response to create a 
“smokescreen” that favours the parasite’s survival (Good, 1992). If pre-existing T cells 
are protective, then malaria vaccines should be targeted to boosting their numbers. 
Otherwise vaccines should target the immune response to epitopes not already recognized 
by the population of pre-existing T cells if such pre-existing responses are known to be 
involved in immunosuppression or pathology during acute malaria.
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ap T cells from malaria un-exposed donors have also been shown to respond to 
membrane-associated components of Pf-iRBC (Dick et al., 1996). This finding suggests 
that VS As found of the surface of Pf-iRBC may stimulate T cells from malaria un- 
exposed individuals. Recently, we have shown that CIDR-la, the CD36 binding domain 
of the membrane associated PfEMP-1 protein, specifically stimulated CD4 T cells in 
malaria un-exposed donors suggesting that pre-existing CIDR-la specific T cells are 
present in such donors (Allsopp et a l , 2002). In that study, CIDR-la also induced IFN-y 
and IL-10 production in malaria naive PBMC cultures.
The current study examined the nature of pre-existing CIDR-la specific CD4 T 
cell responses in malaria naive adults. These responses were analysed in short-term (7- 
hours) cultures by activation (CD69 expression) coupled with intracellular cytokine 
detection, and in long-term (7-days) cultures by proliferation coupled with cytokine 
ELISAs. CD69 is a member of the C-type lectin superfamily and is a costimulatory 
molecule for T cell activation and proliferation (Ziegler et al. ,  1994). CD69 expression is 
a transient response by antigen stimulated T cells and its expression is limited to a narrow 
window of time during which the expressing cells can be examined for cytokine 
production by multi-parameter flow cytometry (Keane et al. ,  2000; Lim et a l ,  1998). 
This method has been used extensively to study cytokine production in antigen activated 
T cells mainly in studies involving HIV (Keane et al., 2000; Krowka et a l ,  1996; Lim et 
a l . ,  1998; Sieg et al. ,  2001; Voiculescu et al. ,  1998) and cytomegalovirus (Hsieh et al.,  
2001; Keane et al. ,  2000). Specifically, the current study investigated IFN-y and IL-10 
production by T cells after 7-hours of activation with antigen. In the case of proliferation 
assays, the amounts of IFN-y and IL-10 were measured from supernatants harvested from
these 7-day cultures by ELISA in addition to the analysis for CD4 T cell proliferation by 
flow cytometry. The CD69 expression assay allowed for the identification of cell 
phenotypes making IFN-y and IL-10, which was not possible with the ELISAs used 
together with the 7-day lymphoproliferation assay. Thus, the combination of these two 
assays provided more information than would have been otherwise obtained from either 
of them.
The 7-hour assay was used to investigate CIDR-la specific responses in 23 
malaria-unexposed individuals. The proportion of CIDR-la specific CD4 T cells 
identified by up-regulation of CD69 in vitro in 7-hour PBMC cultures ranged between 0 
to 60%. 89% of the donors were considered to up-regulate CD69 expression on CD4+ T- 
cells. In 60% of these donors, the activated CD4 T cells also made IFN-y. However, the 
proportion of donors whose CD4 T cells went on to cell division after activation was 
lower; only about 20% of 14 individuals who had been tested with both assays had 
stimulation indices above 2 suggesting that CD69 up-regulation on CD4 T cells was not 
always associated with cell division. As mentioned earlier CD69 is a costimulatory 
molecule for T cell activation and proliferation, and even though it has been previously 
used as an activation marker, it is possible that not all CD69 positive CD4 T cells become 
fully activated and hence go on to proliferate. It may be that they are activated in the 
absence of IL-2 and/or other costimulatory molecules. In addition, these data suggested 
that T cells could respond by IFN-y production in the absence of cell division. This 
observation seem to be in contrast to the conventional stages of activation for CD4 T 
cells where naive uncommitted CD4 T cells first respond to their specific peptide-MHC 
class II complexes by making IL-2 and proliferating before differentiating into either
TH1 or TH2 cells (Janeway et al., 1999). TH1 cells then go on to produce IFN-y as 
discussed in chapter 1. 34 donors were tested for cell division and cytokine production 
using the 7-day proliferation assay. Of these, only 24% responded by CD4 T cell division 
while a higher proportion had made cytokine responses; IL-10 (48%) and IFN-y (56%). 
Even though the sources of IFN-y and IL-10 from the 7-day proliferation cultures were 
not known, it is clear that cytokines could be produced in the absence of significant cell 
division.
The IFN-y producing cells were identified as CD4 T and NK cells in the 7-hour 
flow cytometric assay, and it is highly likely that the same cells produced the IFN-y 
detected in the 7-day culture supernatants by ELISA. IL-10 was not detected in CD4 T 
cells but was present in other cells outside the lymphocyte gate, which were identified as 
DCs in chapter 4. Whilst there was a positive correlation between the presence of IFN-y 
in 7-day cultures and the amount of cell division (though not statistically significant), 
there was no association between the amounts of IL-10 and cell division. This is perhaps 
not surprising since IL-10 is known to suppress proliferation (Groux et al., 1997a; 
Jonuleit et al., 2000; Joss et al., 2000). This observation further suggests that CD4 T cell 
division is not necessary for the production of IFN-y (as point out above). There was an 
un-expected association between the amounts of IL-10 and IFN-y measured in the 7-day- 
cultures since IL-10 is known to suppress T cell responses that have been stimulated via 
CD28 and TCR (Joss et al., 2000). However, since it is likely that the IFN-y induced by 
CIDR-la may be independent of TCR engagement (and co-stimulation), it is possible 
that these responses are not suppressed by IL-10.
Taken together, these data suggest that naive donors have CIDR-la specific CD4
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T cells that respond by proliferation and, or IFN-y production. Since these donors have 
not “seen” P. falciparum before, they are either responding to epitopes that cross-react 
with common environmental microorganisms, or to superantigen (Sag) or even a mitogen 
in CIDR-la. It is also possible that these are bystander responses where T cells and NK 
cells respond to the cytokine environment by making IFN-y; CD4 T and NK cells have 
been shown to make IFN-y in response to the presence of IL12 and IL-18 (Yang et al., 
1999; Yang et al., 2001) as already mentioned in the introduction. If these responses were 
the result of cross-reactivity, then they would involve memory CD4 T cells and will be 
MHC class II restricted and CIDR-la would be recognized as a nominal antigen 
presented in the MHC class II-peptide complex. In contrast, Sag reactive CD4 T cells 
would be both of naive and memory phenotypes. However, Sags also interact with both 
the MHC class II and TCR like the nominal antigen though the nature of this interaction 
is different. Unlike, the nominal peptide antigens, Sags bind to the invariant domains of 
MHC class II molecules outside the antigen-binding groove and are presented as 
unprocessed proteins to T cells expressing appropriate motifs on the variable domain of 
the p chain (V(3) of the TCR with relatively little or no involvement of other TCR 
components (Muller-Alouf et al., 2001; Shoukry et al, 1997). In the case of mitogens, 
there are reports suggesting that some mitogenic lectins like PHA and concanvalin A 
(con A) interact with certain disulfide-linked molecules on human lymphocytes, 
including the TCR a/p and perhaps TCR y chains, while others like Helix pomatia 
agglutinin (HPA) bind other receptors on the T cell surface (Chilson and Kelly-Chilson, 
1989). There are no reports indicating that mitogens may interact with MHC class II in 
activating T cells. On the other hand, the CD4 T cell IFN-y response can be independent
of activation through the TCR/CD3 complex if it is driven by the cytokines, IL12 and IL- 
18 (as mentioned above).
L243, the anti-MHC class II antibody used in this study to test whether the CD4 T 
cell response to CIDR-la is MHC class II restricted clearly inhibited CD4 T cell 
proliferation and IFN-y (measured in the 7-day assay) induction by PPD in a dose 
dependent manner. This confirmed that anti-PPD responses are MHC class II/TCR 
restricted as reported previously (Kumararatne et al., 1990), making PPD a good choice 
for a positive control in experiments investigating T cell responses to various pathogens 
in humans. In contrast, only in 2 of 7 individuals tested was there a clear dose dependent 
reduction of the CIDR-la specific IFN-y response in 7-day cultures suggesting that this 
response is different from the PPD specific IFN-y response. Interestingly, PPD, unlike 
CIDR-la did not induce CD69 expression and IFN-y production in the 7-hour assay (n =
10, data not shown) further suggesting that CIDR-la may be different from PPD in the 
way it stimulates CD4 T cells. Collectively, these data suggest that the CIDR-la specific 
IFN-y response in the majority of malaria-unexposed individuals is not due to a 
TCR/MHC class II mediated response. The anti-MHC class II MAb (L243) failed to 
inhibit the anti-staphylococcal enterotoxin-B (SEB) IFN-y response (data not shown) 
suggesting the it does not have specificity for the particular invariant domain on the MHC 
class II a  chain onto which SEB binds (Shoukry et a l , 1997). This anti-MHC class II 
MAb may therefore not affect activation of T cells by Sags. These observations suggest 
that in the 2/7 donors who gave a clear dose dependent reduction of IFN-y production 
with increasing concentrations of the MHC class II MAb (figure 5.12), cross-reactivity 
may explain the genesis of the anti-CIDR-la response (i.e. CIDR-la was presented to
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the T cell in the same way as a nominal antigen and not as a Sag). It would be interesting 
in future to investigate the memory phenotype of the responding cells. This can be done 
by depleting memory T cells by using immunomagnetic beads coated with an anti- 
CD45RO MAb and then testing whether this activity reduces or abrogates the anti-CIDR- 
l a  response. For the experiment to work properly, T cells would have to be isolated from 
other cells like NK cells that may also produce IFN-y. In addition, other cells that play 
important roles in the immune response like DCs and macrophages do express CD45RO.
In the rest of the donors where the IFN-y response was insensitive to the anti-MHC class 
II MAb, CIDR-la may be recognized as a Sag, a mitogen or it may be the result of a 
bystander effect. In the latter case, CIDR-la may interact with DC via TLRs or another 
receptor (like CD36) inducing IL-12 and IL-18 production, which in turn induces IFN-y 
production by T cells in the absence of conventional antigen presentation.
Cyclosporin A was used to test whether CIDR-la specific CD4 T cell responses 
involve TCR engagement. This drug discriminates between IFN-y responses induced via 
the TCR (i.e. by the nominal antigen or a Sag) from IFN-y induced by a bystander effect. 
Cyclosporin A indeed inhibited (and sometimes abrogated) both IFN-y and CD4 T cell 
proliferative responses in PBMC cultured with PPD in the 7-day assay confirming that 
PPD specific CD4 T cell responses involve TCR engagement. Interestingly, IFN-y 
production induced by CIDR-la in 7-day proliferation cultures was sensitive to 
cyclosporin A in 3 of 5 responding donors suggesting that this response requires TCR 
engagement in some malaria unexposed donors and not others. As it has already been 
pointed out, the TCR dependent response could be explained by cross-reactivity, a Sag or 
even a mitogenic activity in CIDR-la. It was not possible to distinguish between these
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three possibilities since the MAb, L243, failed to block a Sag (SEB) induced IFN-y 
production. On the other hand, the TCR independent IFN-y response could be attributed 
to either a mitogen that may bind receptors other than TCR on the T cell surface or a 
bystander effect
Collectively, the data presented in the current study suggest that the anti-CIDR- 
l a  IFN-y response may be mediated by different mechanisms in different malaria naive 
donors. In the few where there was a clear dose dependent reduction of the response with 
increasing concentrations of L243, the response directed at epitopes that are cross­
reactive to antigens from other microorganisms. In the rest of the donors, CIDR-la could 
be a sag, a mitogen or mediating a bystander effect by tickling DC to make IL-12 and IL- 
18. Cyclospone A did not inhibit the anti-CIDR-la response in some donors. Such TCR 
independent responses are more likely to the result of a bystander effect.
As explained in chapter 1, CIDR-la, because of its functional conservation, 
surface location (and hence accessible by antibody) and involvement with cyto-adhesion 
of Pf-iRBC to endothelial cells (and hence thought to mediate pathology) during malaria 
infections, is now a vaccine candidate for malaria. CIDR-la based vaccines are already 
being developed and have been tested in animals (Baruch et al., 2002a). The 
immunization of Aotus monkeys with a recombinant protein containing the CD36 binding 
segment of mcvarl CIDR-la induced a high level of protection against the homologous 
strain of P. falciparum and even though these monkeys were not protected against a 
heterologous challenge, the heterologous parasite challenge boosted the vaccine response 
(Baruch et al., 2002a). Protection correlated with the titer of agglutinating antibodies and 
occurred despite the expression of variant copies of the gene during recurrent waves of
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parasitaemia. Mice immunized with plasmid DNA expressing CIDR-la domains 
developed antibodies that were reactive to the corresponding PfEMPls as measured by an 
ELISA, flow cytometry, and agglutination of Pf-iRBC (Baruch et al., 2003; Gratepanche 
et al., 2003). These experiments also demonstrated that the level of cross-reactivity could 
be improved by simultaneously immunising with three plasmids carrying different 
variants of CIDR-la suggesting that anti-CIDR-la vaccines are viable (Gratepanche et 
al., 2003). It is not entirely clear how the presence of pre-existing T cells will affect the 
development of CIDR-la specific vaccines for now. Clearly, bystander activated CD4 T 
cells are unlikely to protect the vaccinees from disease since these cells may not give 
cognate help to B cells to make protective antibody. More studies will be needed to find 
out whether the frequency of CIDR-la specific CD4 T cells is associated with pathology 
in naive donors being exposed to P. faciparum for the first time. In the next chapter, the 
nature of the CD4 T cell T cell response in malaria-exposed donors is examined.
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CHAPTER 6
CD4 T CELL RESPONSES to the CIDR-la DOMAIN of PfEMPl in MALARIA- 
EXPOSED INDIVIDUALS
6.1 Introduction
People living in malaria-endemic regions who survive childhood infections 
develop a state of immunity in which even though low-grade P. falciparum parasitization 
may occur, disease symptoms are generally absent (reviewed in (Wipasa et al., 2002)). 
The mechanisms that mediate this state of immune protection from disease and 
hyperparasitaemia are not well understood. However, there is ample evidence that 
antibodies play an important anti-parasite role in vivo both in animal models and humans.
It has been demonstrated that the complete resolution of parasitaemia in the P. yoelii and 
P. chabaudi models is dependent on B cells (Langhome et al., 1998a; van der Heyde et 
al., 1996; von der Weid and Langhome, 1993). In addition, immunity could be passively 
transferred via immune sera from immunized mice to naive recipients (Freeman and 
Parish, 1981).
In humans, the importance of antibody in mediating protective immunity in vivo 
was first demonstrated using adoptive transfer of immune sera into naive individuals in 
the early 1960s (Cohen et a l, 1961; Edozien et al., 1962; McGregor and Carrington, 
1963), and more recently in the 1990s (Sabchareon et a l, 1991). Further evidence for an 
important protective role for antibodies comes from studying pregnancy-associated 
malaria (PAM), and the antibody response to variable surface antigens (VSA) in children 
with and without malaria in endemic areas. In the former study, the loss of acquired 
immunity to placental malaria amongst primigravida was associated with absence of
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antibodies that block the binding of parasites to CSA on the placenta (Beeson et al., 
2004; Fried and Duffy, 1996; Fried et al., 1998; Ricke et al., 2000). Such antibodies 
accumulate in women living in malaria endemic regions with increasing number of 
pregnancies. In the latter study, it was demonstrated that VS A expressed during clinical 
malaria were not recognized by antibodies present in the child before the infection while 
heterologous VS A were recognized (Bull et al., 1998). Collectively, these data provides 
indirect evidence for a role of CD4 T cells in vivo in giving help to B cells to make 
protective antibody in malaria infections.
6.2.0 Study design
6.2.1 Rationale
The protective role for antibodies directed to PfEMP-1 has been emphasized 
above and in chapter 1. The specific CD4 helper T cell epitopes involved are not known. 
Previously, it has been demonstrated CD4 T cell proliferative and PBMC cytokine 
responses to the EXON 2 and DBL-a domains of PfEMP-1 are associated with exposure 
to malaria (Allsopp et al., 2002). In that study, both malaria-exposed and non-exposed 
donors responded to the CIDR-la domain and these responses were similar in frequency 
and magnitude. CIDR-la specific responses in naive donors are largely MHC class II 
independent as shown in chapter 5. However, we do not know whether this is also true of 
the response of donors who are exposed to P. falciparum. It is possible that these 
responses to CIDR-la in malaria-exposed donors will have been modified by continuous 
malaria infection and it might be expected that malaria-exposed donors would have an 
expanded pool of CIDR-la specific memory CD4 T cells whose responses to CIDR-la 
would in turn be MHC class-II restricted. The hypothesis to be tested in this chapter is
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that malaria exposed donors develop classical MHC class II restricted memory responses 
to the CIDR-la domain of PfEMP-1.
6.2.2 Materials and methods 
Donors and blood sampling
Nineteen healthy adult women volunteers, aged between 25 and 40 years living in 
Ngerenya, a malaria endemic area on the Kenyan coast were recruited into the study. A 
detailed history was taken from each of these donors to ascertain that they had lived in 
Ngerenya most of their lives and that they were healthy at the time of blood donation. 
The area has prolonged seasonal P. falciparum transmission following the short and long 
rains in the months of October to November and March through July, respectively. The 
Anopheles gambie si. complex is the main vector contributing to approximately 10 
infective bites per person per annum (Mbogo et al., 1995). All the donors were women, 
none of who were pregnant at the time of blood donation. All experiments followed the 
guidelines of good conduct in clinical research from the Kenyan government and were 
performed after informed consent was obtained from the donors. Ethical clearance was 
granted by the Kenyan government. For each of the donors, 15 mis of blood were drawn 
from a vein on the forearm into heparinized vaccutainers. PBMC were isolated as 
described in chapter 2, section 2.5.
PBMC cultures
PBMC were stained with CFSE and plated out at 1-2 x 105 cells/well (as 
described in chapter 2, section 2.8) in the presence of either the anti-MHC class II 
antibody (L243), or the mouse IgG2a isotype control at 0, 5, 10 and 40 p,g/ml 
(specifically for wells that were stimulated with CIDR-la and PPD) in a 96 well U-
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bottomed plate (Nunclon; Gibco) in 200pl of complete RPMI 1640 (constituted as 
described in chapter 2, section 2.8). Cells were then stimulated in duplicates with medium 
(media control), EXON 2 (for European controls only) and CIDR-la recombinant 
proteins at a final concentration of O.lpg/ml, PPD at lOpg/ml and PHA at 2.0p,g/ml and 
cultured for 7 days. The numbers and proportions of CD4 T lymphocytes dividing in 
response to the various stimulants were determined by flow cytometiy. Supernatants were 
harvested and stored at -30°C for the measurement of cytokines before flow cytometric 
analysis.
Detection of IFN-y bv ELISA
Supernatants from PBMC cultures were tested for the presence of IFN-y by use of 
OPTEIA™ ELISA kits (Pharmingen/Becton Dickinson), according to the manufacturer’s 
instructions (see chapter 2, section 2.9 for details). This ELISA has a sensitivity of 4 
pg/ml.
Data analysis
Data were stored and formatted with Microsoft Excel (Mirosoft Corporation, 
Seattle, USA). Graphs were plotted in and Prism-Graphics (Graph pad software, San 
Diego, CA). Statistical analyses were performed in Stata version 8.0 (Stata College 
station, TX). Wilcoxon Signed Rank Test statistics was used to test whether median 
percent inhibitions were statistically significant.
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6.3.0 Results
6.3.1 General
In total, 19 adults who had lived in an area endemic to malaria throughout their 
lives were investigated for CD4 T cell division and IFN-y production in response to 
CIDR-la, and the medium control. For the positive control, tuberculin PPD, only 17 
donors could be tested due to a limit in the number of PBMC in 2 donors. Since CD4 T 
cells obtained from malaria-exposed individuals had previously been shown to respond to 
EXON 2 by CD4 T cell division and IFN-y production, and a limitation in the number of 
PBMC recovered from these donors, the negative control protein used in assays involving 
non-immune individuals in the previous two chapters, EXON 2 was not included in these 
stimulations. However, these donors did not respond to a purified elute of PGEX6P1 
cloned in BL21, and thereafter purified in exactly the same way as EXON 2 and CIDR- 
la , as described elsewhere (Allsopp et al., 2002).
Briefly, analysis for CD4 T cell division was done on the CD4 T cell gate as 
described in figure 5.6 (chapter 5). The proportions of CD4 T cells varied widely among 
the donors averaging 22.5% (STDEV, 14.4) and ranging from 5.0 to 54%. The proportion 
of divided CD4 T cells, defined as those with reduced CFSE fluoresnce intensity, were 
determined for duplicate wells and averages calculated. IFN-y concentrations in the 
culture supernatants were also determined and averages for duplicate wells calculated. 
For CD4 T cell proliferation, individuals were considered positive if the stimulation 
index was 2 or above. Similarly, those donors whose CIDR-la specific IFN-y 
concentrations were 2 fold or above the medium control were considered positive.
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7 out of the 19 (36%) donors responded to CIDR-la by CD4 T cell proliferation. 
The stimulation indices ranged from 1.2 to 6.3. The percentage of divided CD4 T cells 
was on average 15.44 % (STD, 11.20) and ranged from 3.60 to 47.55%. 11 of the 19 
(57%) donors produced IFN-y in response to CIDR-la the concentration of which was at 
least two folds above the media control. IFN-y concentrations were on average 181.90 
pg/ml, and ranged between 54.80 and 422.40 pg/ml. Figure 6.1 shows the frequencies of 
divided CD4 T cells and IFN-y concentrations for each of the 17 donors. The two donors 
who are not included in these graphs did not respond to CIDR-la and their responses are 
similar to these of donors 16 and 17 on the right side of the graph. The individual results 
shown in this graph are arranged in the order of decreasing stimulation indices (for cell 
division) or the antigen: medium control ratio (for IFN-y concentration) from the left to 
the right side of the graph.
CD4 T cells from 16 out of 17 (94%) individuals responded positively to PPD. 
The percentage of divided CD4 T cells was on average 53.52 % (STD, 18.22) and ranged 
from 16.2 to 78% for PPD. IFN-y concentrations were determined for all the 17 donors, 
and only in 3 of them, the concentrations were 2 folds lower than the media control i.e. 
82% of donors were positive for IFN-y production. The average amount of IFN-y in 
response to PPD was 328.92 pg/ml (STDEV, 81.90) and ranged from 90.60 to 436.70 
pg/ml.
In summary, 37% and 63% of 19 malaria-exposed donors responded to CIDR-la 
by CD4 T cell proliferation and IFN-y production, respectively. 94% and 82% of 17 adult 
donors who had previously been immunized with BCG responded to the positive control 
antigen, tuberculin PPD, by CD4 T cell proliferation and IFN-y production, respectively.
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Individual CD4 T cell (a) and IFN-y (b) responses to CIDR-la. PBMC were obtained 
from donors who had lived in an area endemic to malaria throughout their lives and 
cultured for seven days in the presence o f CIDR-la. Thereafter CD4 T cells were 
analysed for cell division by flow cytometry as described in figure 5.6 (chapter 5). IFN-y 
concentrations in culture supernatants were determined by ELISA as described in section
5.2.2 (chapter 5). Data are shown for 17 out o f 19 donors arranged and numbered in the 
decreasing magnitude o f the CIDR-la response i.e. the antigen: medium ratio 
(stimulation index). Numbers marked by asterix marks donors that were considered 
positive i.e. those that had a stimulation index o f 2 and above or a 2 fold and above ratio 
for cell division and IFN-y concentration, respectively. The open, dark and hatched bars 
represent the medium control, CIDR-la and PPD.
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6.3.2 _The effect of an anti-MHC class II MAb on the CD4 T cell proliferation and 
IFN-y production responses to PPD and CIDR-la in malaria exposed donors
In order to test whether the CIDR-la specific responses seen in malaria-exposed 
individuals are MHC class II restricted, 17 malaria-exposed donors were assayed for CD4 
T cell proliferation and PBMC IFN-y production in response to CIDR-la and PPD in the 
presence of varying concentrations of either the anti-MHC class II antibody, L243, or the 
mouse IgG2a isotype control. Tuberculin PPD was used as a positive control because the 
CD4 T cell response to this antigen in PBMC isolated from donors previously immunized 
with BCG is known to be MHC class II restricted (Shanmugalakshmi et al., 2003; Singh 
and Booth, 2002).
The MHC class II restriction of the anti-PPD (positive control) CD4 T cell 
division and IFN-y production responses in Caucasian PBMC donors was confirmed in 
figure 5.11 (chapter 5). Similarly, L243 added to PBMC cultures in the presence of PPD 
at 0, 5, 10 and 40 |ig/ml inhibited both CD4 T cell division and IFN-y concentration in all 
the 17 malaria exposed donors tested in a dose dependent manner. CD4 T cell and EFN-y 
responses to PPD in the cultures with the isotype control were always higher than those 
of the corresponding concentrations of the anti-MHC class II MAb. Percent inhibitions 
were calculated as described in figure 5.11 (chapter 5). Briefly, percent inhibitions were 
calculated by subtracting the individual responses corresponding to the various 
concentrations of L243 from the corresponding responses in the presence of the 
respective mouse IgG2a isotype control antibody as described in figure 5.11 (see chapter 
5). These differences were then divided by the values for the respective isotype controls 
and multiplied by 100. Figure 6.2 shows the percentage inhibitions of the CD4 T cell
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division and IFN-y production in response to PPD in 14 malaria exposed donors who 
responded positively for both responses. The percent inhibitions for each of the donors 
included increased with increasing concentration of the anti-MHC class II MAb giving a 
dose dependent reduction of both the CD4 T cell and IFN-y responses.
7 and 11 malaria-exposed donors, who were considered positive for CD4 T cell 
division and IFN-y production, respectively, were selected for analysis of dose dependent 
inhibitions responses with increasing concentrations of the anti-class II antibody. The 
anti-MHC class II antibody inhibited the CD4 T cell division in all the 7 donors, and 
IFN-y production in 8 of the 11 donors selected. Figure 6.3 shows the effect of L243 on 
CD4 T cell proliferation and IFN-y production in response to CIDR-la in 4 
representative individual donors. Generally, the anti-MHC class II MAb inhibited both 
CD4 T cell and IFN-y production responses to CIDR-la. Calculations for percentage 
inhibitions for these anti-CIDR-la responses by L243 were calculated as described 
above, and will described in the next section.
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Figure 6.2
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Inhibition o f CD4 T cell (a) and IFN-y (b) responses to PPD by the anti-MHC class II 
MAb, L243, in malaria exposed donors. PBMC from healthy donors who had lived in an 
area endemic to malaria throughout their lives were incubated with PPD, and either the 
anti-MHC class II antibody or the mouse IgG2a isotype control, at different 
concentrations; 0, 5, 10, and 40 mg/ml. They were then cultured fo r  seven days after 
which CD4 T cell division was analysed by flow cytometry as described in figure 5.6, and 
IFN-y concentrations in culture supernatants by ELISA as described in section 5.2.2 (see 
chapter 5). Percent inhibitions were calculated as described in figure 5.11 (chapter 5).
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Individual CD4 T cell (a) and IFN-y responses to CIDR-la in the presence o f anti-MHC 
class 11 MAb, L243. PBMC were obtained from healthy adults who had lived in an area 
endemic to malaria throughout their lives and incubated in the presence o f  CIDR-la  
and, either L243 or the mouse IgG2a isotype control at different concentrations; 0, 5, 10 
and 40 pg/ml fo r  7 days. Thereafter, CD4 T cell division and IFN-y concentrations were 
determined as described in figure 5.6 and section 5.2.2, respectively (chapter 5). Data 
are shown for 4 (numbered 1-4) representative donors who were considered positive fo r  
CD4 T cell proliferation and IFN-y production as described in figure 5.7. The open, 
hatched, grey and black bars represent 0, 5, 10 and 40 pg/ml o f L243, whilst the red, 
blue and green bars represent 5, 10 and 40 pg/ml o f the isotype control, respectively.
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6.3.3 The CD4 T cell and IFN-y responses to CIDR-la in malaria-exposed 
individuals are MHC class II restricted
The ability of the anti-MHC class II MAb, L243, to inhibit CD4 T cell 
proliferation and IFN-y production in response to CIDR-la was expressed as percentage 
inhibition. Figure 6.4 shows how the percent inhibitions for both CD4 T cell proliferation 
and IFN-y production in response to CIDR-la varied with increasing concentrations of 
L243. As mentioned in the previous chapter, L243 inhibited the anti-CIDR-la CD4 T 
cell proliferative response in all the 7 donors who responded positively. Similarly, L243 
inhibited IFN-y production in response to CIDR-la in 8 out of 11 malaria exposed 
donors. Figure 6.5 shows how the median percent inhibitions varied with increasing 
concentrations of L243. As shown in graph 6.5a, the median percent inhibitions of CD4 T 
cell proliferation in response to CIDR-la were 37%, 45%, and 45% for 5 pg/ml, 10 
pg/ml and 40 pg/ml, respectively. These were significantly different from 0% (p= 0.001, 
p= 0.001 and p= 0.001 (Wilcoxon Signed Rank Test), respectively). However, there was 
no significant difference between the median percent inhibitions for 5 and 10 pg/ml (P, 
0.4). In addition, there was no apparent difference between the median percent inhibitions 
for 10 and 40 pg/ml. Thus, even though a dose dependent inhibition of CD4 T cell 
proliferation was not significant, L243 inhibited the CIDR-la specific CD4 T cell 
proliferative response in all the three dilutions tested. In contrast, a dose dependent 
inhibition of CD4 T cell proliferation in response to PPD was observed between the 
median percent inhibitions for 5 and 10 pg/ml (p= 0.002). Similar to the observation 
made, for CIDR-la specific CD4 T cell proliferation, there was no apparent difference
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between the median percent inhibitions for PPD between 10 and 40 jig/ml suggesting that 
L343 had a saturating effect between these concentrations (see figure 6.2).
In the case of IFN-y responses, the median percent inhibitions were 19 for 5 
Hg/ml, 38 for 10 fxg/ml and 35 for 40 p-g/ml of L243. These median percent inhibitions 
were all different from a hypothetical median inhibition of 0%; p= 0.002, p=0.01 and 
p=0.002 for 5 [xg/ml, 10 ^ig/ml and 40 pg/ml (Wilcoxon Signed Rank Test), respectively, 
suggesting that the IFN-y response to CIDR-la in malaria-exposed donors is MHC class 
II restricted. In addition, there was a dose dependent inhibition of the CIDR-la specific 
response between 5 p-g/ml and 10 [xg/ml (p= 0.0002) but no apparent difference between 
10 [xg/ml and 40 p,g/ml concentrations of L243. As with the anti-PPD CD4 T cell 
proliferative response, there was a dose dependent inhibition of the IFN-y response (to 
PPD) with increasing concentrations of L243 from 5 to 10 [xg/ml (p=0.0006). Together, 
these data suggest that both the CD4 T cell proliferative and IFN-y responses in malaria- 
exposed adults are MHC class II restricted. It is likely that these responses are different 
from those seen in malaria unexposed donors and may involve memory T cells.
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Inhibition o f the CD4 T cell (a) and IFN-y (b) responses to CIDR-la by the anti-MHC 
class 11 MAb, L243. PBMC from healthy adults who have lived in a malaria endemic 
area throughout their lives were incubated with CIDR-la, and either the anti-MHC class 
II antibody or the mouse IgG2a isotype control at different concentrations; 0, 5, 10 and 
40 mg/ml. They were then culturedfor seven days after which the cells were analysed fo r  
CD4 T cell division as described in figure 5.6 (chapter 5). IFN-y concentrations in 
culture supernatants were determined by ELISA as described in section 5.2.2. Percent 
inhibitions were calculated as described in figure 5.11 (chapter 5). Each line represents 
data from one o f  7 and 11 donors in the case o f CD4 T cell division and IFN-y 
production, respectively.
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Figure 6.5
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Median percent inhibitions for the CD4 T cell (a) and IFN-y (b) responses to CIDR-la  
by the anti-MHC class II MAb in malaria exposed donors who were considered positive 
fo r both responses. PBMC from adults who had lived in an area endemic to malaria 
throughout their lives were incubated in the presence o f CIDR-la and different 
concentrations o f either the anti-MHC class 11 MAb, or the mouse IgG2a isotype control; 
0, 5, 10 and 40 mg/ml. The cells were cultured fo r  7 days and thereafter analysed fo r  
CD4 cell division by flow  cytometry as described in figure 5.6 (chapter 5). IFN-y 
concentrations were determined in culture supernatants as described in section 5.2.2 
(chapter 5). Percent inhibitions were calculated as described in figure 5.11 (chapter 5). 
Each dot represents an individual donor and data is shown for  7 and 11 donors, fo r  CD4 
T cell division and IFN-y production, respectively. There was a significant dose 
dependent effect between 5 and 10 mg/ml for IFN-y (p= 0.002 Wilcoxon signed ranked 
test) but not fo r  the CD4 T cell response (p= 0.4). In both responses, there was no 
apparent difference between 10 and 40 mg/ml.
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6.4 Discussion
In the previous chapter, CD4 T cell responses to the CIDR-la domain of PfEMP- 
1 in PBMC from malaria-unexposed individuals were found to be largely independent of 
MHC class II. In the present chapter, the same anti-MHC class II antibody MAb used in 
chapter 5, L243, was used to test for the MHC class II restriction of the CIDR-la specific 
CD4 T cell proliferative and IFN-y responses in adults who had lived in a malaria 
endemic area throughout their lives. Such information is critical for understanding the 
mechanisms that mediate these responses in malaria exposed individuals and would be 
useful in designing CIDR-la based vaccines. It is especially important to find out 
whether the CIDR-la specific responses observed in malaria-exposed donors are 
qualitatively different from those seen in naive donors. It is likely that CIDR-la specific 
responses in such adults would involve (at least partially) memory, and would therefore 
be MHC class II restricted.
In this study, 36% and 57% of 19 malaria-exposed donors responded to CIDR-la 
by proliferation and IFN-y production, respectively. The CIDR-la specific CD4 T cell 
proliferative response in malaria-exposed donors was inhibited by the anti-MHC class II 
antibody in all the 7 malaria exposed donors who responded positively by CD4 T cell 
proliferation suggesting that this response is MHC class II restricted. Similarly, the IFN-y 
response to CIDR-la in the 11 malaria-exposed donors that responded positively was 
MHC class II restricted and there was a dose depended reduction of this response with 
increased concentration of the MHC class II MAb.
The IFN-y response in malaria-unexposed individuals was clearly not restricted 
by MHC class II in the majority of donors unlike in malaria-exposed donors where a dose
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dependent inhibition of this response was observed. Collectively, these data suggests that 
malaria-exposed adults have CIDR-la specific CD4 T cells and these CD4 T cells 
respond in an MHC class II restricted fashion in vitro. In addition, the IFN-y response in 
malaria-exposed donors was MHC class II restricted in the majority of donors while the 
converse was true for the malaria-unexposed donors. It is likely that these differences 
between the CIDR-la response in malaria naive and malaria exposed donors is due to the 
presence of memory CD4 T cells in the PBMCs from exposed donors (chapter 5). Naive 
CD4 T cells, responding to their respective specific antigen, undergo profound changes in 
the surface molecules they express and in their activities (Mackay and von Andrian, 
2001). Some of these cells differentiate into effector cells that kill the invading 
pathogens, or stimulate B cells to make antibody against foreign antigens; others become 
memory cells that have the capacity to differentiate into effector cells when they re­
encounter the same antigen (Berard and Tough, 2002). Because, they have been exposed 
to P. falciparum infections throughout their lives, it is reasonable to expect that the 
malaria-exposed adults have accumulated memory CD4 T cells specific to P. falciparum 
antigens in their peripheral circulation. Furthermore, it is generally accepted that adults 
living malaria endemic areas are protected from severe disease and death from malaria by 
naturally acquired immunity (as discussed in chapter 1). As discussed in chapter 1 and 
indeed throughout this thesis, there is longstanding evidence from animal models and 
epidemiological studies that antibodies are effectors in this protection highlighting a 
critical role for the CD4 helper T cell in stimulating B cells to make effective antibodies.
The presumption that naive and memory T cells can be distinguished 
phenotypically is based on the notion that memory T cells retain a permanent imprint of
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having responded to antigen (Berard and Tough, 2002). However, the precise 
identification of memory T cells has always been problematic. Unlike B cells, T cells do 
not mutate their receptor genes during the course of an infection and hence there are no 
clear-cut molecular markers to aid the distinction between naive and memory T cells 
(Berard and Tough, 2002). Despite such difficulties, a number of differences between 
nai've and memory T cells have been noted. Most studies to date have relied on the 
tyrosine phosphatase, CD45, which regulates signalling through antigen receptors and 
cytokine receptors (Berard and Tough, 2002). Naive T cells express a high molecular 
weight (MW) isoform of CD45 commonly referred to as CD45RA (in humans) while 
memory T cells express a lower MW isoform of CD45 called CD45RO (Irie-Sasaki et al., 
2001; Trowbridge and Thomas, 1994). Apart from memory and effector CD4 T cells, 
CD45RO is also expressed on memory CD8 T cells, monocytes, macrophages and 
granulocytes (Janeway et al., 1999). One way to test whether the responding CD4 T cells 
from the malaria exposed adults have a memory or naive phenotype is to isolate CD4 T 
cells form PBMC and then either deplete or enrich for CD45RO positive cells, and 
thereafter test whether this action abrogates or improves the CIDR-la specific response, 
respectively. The difficulty of such an experiment is that it would involve isolating the 
CD4 T cell memory or naive cells and then bring them back to a culture system with 
autologuous APCs and CIDR-la. Another molecular marker that has been used to 
distinguish between naive and memory T cells is the chemokine receptor, CCR7 (Berard 
and Tough, 2002; Mackay and von Andrian, 2001; Sallusto et al., 1999). At least in 
humans, CCR7 is thought to be expressed in naive but not memory T cells (Berard and 
Tough, 2002). However, it has recently become clear that some CD45RO positive T cells
express CCR7 while others do not (Berard and Tough, 2002; Mackay and von Andrian, 
2001). This observation resulted in the classification of memory T cells into effector 
(CCR7-) and central memory (CCR7+) cells with the former responding faster to antigen 
stimulation than the later by cytokine production (Berard and Tough, 2002; Mackay and 
von Andrian, 2001). However, Unsoeld, H. and colleagues (Unsoeld et al.9 2002) recently 
found no differences between IFN-y responses to the lymphocytic choriomenegitis virus 
(LCMV) glycoprotein between CCR7- and CCR7+ cells making this classification 
controversial. It would be interesting to investigate the memory phenotypes for the 
responding cells, firstly by stimulating CD4+CD45RO+ with CIDR-la and if they are 
responsive then find out whether the responding memory cells are CCR7- or CCR7+.
It was not possible to compare the CD4 T cell division response between malaria 
exposed and non-exposed donors since none of the 7 non-immune donors tested in 
chapter 5 responded by CD4 T cell proliferation (a rarer response in these donors). 
However, in that chapter only 24% and 48% of 34 malaria naive donors responded by 
CD4 T cell proliferation and IFN-y production, respectively. In contrast, 36% and 56% 
malaria exposed donors responded positively to CIDR-la by CD4 T cell proliferation 
and IFN-y production, respectively, in the current chapter. Thus, the frequency of 
responders was higher among the malaria-exposed than unexposed donors further 
suggesting that the CD4 T cell response seen in the exposed donors could partly be 
explained by the presence of memory T cells in the PBMC from malaria-exposed donors 
that specifically recognize this CIDR-la variant.
There is now evidence showing that CIDR-la immunization in Aotus monkeys 
protects the animals from homologous P. falciparum challenges (Baruch et al., 2002a).
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More recently, it has also been demonstrated that immunizing mice with more than one 
CEDR-la variant increases the level of cross-reactivity of the resultant antibody response 
(Gratepanche et al., 2003). The observation that semi-immune adults have classical MHC 
class II restricted CD4 T cell and IFN-y responses to CIDR-la is encouraging and 
suggest that these donors have CIDR-la specific memory T cells. In addition, the fact 
these responses seen in 36% and 56% malaria exposed donors for CD4 T cell and IFN-y 
production, respectively, were directed to a single variant of CIDR-la suggest that there 
might be cross-reactive epitopes in this molecule which would make it easier to 
overcome the immense antigenic diversity of PfEMP-1 in a CIDR-la based vaccine. It is 
not known for now how similar the Me var 1 CIDR-la sequence that was the stimulating 
antigen in this study to the CIDR-la variants circulating in Kilifi. With time, it will be 
possible to sequence var genes from field P. falciparum isolates for such comparisons. It 
is also likely that stimulating PBMC with more than one CIDR-la variant would increase 
the number of responders. In summary, the fact these data suggest that humans exposed 
to malaria make a memory CD4 T cell response to CIDR-la, further suggest that CIDR- 
l a  based vaccines to protect humans from clinical malaria may be feasible.
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CHAPTER 7
SUMMARY
Rationale
The studies presented in this thesis examined the nature of cellular responses to 
CIDR-la, the CD36 binding domain of PfEMP-1, which is believed to be the major 
parasite antigen expressed on the surface of the Pf-iRBC. The justification for carrying 
out such studies is two fold. Firstly, interactions between the Pf-iRBC and cells of the 
human immune system are complex, poorly understood and may be involved in 
mechanisms that mediate immune protection and dysregulation, and pathogenesis of 
severe malaria. As it has already been discussed in chapter 1, CIDR-la of PfEMP-1 is 
the ligand for CD36 and by binding CD36, CIDR-la is therefore likely to be involved in 
the pathogenesis of mild malaria. It is now generally accepted that CD36 binding is a 
prominent feature of Pf-iRBC isolated from patients suffering from severe malaria. In 
addition to the observation that malaria-unexposed donors have pre-existing cellular 
responses to CIDR-la, CIDR-la has been implicated in inhibition of DC maturation that 
may modulate the host’s immune response to the parasite’s favour. Secondly, as it has 
been discussed throughout this thesis, CIDR-la, due to its surface location and 
involvement in pathogenesis of malaria, is an important target for antibody and hence has 
potential as an anti-adhesive vaccine against malaria. Information on how such a vaccine 
would stimulate the human host’s immune system would help the design of PfEMP-1 
based vaccines. Basic studies looking at the interaction between CIDR-la and cells of 
the human immune system like the ones described in this thesis will therefore provide 
useful information that would aid understanding mechanisms involved in pathogenesis,
immunity and immunomodulation in falciparum malaria, and may speed up the process 
of developing new therapeutic agents.
DC responses to the CIDR-la domain of PfEMP-1 in malaria unexposed donors
As discussed in chapter 1, previous studies have suggested that DCs have an 
important role in inducing immune responses and immune dysregulation in P. falciparum 
infections (Urban et al., 1999). Pf-iRBCs have been reported to interact with DCs via 
TLRs (Pichyangkul et al., 2004) and CD36 (Britta Urban, personal communication), and 
the CD36-DC interaction has been implicated in inhibition of DC maturation (Urban et 
al., 2001b). Together, these observations and the fact that CIDR-la was shown to induce 
CD4 T cell proliferation and cytokine production in malaria unexposed individuals 
(Allsopp et al., 2002) led to the study presented in chapter 4; i.e. to provide information 
on the nature of DC responses to CIDR-la and their kinetics. CIDR-la stimulated 
production of cytokines by peripheral myeloid DCs in both whole PBMC and isolated 
DC cultures. In general, DCs produced IL-10, IL12p70 and IL-18 in response to 
recombinant CIDR-la. The IL-10 and IL-18 responses could be reproduced with intact 
Pf-iRBCs. These results suggest that DCs might interact with CIDR-la to induce the 
CD4 T cell and cytokine responses seen in malaria-unexposed donors as reported 
previously (Allsopp et al., 2002) and reproduced here in chapter 5. The induction of 
responses seen in malaria-unexposed donors could involve either antigen presentation by 
the activated DC to the T cell via the TCR, or CIDR-la (or Pf-IRBC) may induce the 
production of DC derived cytokines (such as IL-12 and IL-18) that are capable of 
activating differentiated TH1 CD4 T cell to produce IFN-y independent of antigen 
presentation (Yang et al., 1999; Yang et al., 2001).
Even though TLR9 and CD36 have been implicated as the ligands for CIDR-la 
(Pichyangkul et al.9 2004) and Pf-IRBC on DC, it must be stressed that the findings in 
these reports are more speculative than definitive. Furthermore, there is only a single 
report implicating TLR9 as the ligand for P. falciparum on mouse plasmacytoid DCs 
(Pichyangkul et a l , 2004). In addition, most of the studies reporting DC stimulation by 
Plasmodia sp (including this thesis) have reported cytokine production by myeloid rather 
than plasmacytoid DC highlighting the need for more studies looking at Pf-iRBC TLRs 
interaction in this DC subpopulation. In the case of CD36, the evidence for its 
involvement is indirect. As already pointed out in chapter 1, anti-CD36 MAbs inhibited 
maturation of human monocyte derived DC and induced IL-10 production in a similar 
fashion to CIDR-la and Pf-IRBC (Urban et al., 2001b). Further studies are needed to 
identify more precisely the ligand for Pf-iRBC on DC. In addition, stimulation of DC by 
Pf-iRBC may involve other molecules on the surface of Pf-IRBC and given the 
significance of these interactions, investigating this possibility is important.
Previous studies looking at DC-Pf-iRBC interactions reported controversial 
results with some reporting normal DC stimulation (Coban et al., 2002; Pichyangkul et 
al., 2004; Seixas et al., 2001; Stevenson and Riley, 2004) and others reporting inhibition 
of DC maturation (Ocana-Morgner et al., 2003; Urban et al., 1999). It is not clear why 
the results from different studies are discordant. What is clear from chapter 4 of this 
thesis is that IL-10 and IL-12 in CIDR-la stimulated DC were produced with different 
kinetics. This finding highlights the need for time course experiments in studies 
investigating cytokine production in antigen stimulated DCs, otherwise similar studies 
looking at cytokine production in DC at different time points may continue to report
conflicting results. In this case, studies measuring just IL-10 would conclude that DCs are 
inhibitory whereas the detection of 11-12 alone would lead to the conclusion that the DCs 
are activated. DCs are in fact known to produce both the inflammatory IL-12 (and IL-6, 
TNF and IL-a) and regulatory IL-10 cytokines in response to stimulation by pathogens, 
with the production of IL-12 being tightly regulated and transient (Langenkamp et al., 
2000; Reis e Sousa et al., 1999). IL-12 polarises the CD4 T cell response to a TH1 type 
response which is highly effective at clearing intracellular pathogens (as described in 
chapter 1) (Kapsenberg, 2003; Sher et al., 2003), while IL-10 can inhibit activation and 
effector responses of T cells and macrophages resulting in the down-regulation of 
inflammatory responses (Moore et al., 2001). Strong pro-inflammatory responses in 
rodent malarias and in human infections characterised by production of IL-12, TNF, IL-6 
and IL-a by DC and macrophages, and IFN-y by CD4, CD8 T cells, y5 T cells, and NK 
cells have been associated with severe complications of malaria (Langhome et al., 2004).
It has been suggested that a tight regulation of the balance between regulatory cytokines 
like IL-10 and TGF-p, and inflammatory cytokines, such as IFN-y and TNF, is critical for 
survival in a mouse malaria infection (Langhome et al., 2004). This is probably also true 
in humans but it is difficult to test in vivo for ethical reasons.
CD4 T cell and cytokine responses to the CIDR-1 domain of PfEMP-l in malaria naive 
donors
Previously, it was shown that a recombinant protein fragment of the CIDR-la 
domain of PfEMP-1 stimulated CD4 T cells in both malaria-exposed and non-exposed 
donors to proliferate, and the supernatants collected contained IL-10 and IFN-y (Allsopp 
et al., 2002). The presence of CIDR-a specific CD4 T cells in the peripheral blood of
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malaria-unexposed donors was further confirmed in this thesis. The fact that some 
individuals responded by IFN-y production, but without CD4 T cell division in the 
PBMC cultures suggests that the production of this cytokine may not always be 
associated with cell division. This challenges the classical T cell activation model found 
in immunology textbooks suggesting that CD4 T cells proliferate before producing IFN-y 
(Janeway et a l ., 1999). However, recent studies on the generation of protective 
immunological memory have described a subset of memory T cells with the ability to 
secrete IFN-y rapidly in response to antigen challenge (Sallusto et a l., 1999). These cells 
were termed effector memory T cells (CCR7- as described in chapter 6, section 6.4) as 
opposed to central memory T cells (CCR7+), which do not exert immediate effector 
functions and produce IL-2 preferentially and not IFN-y in response to in vitro 
stimulation with antigen (Sallusto et a l., 1999). In addition, effector memory T cells are 
found in non-lymphoid tissues including the lungs, liver, and intestinal mucosa from 
where they are best placed to provide rapid protection against re-infection with pathogens 
while central memory T cells migrate to peripheral lymph nodes (Lefrancois, 2002; 
Reinhardt et a l., 2001). In the peripheral lymph nodes, central memory T cells are 
thought to be available, to provide help to B cells for antibody production and/or generate 
a second wave of effector T cells (Kaech et a l., 2002).
Since these donors have not been previously exposed to malaria antigens and 
therefore would not be expected to have immunological memory to such antigens, we can 
only speculate that they have either experienced something similar to CIDR-la in the 
environment, or CIDR-a is a superantigen, or a mitogen. If these responses are the result 
of a cross reactivity, we would expect such CD4 T cell and IFN-y responses to involve
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immunological memory and therefore MHC class II restriction. When this possibility was 
explored, the IFN-y response was largely MHC class II independent, but required TCR 
engagement in some donors and not others. It is therefore likely that the induction of this 
response in most malaria-unexposed individuals involves a different mechanism from the 
normal MHC class II-TCR interaction. It was not possible to test for the presence of a 
super-antigen activity in CIDR-la since the MHC class II antibody did not inhibit SEB 
induced IFN-y production suggesting this antibody does not bind onto the super-antigen 
binding-epitope on MHC class II.
The activation of CD4 T and CD56 positive NK cells in CIDR-la stimulated 
cultures could be due to the presence of IL-12 and IL-18 produced by activated DCs. 
Indeed a bidirectional cross talk between NK and DCs in which activated DCs induce 
CD69 expression on NK cells and IL-2 activated NK cells induce DC maturation has 
been reported (Marten et al., 2001). The involvement of IL-12 and IL-18 in stimulating 
CD4 T and NK cells to produce IFN-y could be investigated further by testing the effect 
of anti-IL-12 and anti-IL-18 MAbs on inhibition of IFN-y induction by CIDR- la .
CD4 T cell and cvtokine responses to the CIDR-la domain of PfEMP-l in malaria 
exposed donors
There is indirect evidence for a critical role of CD4 T cells giving help to B cells 
for production of protective antibodies in individuals living in malaria endemic areas, as 
discussed in chapters 1 and 6 of this thesis. The data presented in chapter 6 demonstrates 
that healthy adults who have lived in a malaria endemic area on the coast of Kenya for 
the majority of their lives have both CD4 T cell and IFN-y responses that are MHC class 
II restricted. These responses were similar to the CD4 T cell and IFN-y responses to the
200
commonly used positive control for memory CD4 T cell responses in BCG immunised 
individuals. In addition, the frequency of responders was higher among the exposed 
adults than the unexposed. Taken together, these data suggests that adults living in 
malaria endemic areas have memory CD4 T cell responses to CIDR-la.
Concluding remarks
Whilst these observations provide interesting insights into the interactions 
between Pf-iRBCs and the human host’s immune response, further studies are needed to 
investigate the MHC class II requirement for CD4 T cell proliferative response to CIDR- 
la , to further elucidate the mechanisms of CD4 T and NK cell activation in the absence 
of antigen presentation, and to compare cellular responses induced by different CIDR-la 
variants. In addition, future studies to define precisely the ligands for Pf-iRBC on DCs 
will greatly contribute to an understanding of pathogenesis of, and immunity to malaria.
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APPENDICES
AP 1.0 SOURCE OF REAGENTS AND CONSUMABLES
Below is a list of the reagents used in the studies described in this thesis with the 
exception of antibodies for flow cytometry, ELISA and the MHC class II inhibition 
experiments. The information on these antibodies and the antigens used to stimulate cells
can be found in chapters 2.
PROCEDURE SUPPLIER REAGENT
Protein expression BHC (Merck Ltd.), UK Ethanol
Glycerol
Glycine
Sodium azide
Othoboric acid
Boerhinger Mannheim, 
UK
Magnesium chloride
Gibco/Life Technologies Tris-Hcl
Ltd., UK Agarose
BSA
T4 DNA ligase
Taq polymerase
IPTG
E. coli BL21 strain
E. coli DH5a
DNA molecular weight markers
SDS-PAGE running buffer
Ammonium sulphate
Coomasie blue
Sigma Potassium chloride
Ethidium bromide
Ampicilin
Glutathione
SDS
Glycerine
Sodium chloride
dATP
dTTP
dGTP
Sodium deoxycholate
E-toxate
Mineral oil
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TX-100
Glycerol
EDTA
Xylene cyanol
Bromophenol blue
Promega, UK Restriction enzymes; Notl, Ecor 1, 
buffer H
Roche Diagnostics, UK Calf intestinal phosphatase
LB media
Amersham phamacia Glutathione-sepharose
Biotec, USA PreScision protease
PGEX6p.l
dNTPs
Peirce Biotechnology, 
UK, Ltd.
Affinity pak detoxi-gel (polymixin 
B)
Bio-Rad, UK Protein assay kit
Qiagen Miniprep kit
Blood collection Leo Labs LTD, Bucks, 
UK
Heparin
PBMC AND P. GIBCO/invitrogen L-glutamine
falciparum cultures Hepes huffer
RPMI1640
Penicillin/streptomycin
Phosphate buffered saline
Blood transfusion service, Human AB serum
Colindale, North London Buffy coats
Red blood cells
BOC, UK and Kenya Special culturte, CO2
M olecu lar probes, 
Netherlands
Carboxyfluorescein diacetate  
succinimidyl ester (CFSE)
Pharmacia biotec Ficoll-paque
Sigma Trypan blue
EDTA
LC Laboratories, Woburn, 
USA
Cyclosporin A
Serotec, UK Micoplasma removal agent
Flow cytometry Sigma Bovine serum albumen
Sodium azide
Paraformaldehyde
ELISA Sigma Foetal calf serum
BHC (Merck Ltd.), UK Sulphuric acid
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Becton Dickinson, France Tetramethylbenzidine and hydrogen
__________________________________________ peroxide_________________________
CONSUMABLES
ITEM SUPPLIER
Syringes Becton Dickinson, France
Needle Becton Dickinson, France
Aspirating pipettes 2ml Farenheit, Milton Keynes, UK
Pipettes plastic disposable 1ml, 5ml, 10ml, 
25ml, 50ml
Farenheit, Milton Keynes, UK
Falcon centrifuges tubes Becton Dickinson, France
Pastteur pipette plastic sterile Alpha, Hampshire, UK
Pipette micro-volume tips (0.5-1 Op 1) 
(Eppendorf)
Fisher Scientific, UK
Pipette tips yellow (200p, maximum) 
(Eppendorf)
Fisher Scientific, UK
Pipette tips blue (lOOOpl maximum) Fisher Scientific, UK
(Eppendorf)
Eppendorf tubes Anderman and Co., Surrey, UK
LD columns Miltenyi Biotec, Germany
LS columns Miltenyi Biotec, Germany
Film Amersham life sciences Ltd., UK
Haemocytomter Sigma, UK
Falcon 96 well plates Becton Dickinson, UK
Falcon tubes Becton Dickinson, UK
Costar 96,48 and 24 well plates Fisher Scientific, UK
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AP 2.0 CIDR-la SEQUENCES
Shown below are the DNA and protein sequences for the MCvarl CIDR-la used in the 
studies described in this thesis.
gaagacaaaatt 
E D K I
atgtcctataatgcttttttttggatgtgggtacacgatatgttaattgattctatcaaa
M S Y N A F F W M W V H D M L I D S I K
tggagagacgaacatggtaggtgtataaataaagataagggaaaaacatgtataaaagga
W R D E H G R C I N K D K G K T C I K G
tgtaacaaaaaatgtatatgtttccaaaaatgggttgaacaaaaaaaaaccgaatggggg
C N K K C I C F Q K W V E Q K K T E W G
aaaataaaagaccactttcgcaagcaaaaagatattccaaaggattggactcatgatgat
K I K D H F R K Q K D I P K D W T H D D
tttcttcaaactcttttgatgaaagatctacttttggaaattattcaggatacttatggg
F L Q T L L M K D L L L E I I Q D T Y G
gatgcaaatgaaataaaacgtattgaggcactgttggaacaagcaggcgttggtggtatc
D A N E I K R I E A L L E Q A G V G G I
gattttgctgctcttgctggtctgtatactaaaggttttgtcgctgaaaaggacactaca
D F A A L A G L Y T K G F V A E K D T T
attgataaattactacaacacgaacaaaaggaagccgataaatgcctaaaaacccacaca
I D K L L Q H E Q K E A D K C L K T H T
gatgacacctgtccaccacaagaagatagaagtgtcgcccgctccgaatccgccaccgtc
D D T C P P Q E D R S V A R S E S A T V
ccctcaccacctgccgaccctaaggccactgaggaagtcgacgccaacgcctcctcagac
P S P P A D P K A T E E V D A N A S S D
gacgaagacgacttcgaagaggaagaggaagaagaagaagacgaaggcgaggaggaggcg
D E D D F E E E E E E E E D E G E E E A
gaggaagtccaggaggaaaagacggatgagtcggcaacagaggcggtggcaccgtcacca
E E V Q E E K T D E S A T E A V A P S P
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AP 2.2 CIDR-la PEPTIDE SEQUENCES
The table below shows the protein sequences for the contiguous peptides covering the 
recombinant CIDR-la protein used in chapter 5. These peptides were made 
commercially by CN Biosciences (UK) Ltd.
Peptide Sequence
CIDR-1 H-Glu-Asp-Lys-Ile-Met-Ser-Tyr-Asn-Ala-Phe-Phe-Trp-Met-Trp-Val-His-Asp-
Met-Leu-Ile-Ile-Asp-Ser-Ile-Lys-Trp-Arg-Asp-Glu-His-Gly-Arg-Cys-Ile-Asn-
Lys-Asp-Lys-Gly-Lys-Thr-Cys-Ile-Lys-Gly-Cys-Asn-Lys-Lys-Cys-Ile-Cys-
Phe-Gln-Lys-Trp-Val-Glu-Gln-Lys-Lys-Thr-Glu-Trp-Glu-Lys-Ile-Lys-Asp-
His-Phe-OH
CIDR-2 H-Thr-Glu-Trp-Glu-Lys-Ile-Lys-Asp-His-Phe-Arg-Lys-Gln-Lys-Asp-Ile-Por-
Lys-Asp-Trp-Thr-His-Asp-Asp-Phe-Leu-Gln-Thr-Leu-Leu-Met-Lys-Asp-Leu-
Leu-Leu-Glu-Ile-Ile-Gln-Asp-Thr-Tyr-Gly-Asp-Ala-Asn-Glu-Ile-Lys-Arg-Ile-
Glu-Ala-Leu-Leu-Glu-Gln-Ala-Gly-Val-Gly-Gly-Ile-Asp-Phe-Ala-Ala-Leu-
Ala-OH
CIDR-3 H-Val-Gly-Gly-Ile-Asp-Phe-Ala-Ala-Leu-Ala-Gly-Leu-Tyr-Thr-Lys-Gly-Phe-
Val-Ala-Glu-Lys-Asp-Thr-Thr-Ile-Asp-Lys-Leu-Gln-His-Glu-Gln-Lys-Glu-
Ala-Asp-Lys-Cys-Leu-Lys-Thr-His-Thr-Asp-Asp-Thr-Cys-Pro-Pro-Gln-Glu-
Asp-Arg-Ser-Val-Ala-Arg-Ser-Glu-Ser-Ala-Thr-Val-Pro-Ser-Pro-Pro-Ala-
Asp-OH
CIDR-4 H-Ser-Ala-Thr-Val-Pro-Ser-Pro-Pro-Ala-Asp-Pro-Lys-Ala-Thr-Glu-Glu-Val-
Asp-Ala-Asn-Ala-Ser-Ser-Asp-Asp-Glu-Gly-Asp-Phe-Glu-Glu-Glu-Glu-Glu-
Glu-Glu-Glu-Asp-Glu-Gly-Glu-Glu-Glu-Ala-Glu-Glu-Val-Gln-Glu-Glu-Lys-
Thr-Asp-OH
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Appendix 3.0
3.1 NATIONAL INSTITUTE FOR MEDICAL RESEARCH, LONDON, UK, 
INFORMED CONSENT
Title o f study: Characterisation of cellular immune responses to CIDR-a: the CD36 
binding domain of PfEMP-1
Investigators: Francis Ndung’u, Prof. Kevin Marsh and Dr. Jean Langhome
During the erythrocytic cycle, the malaria parasite Plasmodium falciparum , 
inserts it’s own molecules into the membrane of the infected red blood cell (Pf-iRBC). 
One of these molecules, Plasmodium falciparum  Erythrocyte Membrane Protein 1 
(P/EMP1) belong to a large gene family (Var) with around 60 copies per haploid genome 
distributed in all chromosomes. Var genes show extreme diversity but all contain a 
number of domains displaying homology to the previously described Duffy Binding Like 
(DBL) molecules or in the case of CD36 binding, to another relatively conserved region, 
the Cysteine Rich Interdomain Region (CIDR-la). Due to their surface location, 
antigenicity and involvement in pathogenesis of severe malaria, these molecules form an 
important candidate for a malaria vaccine.
Previously, we studied the CD4 T cell response to relatively conserved
recombinant segments expressed from three different domains of P/EMP-1: EXON 2,
CIDR-la and DBL-a. We measured in vitro CD4 T cell proliferation, Interferon- (IFN)-y
and Interleukin (IL)-IO production in peripheral mononuclear cells (PBMC). Only
responses to EXON 2 and DBL-a were associated with exposure to malaria. The
response to CIDR-la was striking in that both exposed and non-exposed donors
responded similarly. We are carrying out a study to analyse further the nature, function
and kinetics of these responses to CIDR-la further in both malaria-unexposed
individuals. We are appealing for blood donations from people working at the National
Institute for medical research who have never travelled to a malarias country.
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If you agree to participate in this study, we will take a small blood sample (20 
mis) from a vein on your forearm. Except for the discomfort of the needle prick, this 
process will not be harmful to you.
If you have any questions, you may contact Francis Ndung’u or or Dr. Jean 
Langhome of the parasitology division on extension 2409.
CONSENT FORM
I ------------------------------------------------------------- confirm that that the details of this
study have been explained to me. I have understood what the study involves and I am 
willing to participate.
Your name:---------------------------------------------------------------------------------------------
Signature: -------------------------------------date:-------------------------------
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3.2 KEMRI RESEARCH UNIT, KENYA: INFORMED CONSENT
Title o f study: Characterisation of cellular immune responses to CIDR-a: the CD36
binding domain of PfEMP-1
Investigators: Mr. Francis M Ndung’u, Prof. Kevin Marsh and Dr. Jean Langhome
As you may be aware, KEMRI does medical research work in an attempt to 
improve prevention and treatment of children from various diseases including malaria, 
which kills many children every year. The most effective way of preventing children 
from being infected with malaria would be to vaccinate them. Unfortunately, malaria 
vaccines are currently not available. We would like to involve you in a study that seeks to 
understand how people develop natural resistance to malaria. By doing this study, we will 
obtain information that can help us in the development of a malaria vaccine that can be 
used to reduce the number of children who become sick and die from malaria. We want 
to do this study using blood samples from adults who have grown up in an area with 
malaria like you because we already know that your blood contain particles and 
substances that kill malaria parasites. That’s why adults don’t get as much malaria 
disease as small children. If we can understand what these protective particles and 
substances are, and how they protect adults from getting sick with malaria, we will have 
information that can be used to develop a vaccine that can protect children in the same 
way. The information obtained from this study will be published in an internationally 
recognised journal so that it is available to all people in the entire world.
If you agree to participate in this study, we will take a small blood sample (20 
mis) from
a vein on your hand. Except for the discomfort of the needle prick, this process will not 
be harmful to you. This blood will not be used for any other tests and the results will be 
published in an international science/medical journal so that any new information can be 
accessed by all peoples in the entire world.
This study will not benefit you and your family immediately but we hope that the
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results will help us understand better how we might prevent children from getting sick 
with malaria in future by using a vaccine.
I will now answer any questions that you might have, and if after this discussion 
you arehappy to participate I will request you to kindly sign the consent form below 
indicating that you have understood what the study involves and you are willing to 
participate. Please note that your participation is voluntary and that you may withdraw 
from the study any time you wish without explanation or penalty. If you have any 
questions in future, you may contact Francis Ndung’u at the KEMRI laboratories in Kilifi 
District Hospital.
CONSENT FORM
I --------------------------------------------- from------------------------------------- (village) in
Kilifi District confirms that that the details of this study have been explained to me in a 
language that I am fluent in and that I have understood what the study involves. I am 
willing to participate in the study.
Your name:----------   —
Signature or thumb print-------------------------------------date-------------------------------
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